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Serum Amyloid P Component (SAP), a putative molecular chaperone, is a homo-
pentameric  plasma  protein  of  25kDa  subunits.  It  binds  to  the  amyloid  fibrils  of 
misfolded proteins, which cause amyloidosis in humans. SAP not only stabilizes 
amyloid  fibrils  but  also  protects  them  from  proteolytic  and  cell  mediated 
degradation.  SAP  has  been  co-crystallized  with  three  different  aminoalkyl 
phosphonates  that  bind  at  the  amyloid  recognition  site  of  SAP,  and  the  X-ray 
crystal structures were determined at atomic resolution. 
  
A  secondary  aim  of  this  work  was  to  understand  the  enhanced  amyloidogenic 
potential of L55P and V30M transthyretin (TTR) protein. TTR misfolding has been 
implicated  in  number  of  human  diseases  such  as  senile  systemic  amyloidosis, 
familial amyloid polyneuropathy and familial amyloid cardiopathy. TTR protein is a 
thyroxine binding protein (14kDa) existing as a tetramer in vivo. L55P and V30M 
mutant TTR are the most aggressive and most common mutants, respectively, in 
causing FAP. L55P and V30M mutant TTR protein were expressed in E.coli and 
purified using anion-exchange chromatography and gel filtration. L55P and V30M 
TTR were co-crystallised with MDS84, a compound that has been demonstrated to 
stabilize the tetramer in vitro. The X-ray structures of L55P and V30M, TTR mutant 
proteins have been determined at 1.5Å and 2.1Å resolution. 
 
In addition, research was carried out on the bacterial protein Burkholderia invasion 
protein D (BipD). BipD (33kDa) belongs to type III secretion system of Burkholderia 
pseudomallei.  It  creates  a  pore  in  the  host  cell  membrane  to  help  the  B. 
pseudomallei  invasion.  This  bacterial  infection  causes  melioidosis  disease  in 
humans. To determine the ligand recognition site of BipD, its high-resolution crystal 
structure has been determined at 1.5Å. This high resolution BipD structure is more 
complete than its previously solved structures and is in the new space group C2. 
The  BipD  structure  presented  in  this  research  may  help  to  design  potential 
chemical inhibitors of BipD to prevent bacterial invasion into human body.   
 
The  molecular  chaperones  play  an  important  role  in  the  protein  refolding  and 
assembly. ATJ11 is of 14kDa protein belongs to DnaJ co-chaperone family. The 
protein has been expressed in E.coli and purified by affinity and cation exchange 
chromatography.  The  biophysical  study  of  ATJ11  (CD  spectrum)  has  been 
conducted showing its predominant α-helical structure and attempts were made to 
crystallise it but no protein crystals have been obtained.  
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Chapter 1 
 
General Introduction   2 
1 Introduction 
 
1.1 Protein mis-folding/Amyloidosis  
 
The  native  protein  structure  is  vital  to  undertake  many  functions  in  the  living 
system  (Gutteridge  &  Thornton,  2005).  The  change  in  the  conformation  of  the 
protein  directly  affects  its  functions  (Todd  et  al.,  2002).  Under  certain 
circumstances some proteins can undergo denaturation, which leads to their mis-
folding and in some cases forming amyloid fibres (a cross-beta structure). This can 
result  in  several  different  human  diseases  e.g.  Alzheimer’s,  prion,  and 
amyloidosis, etc (Dunker et al., 2008). 
 
Protein  folding  and  assembly  is  a  complex,  sequential  and  highly  co-operative 
process (Dinner et al., 2000). The process of protein folding can be described with 
the concept of an energy landscape. Small proteins attain the native conformation 
quicker and adopt the funnel shaped energy landscape (Watter et al., 2007). On 
the other hand, the larger proteins with multimeric compositions posses a wider 
energy landscape which leads to a greater possibility for mis-folding (Brockwell & 
Radford, 2005). The protein adopts the native folded or misfolded conformation, 
which  depends  upon  its  kinetics,  thermodynamic  properties  (Jahn  &  Radford, 
2008) in addition to the Anfinsen’s findings, which state that amino acid sequence 
of a protein do have information for its correct folding (Anfinsen, 1973). 
 
The free energy landscape of proteins is complex and the potential exists for them 
to get trapped in local energy minima. In the case of the amyloid-related diseases, 
mature amyloid fibers may have an even lower free energy than native soluble 
protein, resulting in the formation of alternative conformations. In general amyloid 
fibres  are  composed  of  cross-beta  sheet  structures.  The  energy  landscape  of 
protein folding is shown in Figure1.1. 
   3 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
 
Figure 1.1 The energy landscape model of protein folding, misfolding and amyloid 
fibril  formation.  Initially,  protein  folding  was  modelled  as  a  two-step  process  in 
which the nascent polypeptide chain folded into the native state. More recently 
protein folding and assembly is understood to involve different pathways and has 
therefore been modelled as a multistep process (Korzhnev et al., 2004; Jahn et al., 
2007; Jahn & Radford, 2008). 
 
It  is  now  established  that  different  types  of  protein  can  form  similar  types  of 
amyloid fibres/fibrils without any similarity in their primary sequences. More than 
20 different types of proteins are known to form amyloid fibres in vivo (Merlini & 
Vittorio  et  al.,  2003)  (Table  1.1).  In  some  cases  amyloid  formation  is  non-
pathological. On the other hand some of them cause diseases so the nature of the 
amyloid is not well understood up to now (Jahn & Radford, 2008). 
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Table 1.1 Amyloidogenic proteins involved in human disease (Merlini & Vittorio, 
2003). 
 
1.1.1 A history of amyloid 
 
Amyloid  (Virchow,  1854)  was  first  observed  as  microscopic  tissue  deposits 
originally thought to be cellulose. It was characterised as starch as it stained with 
iodine.  In  1859,  Freidreich  and  Kekulé  demonstrated  that  amyloid  is  also 
proteinaceous in nature. Further microscopic study showed that amyloid is fibrous 
(Cohen & Calkin, 1959) and amyloidosis as a pathology was first described in 
1952 by Andrade and Falls (Falls et al., 1955). 
 
Under the microscope it became apparent that amyloid fibrils accumulating in the 
tissues  of  different  organs  have  a  similar  structure  and  morphology  (Cohen  & 
Catkin, 1964). The composition of the amyloid fibrils was analysed later in 1968. 
The first amyloid fibrils constituent protein was transthyretin (TTR) or prealbumin   5 
(Costa, 1978, Skinner et al., 1982) but other circulatory proteins were discovered 
later  on  (Sipe,  1992,  1994)  including  serum  amyloid  P  component  (SAP), 
apolipoprotein  E  (ApoE),  proteoglycans  and  among  carbohydrates,  a  heparin 
sulphate as being the most common. It was later noted that amyloid fibres could 
be formed even in the absence of bound circulatory proteins (Pepys et al., 1996). 
Different pathways of protein mis-folding and amyloid formation have also been 
suggested. Protein folding and inter-conversion between the partially denatured 
states and the fibrillar state is affected by chaperone activity, cellular stress and 
impaired  cellular  machinery  due  physico-chemical  factors  and  genetic  defects 
(Chiti & Dobson, 2006).  
 
1.1.2 Structure of amyloid fibrils 
 
Enormous efforts have been made in the last decade to determine the structure of 
amyloid  fibrils  using  transmission  electron  microscopy  (TEM),  atomic  force 
microscopy (AFM), solid state NMR (ssNMR) and X-ray crystallography (Sunde & 
Blake, 1997; Serpell et al., 2000; Harper et al., 1997). 
 
A ssNMR study on Aβ
1-40 amyloid fibrils in combination with scanning TEM and X-
ray  diffraction  revealed  that  they  are  made  up  of  protofilaments.  Each  single 
protofilament has a cross β-sheet in which two β-sheet layers are separated by 
~10Å (Petkova et al., 2002; Goldsbury et al., 2000) with a distance between the 
beta strands of  ~4.7Å (Blake & Serpell, 1996) (Figure 1.2). These findings helped 
to interpret the earliest X-ray fibre diffraction study of amyloid fibrils (Burge, 1963). 
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Figure 1.2 The structure of amyloid fibrils formed by different proteins. Amyloid 
fibrils  are  composed  of  crossed  beta-sheet  protofilaments.  Different  techniques 
including X-ray fibre diffraction, TEM and polarised light microscopy have been 
used to analysed amyloid fibrils (Merlini & Vittorio, 2003) 
 
1.1.3 Pathology of amyloids 
 
It has been assumed that the fibrils detected in pathological amyloid deposits are 
responsible for cell toxicity (Stefani & Dobson, 2003). Several hypotheses have 
been  proposed  which  suggested  the  relation  of  amyloid  deposition  and  the 
disruption  of  organ  functions.  The  location  of  amyloid  deposition  also  plays  an 
important role in disease progression. There are certain amyloid-forming proteins 
which  deposit  in  specific  organs  of  the  human  body  and  damage  them  (the 
localised amyloidosis), e.g. β2-microglobulin deposits in joints, V30M transthyretin 
variant in the peripheral nerves and α-fibrinogen in the kidney (Merlini & Vittorio, 
2003; Benson et al., 1993). 
 
Recent  studies  reveal  that  oligomeric  species  present  in  solution  before  the 
amyloid fibril formation are more toxic to the cells than the mature amyloid fibrils   7 
(Stefani & Dobson, 2003). More specifically, experimental observations support 
this hypothesis in the case of Aβ
1-42 peptide in Alzheimer’s disease, transthyretin 
and α-synuclein protofilaments  (Conway et al., 2000; Bhatia et al., 2000; Nilsberth 
et al., 2001; Sousa et al., 2000). The exact reason for protofilaments toxicity is not 
known but different studies have suggested a number of possible mechanisms. An 
in-vitro study revealed that the protofilaments of amyloid fibrils could affect the 
intracellular redox potential, which may generate reactive oxygen. This process 
leads  to  mitochondrial  damage  and  ultimately  cause  cell  apoptosis  (Kourie  & 
Henry,  2002;  Kawahara  et  al.,  2000).  Another  study  proposed  that  exposed 
hydrophobic regions of fibrillar protofilaments might interact with the cell/plasma 
membrane  leading  to  non-specific  ion  channel  formation  and  subsequent  cell 
death (Kourie & Shorthouse, 2000).  
 
1.2 Intrinsically unstructured proteins, molecular chaperones and 
amyloidosis  
 
A recent study revealed that more than 30% of eukaryotic proteins are intrinsically 
disordered  (also  called  intrinsically  unstructured  or  natively  unfolded  proteins). 
These unstructured proteins also act as molecular chaperones and have diverse 
functions ranging from transcriptional to translational regulation in the cell. They 
are also involved in signal transduction, protein phosphorylation and in the self-
assembly  of  large  multimeric  proteins  (Dyson  &  Wright,  2005).  Surprisingly, 
despite being unstructured, this class of proteins are still biologically active. This 
argument is against the view that the function of a protein depends upon a well 
defined structure (Fink, 2005). 
 
Intrinsically  disordered  proteins  may  be  divided  into  two  groups  based  on  the 
extent of the disorder, i) the natively disordered and ii) the partially disordered. The 
natively disordered proteins are further subdivided into two classes, one with no 
secondary structure and the second with few secondary structures (also called 
molten globules).  
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A recent study reveals that the proteins susceptible to misfolding and amyloid fibre 
formation  belong  to  the  intrinsically  disordered  group  e.g.  Aβ
1-42  peptide  of 
Alzheimer’s disease, Prp of prion disease, α-synuclein of Parkinson’s disease, the 
exon 1 region of Huntington’s which all contain long unstructured regions. (Linding 
et al., 2004). 
 
Furthermore, some of the intrinsically disordered proteins also function as RNA 
chaperones which have smaller disordered regions than amyloidogenic proteins. 
The  disordered  regions  of  chaperones  may  interact  with  a  wide  range  of 
ligands/misfolded proteins (Tompa & Csermely, 2004). 
 
1.3 Molecular chaperones, protein refolding and degradation 
 
Molecular chaperones are proteins that interact non-covalently with other proteins 
to assist in their folding without taking any active part in their biological functions 
(Ellis  &  Hemmingsen,  1989).  Different  molecular  chaperones  like  heat  shock 
protein40 (Hsp40), heat shock protein70 (Hsp70), heat shock protein90 (Hsp90), 
GroEL and GroES proteins are present in the cell (George et al., 2000). 
Why do molecular chaperones exist in the cell when it has been established that 
the amino acid sequence of a protein contains all of the information required for its 
correct  folding  (Anfinsen,  1973).  One  reason  may  be  the  highly  crowded 
intracellular  protein  environment  (~200-400  mg/ml)  in  which  the  nascent 
polypeptide  is  exposed  to  many  non-specific  protein  interactions.  These  non-
specific  interactions  could  interfere  with  correct  folding  (Ellis,  1996).  Molecular 
chaperones are also involved in the trafficking of many proteins to their correct 
locations within the cell. Chaperones may be divided into two classes according to 
their size and each class performs different functions within the cell (Hartl, 1996; 
Martin & Hartl, 1997; Martin, 1997). Small co-chaperones include DnaJ (Hsp40) 
and DnaK (Hsp70). DnaJ activates the ATPase activity of DnaK. DnaJ belongs to 
the J domain family and recognises the nascent or mis-folded protein and escorts 
it to DnaK for refolding and assembly (Wall et al., 1994). Both chaperones prevent 
non-specific  interactions  between  the  hydrophobic  residues  of  the  nascent 
polypeptide  and  act  as  anti-aggregation  agents  (Ellis,  1996).  The  larger   9 
chaperones include Hsp90, the GroEL/GroES family of chaperonins in E.coli and 
their homologs Cpn60 and Cpn10 in the chloroplast of higher plants. These larger 
chaperones are needed to assist the folding of longer nascent polypeptide chains 
(>30 kDa) (Horwich et al. 1993; Horwich & Willson, 1993; Ellis, 1996). 
More recently, HsJ1, another member of the J domain co-chaperone family has 
been  discovered.  HsJ1  recognises  and  delivers  misfolded  proteins  to  the 
ubiquitin/proteosome  complex  for  degradation  (Westhoff  et  al.,  2005). 
Furthermore, another co-chaperone protein called C terminus of Hsp70-interacting 
protein (CHIP) has been discovered to negatively regulate the refolding activity of 
chaperones (Connell et al., 2001; Ballinger et al., 1999). CHIP also interacts with 
large  chaperones  to  switch  the  activity  from  protein  refolding  to  protein 
degradation (Arndt & Höhfeld, 2007). Molecular chaperones check the quality of 
intracellular  protein  folding.  However,  in  higher  multicellular  organisms,  many 
proteins are secreted out of the cell into the extracellular environment and very few 
protective and repair mechanisms are known to stabilize the native state in this 
environment (Stefani and Dobson, 2003). 
 
1.4 The role of TTR and SAP in amyloidosis 
 
SAP  is  a  universal  constituent  of  amyloid  fibrils  in  different  human  diseases 
(Pepys, 2006). Chaperone activity of SAP has been determined previously (Coker 
et al., 2000) and this may account for its binding to amyloid. SAP not only binds 
and stabilizes amyloid fibrils but it also protects them from proteolytic degradation 
and clearance from the body. The binding of SAP to amyloid is calcium dependent 
(Tennent  et  al.,  1995).  The  disruption  of  the  SAP-amyloid  recognition  site  with 
different drug compounds has already been considered as a potential therapy for 
amyloidosis.  
 
On the other hand, TTR is well known as an amyloidogenic protein. There are 
more than 100 different TTR gene variants (Costa et al., 1978). Interestingly, the 
native  as  well  as  variant  TTR  molecules  are  implicated  in  amyloidosis.  The   10 
stabilisation of variant TTR could be a potential target to cure different types of 
amyloidosis. According to recent statistics approximately 10,000 people worldwide 
are suffering from inherited TTR amyloidosis (Pepys, 2006) including the ~25% of 
the elderly over the age of 80 years who are affected by native TTR related senile 
systemic amyloidosis (Cornwell et al., 1983; Pitkanen et al., 1984).  
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1.5 Thesis summary 
 
In the research presented in this thesis I have worked on several different proteins. 
Chapters 1 describes the introduction and section described in chapter 2 and 3 
represents the properties of SAP and use of X-ray crystallography to determine 
the three dimensional structure of SAP with different alkyl phosphonate ligands 
bound to understand the role of head group geometry and alkyl chain length in 
ligand binding. In chapter 4 I describe the use of isothermal titration calorimetry 
(ITC) to determine the binding affinity of SAP to these alkyl phosphonate ligands. 
 
I have also presented the studies on two amyloidogenic TTR mutants, first the 
L55P TTR, which is rare but the most toxic. The second V30M TTR mutant is a 
very common variant in humans. In chapters 5 and 6 I summarize the current state 
of TTR research and approaches to ligand stabilization of the molecule to inhibit 
fibrillogenesis.  X-ray  structures  of  L55P  and  V30M  TTR  bound  to  the  bivalent 
compound Mds84 are presented. 
 
Also presented is research on the bacterial protein BipD (Burkholderia invasive 
protein  D),  which  belongs  to  the  type  III  secretion  system  of  Burkholderia 
pseudomallie.  BipD  contributes  to  the  development  of  melioidosis  disease  in 
humans.  In  ITC  studies  BipD  displayed  significant  affinity  for  phosphocholine, 
which is a head group present on cell membranes. 
 In chapter 7 I describe the expression and purification of recombinant BipD and its 
co-crystallization  with  phosphocholine.  Unfortunately  phosphocholine  was  not 
bound to BipD in the crystal but the structure presented is of the highest resolution 
determined to date.  
 
The final chapter describes work on the expression of recombinant ATJ11, a J 
domain co-chaperone, in E.coli. Refolding and solubilisation of ATJ11 inclusion 
bodies allowed the determination of its secondary structure by circular dichroism. 
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Chapter 2 
Introduction to the pentraxin protein family   13 
2 Introduction 
 
2.1 The pentraxin family and Serum amyloid P and C-reactive 
protein  
 
Serum amyloid P (SAP) component belongs to the pentraxin family, which plays 
an important role in innate host immunity (Agrawal et al., 2009). The family is a 
classic example of evolutionarily conserved multimeric structures (Deban et al., 
2008), which is further subdivided into two classes based on the protomer size. 
The short pentraxins include the structurally homologous C-reactive protein (CRP) 
and  Serum  amyloid  P  component  protein  (SAP).  The  long  pentraxins  are 
composed of pentraxin domain at the C-terminal end and an unrelated N-terminal 
domain.  Interestingly,  some  of  the  large  pentraxins  have  some  what  different 
structures to the short pentraxins e.g. PTX3 is a long pentraxin sub-group which is 
different from the short pentraxin in terms of structure, mode of interaction and 
source of production (Garlanda et al., 2005). The long pentraxins were initially 
identified as cytokine-inducible molecules expressed in macrophages, dendrites 
and endothelial cells (Agrawal et al., 2009). But short pentraxins CRP and SAP 
are secreted by the liver in response to the cytokine interleukin-6 (IL-6) in mice. 
The secretion of pentraxins and their roles in innate immunity are summarized in 
the Figure 2.1. 
 
The term “pentraxin” was originally coined by Alex Osmond and Henry Gewurz in 
1977. Both researchers independently discovered the homologous N-terminii of 
SAP  and  CRP  (Osmand  et  al.,  1977).  The  pentameric  nature  of  both  protein 
complexes gave rise to the name pentraxin, derived from the Greek penta (five) 
and ragos (berries).  
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Figure 2.1 Pentraxin production in mice is stimulated by the protective mechanism 
of the innate immune system (Bottazzi et al., 2006). 
 
C-reactive  protein  was  first  discovered  in  1929  as  an  acute  phase  protein  in 
humans (Tillett & Francis, 1930) and Haupt discovered SAP much later in 1965. 
SAP  was  initially  characterised  as  a  9.5  α-glycoprotein.  Sequence  analysis 
revealed that SAP and CRP share 60% sequence homology (Skinner et al., 1982) 
and electron microscopy revealed indistinguishable cyclic disc-like configurations 
of (Figure 2.2). 
 
Both SAP and CRP like proteins are present in the blood plasma of all vertebrates 
and in the hemolymph of some of invertebrates such as Limulus polyphemus and 
Achatina fulica.  
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Figure  2.2  The  negatively  stained  electron  micrograph  showed  the  disc  like 
structures of human SAP in panel (a) and CRP in panel (b) (Dr Munn, EA, ARC 
Institute of Animal Physiology, Babraham, presented in Pepys et al., 1978). 
 
The SAP and CRP homologues in invertebrates are also thought to be involved in 
the host defence system against pathogens (Deban et al., 2008). Both proteins 
were first purified from rat serum by calcium-dependent affinity chromatography 
(De  Beer  et  al.,  1981).  SAP  and  CRP  have  the  ability  to  bind  different  ligand 
moieties  calcium  dependently  (Schwalbe  et  al.,  1992).  However,  despite  their 
sequence  homology  and  calcium  dependent  ligand  binding,  their  mode  of 
regulation in different species is not identical. For example, human CRP acts as an 
acute phase protein and its level rises sharply during the inflammatory response, 
while  the  SAP  protein  level  remains  constant  under  all  the  circumstances. 
Interestingly, mouse SAP does act as an acute phase protein during inflammation 
reaction (Pepys et al., 1979).  
 
The concentration of human CRP in the healthy individual is ~ 0.8mg/L of blood 
plasma  but  may  rise  to  500mg/L  during  inflammation.  On  the  other  hand  the 
concentration of SAP remains constant in healthy human being (~33mg/L). High 
levels  of  SAP  have  been  detected  in  macroglobulinaemia  patients  and  it  is 
possible that the SAP interacts with IgM antibody or that the elevated levels are 
due  to  the  existence  of  some  unknown  interruption  in  the  pathway  of  SAP 
catabolism  (Pepys  et  al.,  1982).  The  exact  role  of  SAP  in  humans  is  not  well 
understood  apart  from  the  chromatin-binding  role  in  autoimmune  disease. 
However, SAP is a universal component of all kinds of amyloid deposits.  
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In humans, the main source of production of CRP and SAP is the liver (Hurliman 
et al., 1966) although CRP production has also been reported in other tissues 
(Jabs  et  al.,  2005).  Trace  amounts  of  SAP  have  also  been  identified  in  the 
vascular basement membrane of human tissues (Dyck et al., 1980) and in the 
fibroblasts under different circumstances (Breathnach et al., 1981).  
 
2.1.1 Serum amyloid P component (SAP) protein  
 
Serum  amyloid  P  component  (SAP)  protein  is  a  plasma  glycoprotein.  It  is 
composed of 204 residues with a molecular weight of ~ 25 kDa and the precursor 
of  SAP  includes  an  approximately  20-residue  signal  peptide.  SAP  was  first 
discovered as the α-globulin (Cathcart et al., 1965) and found in amyloid deposits 
by Bladen and co-workers in 1966. It exists as a non-covalently bound pentameric 
complex in the circulation with molecular weight of ~ 125 kDa. SAP can also exist 
in  decameric  form  (Srinivasan  et  al.,  1994)  depending  upon  the  pH  and  salt 
strength (Wood et al., 1988; Pepys, 1988). SAP possesses the conserved HXCXS 
or T/TWXS or T pentraxin motif, also called the pentraxin “signature sequence” 
(Garlanda  et  al.,  2005)  (Figure  2.3).  The  pentraxin  signature  sequence  is 
conserved throughout evolution and can be traced from the horseshoe crab to 
humans (Deban et al., 2009). The Cys36 present in the pentraxin motif forms a 
disulfide bond with Cys95 of the SAP protomer. Calcium saturated SAP is very 
stable and insensitive to proteolytic cleavage (Kinoshita et al., 1992). SAP binds to 
negatively charged ligands in a calcium-dependent manner (Osmand et al., 1997). 
 
Figure 2.3 The location of the conserved pentraxin “signature sequence (in red) of 
SAP (Garlanda et al., 2005). 
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Sequence  alignment  of  human  SAP  with  pig,  rat,  mouse  and  CRP  of  pig,  rat, 
mouse,  chicken  and  rabbit  demonstrates  conservation  of  the  pentraxin  motif 
across these species (Figure 2.4).  
A 
 
 
B 
 
Figure 2.4 Alignment of the sequences of human SAP with pig, rat and mouse 
SAP in panel A and human SAP with CRP of pig, rat, mouse chicken and rabbit 
using MULTIALIGN (High consensus sequences in red, low consensus in blue and 
neutral in black).  
 
2.1.2 SAP genetics 
 
The CRP gene (Whitehead et al., 1983) and the SAP (APCS) gene (Mantzouranis 
et al., 1985) are located adjacent to each other on human chromosome 1 (Floyd-
Smith et al., 1986). The SAP gene sequence is thought to have diverged after 
duplication of the CRP gene a million years ago. The similar size of cDNA of SAP 
and  CRP  suggests  that  both  genes  remained  closely  linked  through  out  the 
process of evolution (Mantzouranis et al., 1985). Both SAP and CRP proteins are 
found in human serum. Human CRP acts as an acute phase protein but human 
SAP acts as normal plasma protein while in mice SAP also acts as acute phase 
protein. SAP is encoded by two exons (Figure 2.5). The first exon encodes the   18 
signal peptide and also contains the first two amino acids of the mature protein. 
The  second  exon  encodes  the  remainder  of  the  204  residues  of  protein. 
Interestingly,  the  CRP  and  APCS  genes  are  located  near  the  genes  encoding 
histones  3  (H3)  and  4  (H4)  (Green  et  al.,  1984)  and  both  the  proteins  have 
significant affinity for chromatin (Robey et al., 1984). 
 
 
Figure 2.5 The human SAP (APCS) gene structure 
 
In-vitro studies in cultured mouse hepatocytes demonstrated upregulation of SAP 
gene expression by interleukin1, 6 and tumour necrosis factor-α (Zahedi et al., 
1993), but in humans, SAP gene expression and regulation is not well understood. 
 
2.1.3 The crystal structure of SAP 
 
X-ray  structures  of  human  SAP  in  complexes  with  calcium  and 
phosphoethanoloamine (PE) and methyl 4,6-O-(1-carboxyethylidene)-β-D-galacto-
pyranose (MOβDG) were determined at 2.0Å resolution by X-ray crystallography 
using  multiple  isomorphous  replacement  (MIR)  to  solve  phase  problem.  The 
crystals were obtained at acidic pH and grew in the P21 space group (Emsley et 
al.,  1994).  Later  structural  studies  characterised  the  interaction  with  dAMP  
(Hohenester et al., 1997), GABA (Pye, 1997), N-acetyl proline (Purvis, 2002) and 
(R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic  acid 
(CPHPC)  (Pepys  et  al.,  2002).  All  of  these  studies  consistently  reveal  the 
existence of pentameric SAP, composed of five identical protomers. Each SAP 
protomer possesses 15 β-strands named A to O (Figure 2.6) which adopt a β jelly-
roll  like  topology  similar  to  that  of  the  legume  lectin  conconavalin  A,  despite 
sharing only 11% sequence identity.   19 
 
Figure 2.6 The β-jellyroll structure of human SAP with a single α-helix (yellow in 
colour at the A face) (Emsley et al., 1994: 1SAC.pdb). 
 
One face of each subunit (the B face) is more concave due to beta sheet twist. 
This face acts as the binding face. The opposing face (the A face) is flatter and is 
the effector face. The A face has one α-helix packed against the β-sheet structure  
(Emsley et al., 1994) (Figure 2.7).  
 
The SAP protomers interact with each other to form the pentamer. There are three 
salt bridges and hydrogen bonding between the main chains and the side chains 
in addition to some other interactions. The majority of interactions involve the G, I, 
J strands of one protomer with the N-terminal and loop regions of the neighbouring 
protomer  (Gewurz  et  al.,  1995).  The  burial  of  approximately  3.1%  of  the  total 
protomer  surface  area  in  the  pentameric  assembly  makes  the  structure  into  a 
stable plasma protein. Each SAP protomer possesses an intra-molecular disulfide 
bond (Cys36-Cys95) located just below the α-helix of face A, which adds further 
structural  stability.  As  discussed  in  the  previous  chapter,  each  human  SAP 
protomer also posseses a long N-linked sugar chain covalently attached to Asn32 
(Emsley et al., 1994).   20 
The detailed X-ray structural studies demonstrate that the SAP pentamer has a 
diameter of ~100Å with a central depth of ~35Å and the central cavity is ~ 20Å in 
diameter (Emsley et al., 1994)                                                                                       
 
 
 
Figure  2.7  Different  views  of  the  SAP  pentamer,  1)  The  A  face  with  α-helices 
depicted  in  green.  2)  The  B  face  showing  the  five  calcium  binding  sites  with 
calcium ions depicted in yellow. 3) A side view (Emsley et al., 1994; 1SAC.pdb). 
 
2.1.4 Calcium dependent ligand binding of SAP  
 
Each SAP protomer possesses a calcium binding site at the B face which binds 
two calcium ions ~ 4 - 4.3Å apart. The positively charged calcium ions are held at 
the  site  by  the  electrostatic  interactions  created  by  an  evolutionarily  conserved 
motif (Figure 2.8).   21 
                    
 
Figure 2.8 The calcium-binding site at the B-face of the SAP protomer interacting 
with PE in the presence of two calcium ions (depicted in yellow) (Mikolajek, 2008) 
 
One  calcium  ion  coordinates  with  the  side  chain  oxygens  of  Asp59,  Glu136, 
Asp138  and  the  main  chain  carbonyl  of  Gln137  in  a  pentagonal  bipyramidal 
arrangement. The other calcium ion co-ordinates with the side chain oxygens of 
Glu136,  Asp138,  Gln148,  the  ligand  phosphate  and  two  water  molecules.  The 
second  calcium  has  fewer  co-ordination  partners  and  is  more  loosely  attached 
than the first and is easily displaced by other bivalent metal ions such as cerium 
(Emsley et al., 1994), zinc and manganese (Gill et al., unpublished). This loosely 
bound calcium ion is also susceptible to being washed away in calcium free buffer. 
Apart from its role in ligand binding, calcium ions also protect SAP from proteolytic 
cleavage. It may be possible that this is due to tighter packing of the exposed 
surface loop regions of the subunit, which prevent their exposure to the solvent 
contents  (Gewurz  et  al.,  1995).  Previous  studies  have  confirmed  that  in  the 
absence of calcium, proteolytic cleavage occurs between residues 144 and 145 
(Kinoshita et al., 1992). Along the calcium-binding pocket on the B face, a small 
hydrophobic pocket is also formed by the contribution of the side chains of Leu62, 
Tyr64  and  Tyr74.  This  hydrophobic  pocket  acts  as  the  binding  site  for  the 
hydrophobic components of different ligands (Pepys et al., 2002). 
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2.1.5 Functions of SAP  
 
The  importance  of  SAP  in  the  immune  defence  mechanism  of  mice  is 
demonstrated  in  sap-/-  mice,  which  showed  delayed  and  reduced  amyloid 
deposition (Botto et al., 1997). The SAP knockout mice developed autoimmune 
disease and glomerulonephritis. Although SAP is known to bind to many types of 
bacteria, it is also possible that SAP prevents autoimmune activity by binding to 
exposed chromatin after cells death (Bickerstaff et al., 1999). Like human CRP, 
SAP is also known to bind to C1q and activate the protein of the complement 
system, specifically by binding to the collagen-like region of C1q (Ying et al., 1993; 
Hicks et al., 1992). An in-vitro study revealed that SAP also forms non-covalent 
complexes with C4 binding protein (C4bp) and SAP has been speculated to play 
an  active  role  in  the  regulation  of  the  classical  complement  pathway  in  vivo. 
Another in vitro study showed that human SAP binds to and is internalized by 
neutrophils  and  macrophages,  ultimately  being  degraded  into  small  peptides 
(Landsmann et al., 1994).  
 
2.1.6 Calcium dependent aggregation property of SAP 
 
SAP  aggregates  at  physiological  concentrations  of  calcium  (~3mM),  the 
precipitation  not  requiring  any  additional  co-factors  (Baltz  et  al.,  1982).  The 
precipitation  of  SAP  is  thought  to  arise  from  the  stacking  of  the  pentameric 
complexes into long polymers.  The carboxylate of Glu167 positioned on the A-
face  α-helix  interacts  with  the  B-face  of  an  adjacent  pentamer  in  a  calcium-
dependent manner (Emsley et al, 1994). Substitution of Glu167 with an uncharged 
residue prevents the calcium dependent aggregation of SAP. Precipitated SAP 
can be solubilised into active state by the addition of the metal chelator EDTA 
(Pepys et al., 1996). 
 
More  recent  studies  have  demonstrated  the  increased  stability  of  SAP  at  non-
physiologically high calcium levels of 200 mM and above. At these concentrations, 
dissociated chloride ion levels are high enough to compete with Glu167 of SAP for   23 
the  calcium  ions,  which  stop  the  stacking  process  of  SAP  (Pepys  et  al,  2002) 
(Figure 2.9). The stability of the SAP pentamer is further enhanced at high ionic 
strength.  The  SAP  stays  in  solution  in  700mM  sodium  chloride  even  in  the 
presence  of  physiological  levels  of  calcium  (Prof  Steve  Wood,  personal 
communication).  Although  in  vitro  studies  suggest  that  the  calcium-dependent 
aggregation of SAP might yield amyloid deposits (Pinteric & Painter, 1979; Painter 
et al., 1982), in vivo studies in mice did not demonstrate SAP aggregation in a 
manner similar to that observed in human amyloid deposition (Baltz et al., 1982). 
Interestingly,  unlike  SAP,  the  structurally  similar  CRP  molecule  does  not 
aggregate in the presence of calcium ions. Structural analysis reveals that each 
CRP  protomer  is  twisted  ~22º  towards  the  pentameric  five-fold  axis  when 
compared to the SAP protomer. This has the effect of directing the dipole of the α-
helix  of  CRP  away  from  the  calcium-binding  site  of  the  neighbouring  CRP 
pentamer (Thompson et al., 1999).  
 
2.1.7 SAP as an amyloid binding protein 
 
More  than  20  different  human  proteins  are  amyloidogenic  (Westermark  et  al., 
1998)  and  SAP  is  detectable  in  all  of  these  amyloid  deposits  (Pepys,  2005). 
Furthermore,  the  universal  presence  of  SAP  in  amyloids  is  also  detected  in 
different species like mice (Baltz et al., 1980), guinea pig (Skinner et al., 1976) and 
cattle  (Pepys,  2005).  SAP  accounts  for  ~15%  of  the  mass  of  amyloid  and  its 
protective  and  stabilising  role  is  well  established  (Tennent  et  al.,  1995).  SAP 
extracted from amyloid is indistinguishable from normal plasma SAP (Skinner et 
al., 1982). The electron micrograph of SAP stacked on to the amyloid fibrils is 
shown in Figure 2.9. 
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Figure 2.9 A negatively stained electron micrograph demonstrating stacking of 
SAP pentamers upon amyloid fibres extracted from spleen of patients suffering 
from primary and secondary amyloidosis (Shirahama & Cohan, 1967). 
 
Other  major  constituents  of  amyloid  are  heparan  sulfate,  dermatan  sulfate 
proteoglycan  and  glycosaminoglycan.  These  polysaccharides  may  also  play  an 
important  role  in  the  formation  and/or  stability  of  amyloid.  It  has  been 
demonstrated  that  SAP  protein  binds  to  glycosaminoglycan  in  a  calcium 
dependent  manner  (Tennent  et  al.,  1995).  It  is  likely  that  the  amyloid  deposits 
involved  in  different  diseases  share  a  common  structural  configuration,  which 
binds SAP. 
 
2.1.8 Characterisation of SAP-ligand interactions 
 
The calcium dependent interaction of SAP with agarose was first discovered in 
1977 (Pepys et al., 1977a, b). The calcium dependent binding of SAP to many 
other  natural  and  synthetic  compounds  has  been  characterized  (Baltz  et  al., 
1982a; Pepys et al., 1982a). The crystal structures of SAP complexes with dAMP  
(Hohenester et al., 1997), N-acetyl D-proline (Purvis, 2002), (R-1-[6-[R-2-carboxy-
pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic  acid  (CPHPC)  (Pepys  et 
al.,  2002),  O-phosphoethanolamine  (PE)  and  GABA  (Pye,  1997)  have  been 
determined. The high resolution structural information obtained from these studies   25 
has shed light on the possible binding modes of SAP to amyloid and facilitated the 
design of competitive inhibitors in amyloid therapy. 
 
Methyl  4,6-O-(1-carboxyethylidene)-β-D-galacto-pyranose  (MOβDG)  and  O-
phosphoethanolamine (PE) were first co-crystallised with SAP and their structures 
were determined at low resolution in acidic pH (Emsley et al., 1994). Subsequently 
the structure of the SAP-MOβDG complex was determined at high resolution at 
neutral pH (Thompson et al., 2002). The oxygen atoms of the MOβDG ring H-bond 
with the side chains of Asn59, Lys79, and Gln148 residues of SAP. The calcium 
ions played a central role in engaging the Gln148 and Asn59 for optimal ligand 
interaction.  The  bulky  methyl  group  of  MOβDG  rests  in  a  hydrophobic  pocket 
formed by Tyr74, Tyr64 and Leu62, which provided the stability for ligand binding 
(Thomson et al., 2002). PE binds to SAP in a manner similar to MOβDG, with the 
oxygen atoms of the phosphate head group bridging the two calcium ions and the 
amine group hydrogen bonding with side chains of residues Tyr64, Tyr74 and with 
Glu166  via  a  water  molecule.  The  interaction  of  GABA  with  SAP  is  also  very 
similar with the exception that the amine group allowed H-bonding with Tyr74 only 
(Pye, 1997). 
 
The crystal structure of the SAP complex with deoxy-adenosine monophosphate 
(dAMP) at 2.8Å demonstrated a new arrangement of the decameric form of SAP 
with B to B face stacking (Hohenester el al., 1997). The base of the dAMP ligand 
bound to the SAP protomer, stacks the base moiety of an adjacent dAMP ligand 
bound to neighbouring SAP pentamer. The negatively charged phosphate group 
coordinates the two calcium ions in a manner similar to PE and MOβDG with the 
pentose moiety hydrogen bonding with Gln148 and Tyr64. Uniquely, dAMP also 
interacts with the side chains of Asp145 and Ser147 residues. The conformation of 
this new decameric SAP-dAMP complex was further investigated by gel filtration 
(Wood et al., 1988). The free energy of stacked dAMP was determined to be ~ 2-6 
kcal/mole (Friedman & Honig, 1995; Norberg and Nilsson, 1996). The formation of 
the SAP-dAMP decamer engages all of the calcium-dependent ligand binding sites 
on both pentamers. 
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2.1.9 SAP as a therapeutic target 
 
Approximately 100,000 different compounds from the Roche library were screened 
for inhibition of SAP binding to amyloid. Serendipitously, oxidation of Captopril and 
similar compounds during storage led to disulfide cross-linking of the molecule into 
a  palindromic  compound  with  enhanced  inhibition  activity  (Figure  2.10).  This 
incident further provided an idea to develop palindromic N-acetyl D-proline as a 
lead compound (Pepys, 2007).  
                          
Figure 2.10 a) CPHPC compound structure and b) The crystal structure of SAP in 
decameric formation in complex with CPHPC compound (Pepys, 2007). 
 
A similar palindromic compound with two cis-D-proline head groups linked by 4-
carbon  linker ( R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-
carboxylic acid (CPHPC)) was subsequently developed (Pepys et al., 2002). The 
nanomolar  affinity  of  CPHPC  for  SAP  (~10nM)  can  compete  strongly  for  the 
amyloid binding site of SAP (Hawkins et al., 1991). X-ray structure of the SAP-
CPHPC  complex  at  3.3Å  demonstrated  the  formation  of  B-to-B  face  decamer 
(Pepys et al., 2002). The CPHPC terminal carboxylates bridged the two calcium 
ions of SAP. The hydrophobic pocket of SAP was composed of Tyr74, Tyr64 and 
Leu62, which was occupied by the bulky pyrrolidine ring of CPHPC (Figure 2.11). 
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Figure  2.11  The  detailed  interaction  of  CPHPC  head  group  with  the  calcium-
binding site of SAP. The diagram showed the carboxylate of CPHPC interacts with 
two  calcium  ions  and  the  pyrrolidine  ring  dipped  in  the  hydrophobic  pocket, 
composed of side chains of Tyr64, Tyr74 and Leu62, of SAP.  
 
2.2 Aims of the research 
 
Serum Amyloid P component is universally present in all amyloid deposits and 
contributes significantly to all types of amyloidosis. Ligand binding to the amyloid 
recognition  site  of  SAP  could  inhibit  binding  to  amyloid  fibrils  and  facilitate  the 
proteolytic cleavage and clearance of amyloid fibrils from tissues. All SAP ligands 
studied to date possess phosphate or carboxylate head groups. In this research I 
investigated  the  structural  aspects  of  ligand  binding  to  SAP,  in  particular  the 
importance of the alkyl chain length and the nature of the phosphorous head group 
of the natural ligand phosphoethanolamine (PE).  
 
In the next chapter the crystallographic analysis of the complexes of SAP with 2-
aminoethyl  phosphonate,  3-aminopropyl  phosphonate  and  4-aminobutyl 
phosphonate in the presence of calcium are described. Furthermore, the affinities 
of all these ligands were also determined by isothermal titration calorimetry.  
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Chapter 3 
The structural study of SAP and small alkyl 
phosphonic acid ligands   29 
3 Introduction  
 
3.1 The structural study of SAP and small alkyl phosphonic acid 
ligands 
 
Different  structural  studies  have  been  conducted  up  to  now  to  elucidate  the 
binding mode of SAP with different chemical ligands e.g. MOβDG (Emsley et al., 
1994),  CPHPC  (Pepys  et  al.,  2002).  SAP  is  a  universal  constituent  of  amyloid 
fibres and it binds to amyloid fibres. In addition it also protects and stabilises them 
from  the  natural  proteolytic  degradation  (Tennent  et  al.,  1995).  The  amyloid 
deposition in tissue causes a wide range of diseases in human like Alzheimer’s 
disease, amyloidosis and prion disease etc.   
 
SAP interacts with negatively charged carboxylate (CPHPC with KD=~10nm) or 
phosphate  (PE  with  KD=37µM)  head  group  calcium-dependently.  SAP  strictly 
prefers the phosphate and carboxylate head groups. A recent study revealed the 
structure of SAP in complex with PE at high resolution (Mikolajek, 2008). 
 
It  was  determined  that  the  phosphate  head  group  interacts  with  SAP  calcium- 
dependently and the amine group of the PE makes hydrogen bonds with Glu66 via 
a water molecule. But the geometric preference towards different head groups is 
not  well  understood.  In  this  study  I  explored  the  importance  of  the  phosphate 
moiety  of  PE,  which  is  a  natural  ligand  of  SAP.  Essentially,  I  replaced  the 
phosphate  head  group  with  phosphonate  to  understand  the  contribution  of 
phosphate towards the binding affinity top SAP.  
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Figure  3.1  The  structure  of  2-aminoethyl  phosphonic  acid  (AEPA),  O-
phosphoethanolamine  (PE),  3-aminopropyl  phosphonic  acid  and  4-aminobutyl 
phosphonic acid (ABPA), are shown in the diagram. 
 
Secondly,  different  lengths  of  alkyl  side  chains  (ethyl,  propyl  and  butyl)  were 
included  to  elucidate  the  role  of  the  amine  group  in  the  binding  affinity.  The 
chemical diagrams of alkyl phosphonate ligands are shown in Figure 3.1. This 
study can play a vital role to understand the strict head group geometry and could 
be used to design different potential chemical ligands to block amyloid recognition 
binding sites of SAP.  
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3.2 Methods and results 
 
3.2.1 Crystallisation of the SAP-chemical ligand complexes 
 
Purified  recombinant  human  SAP  was  kindly  provided  by  the  Centre  for 
Amyloidosis  and  Acute  Phase  Proteins,  The  Royal  Free  Hospital,  University 
College,  London.  The  2-amino  ethyl  phosphonic  acid  (AEPA),  3-amino  propyl 
phosphonic  acid  (APPA)  and 4 -amino  butyl  phosphonic  acid  (ABPA)  were 
purchased from Sigma-Aldrich. 
 
Several  different  crystallisation  techniques  exist  that  control  the  nucleated 
precipitation of a protein from a supersaturated solution to form a well-ordered 
protein crystal (Odahara et al., 1994). Supersaturation of the protein solution is 
achieved via the vapour diffusion method (Figure 3.2). Protein crystallisation is 
also  affected  by  the  presence  of  salt  and  the  choice  of  precipitant  e.g. 
polyethylene glycol. 
 
 
 
 
 
 
 
Figure 3.2 The hanging drop (vapour diffusion) method for protein crystallization 
(www.jenabioscience.com). 
 
In this study the hanging drop vapour diffusion method was used to crystallise 
human SAP in complex with the alkyl phosphonates 2-amino ethyl phosphonate, 
3-amino propyl phosphonate and 4-amino butyl phosphonate.  
 
The  2µl  of  SAP  (15mg/ml)  was  mixed  with  2µl  of  10  molar  excess  alkyl 
phosphonate  (in  10mM  Tris-HCl  pH  7.0,  140mM  NaCl).  4µl  of  reservoir  well   32 
solution containing the appropriate precipitant, salt and buffer was placed on a 
siliconised cover slip and the SAP-alkyl phosphonate mixture added. The cover 
slip was inverted and placed over a greased well containing 1ml of mother liquor, 
which formed the closed system. The diffusion of water from the hanging drop to 
the  reservoir  solution  gradually  increases  the  protein  concentration  in  the  drop 
towards the supersaturated state.  
 
The process of nucleation initiates crystal growth and growth continues in the post 
nucleation phase until it stops at the cessation stage. The phase diagram below 
illustrates  how  protein  and  precipitant  concentration  affect  the  crystallisation  of 
lysozyme. The slightest change in either parameter not only affects the rate of 
crystallisation but also the quality and size of the crystals obtained (Luft et al., 
1996,  1999).  The  concentrated  protein  attains  the  super-saturation  state  and 
crystal  growth  starts  by  nucleation  in  the  metastable  region  (Figure  3.3).  The 
process of nucleation is the starting point for crystal growth and the further growth 
is dependent on other thermodynamic conditions. In the process of crystal growth, 
protein molecules move from the protein solution by diffusion and convection (Lin 
et al., 1995, Pusey et al., 1988) and attach to the crystal surface in the form of 
layers. The crystal continues to grow until the soluble protein concentration in the 
drop falls below the supersaturation concentration (Durbin et al., 1986). At this 
point the transport of protein molecules to the surface of the crystal stops and 
crystal growth ceases. 
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Figure 3.3 A phase diagram shows the effects of protein and precipitant 
concentration on the crystallisation of the protein from the supersaturated state 
(www.jenabioscience.com). 
 
3.2.2 Optimization of SAP-ligand crystallization 
 
The crystals of SAP (15mg/ml) in complex with alkyl phosphonate (10mM) ligands 
were grown in 12-16% PEG550, 18% glycerol, 60mM Tris-HCl (pH 8.4), 140mM 
NaCl  and  20mM  CaCl2.  The  crystallization  recipe  was  optimized  around  the 
original conditions for the SAP-alkyl phosphonate complexes.  
 
The best single crystals of SAP-2-aminoethyl phosphonate were obtained in 16% 
PEG550, 18% glycerol, 60mM Tris-HCl (pH 8.2), 140mM NaCl & 20mM CaCl2. 
The best SAP-3-aminopropyl phosphonate and 4-aminobutyl phosphonate crystals 
grew under the same condition at the slightly lower pH of 8.2 (Table 3.1). The 
crystals appeared within 4 weeks at room temperature (Figure 3.4-6). 
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              PEG 550 (%) 
           12         14        16 
 
 
7.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60mM Tris-HCl 
(pH) 
 
 
 
 
 
 
 
 
 
 
 
8.2 
    Best crystals 
were found at 
this conditions 
                                                Glycerol 18%  
                                      10fold excess ligand, 20 mM CaCl2 /140mm NaCl 
    
Table  3.1  Optimization  of  SAP-alkyl  phosphonate  ligand  complex  (1:10  molar 
ratio) crystal growth by varying the precipitant (PEG550) concentration and the 
Tris-Cl buffer pH.  
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Figure 3.4 Crystals of SAP-2-aminoethyl phosphonate grown at pH 8.4 with size of 
approximately 70 µm. 
 
                              
Figure 3.5 Crystals of SAP-3-aminopropyl phosphonate grown at pH 8.2. 
 
                                                 
   Figure 3.6 Crystals of SAP-4-aminobutyl phosphonate grown at pH 8.2. 
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3.2.3 Crystal Freezing  
 
Protein  crystals  must  be  frozen  at  100K  to  reduce  free-radical  or  radiation  
damage  during  X-ray  data  collection.  Cryo-protectants  (e.g.  glycerol,  PEG550, 
MPD) are used to minimise crystal disruption and to prevent ice formation during 
the  cooling  procedure  (Garman  et  al.,  1999).  Fortunately,  the  SAP-alkyl 
phosphonate  co-crystallisation  conditions  already  included  the  cryo-protectants 
PEG550  (16%)  and  glycerol  (18%),  so  there  was  no  need  for  additional  cryo-
protectants. Selected SAP-alkyl phosphonate crystals were picked up with a fibre 
loop  and  quickly  dipped  into  liquid  ethane  and  then  immediately  into  liquid 
nitrogen.  The  frozen  crystals  were  transported  to  the  synchrotron  under  liquid 
nitrogen and maintained at cryogenic temperature with a stream of nitrogen during 
data collection.  
 
3.3 The Synchrotron radiation source 
 
X-rays are used for the three-dimensional structure determination of proteins. A 
protein crystal is made up of a continuous, well-ordered lattice. The X-rays are 
suitable  for  the  protein  structure  determination  because  they  have  short 
wavelength  of  approximately  1.0Å.  This  wavelength  is  suitable  for  the 
determination of protein structure since the atoms are arranged with inter-atomic 
distances of approximately 1.5Å.  
 
Traditionally the X-rays used for protein crystallography have been obtained from 
vacuum tubes and rotating anode sources. More recently, synchrotrons have been 
built to generate the X-ray radiation by high velocity electrons rotating in a circular 
ring. Synchrotron X-ray radiation intensity is much higher than that of in-house X-
ray source. The high intensity X-rays allows the collection of complete data sets in 
minutes rather than hours. 
 
The  European  Synchrotron  Radiation  Facility  (ESRF),  Grenoble  in  France  is  a 
third generation X-ray source. Powerful electromagnets accelerate the electrons, 
which  are  initially  generated  from  a  small  filament  and  then  injected  into  the   37 
evacuated  storage  ring.  The  wigglers  and  undulators  provide  the  additional 
bending  of  the  beam,  which  also  increase  the  intensity  of  the  radiation. 
Additionally, focussing mirrors and monochromators (silicon crystal) tangential to 
the  storage  ring  provide  the  monochromatic  X-ray  radiation  for  diffraction 
experiments (Figure 3.7). 
 
 
 
 
 
Figure 3.7 The diagram shows a synchrotron radiation source. Electrons with high 
velocity  are  held  in  the  circular  booster  synchrotron  and  then  injected  into  the 
storage  ring.  The  circular  path  of  the  electrons  is  maintained  with  the  help  of 
powerful magnets present around the storage ring. The X-ray radiation emitted 
tangentially is used for protein crystallography (www.lls.cells.es). 
 
 
   38 
 
3.4 Crystal diffraction 
 
The crystal is bombarded with X-rays and the diffraction recorded as reflections 
from planes of the crystal lattice. The crystal can be viewed as being composed of 
a  repeating  unit  cell  (with  dimensions  a,  b  &  c)  forming  the  real  lattice.  The 
reflections recorded at the detector fall at points inversely related to the real lattice 
spacings called reciprocal (h, k, l) lattice. The dimensions of the reciprocal lattice 
(diffraction  pattern)  are  the  Miller  indices:  a*∝1/a,  b*∝1/b  &  c*∝1/c,  (Rhodes, 
2000). 
 
The diffraction of X-rays by the electron clouds around the nuclei of the atoms in a 
protein crystal may be understood with the help of the Bragg’s law (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 The diagram shows Bragg’s law for the diffraction pattern 
(http://serc.carleton.edu).  
 
According to Bragg’s law, X-rays strike the plane of electron density in the protein 
crystal and the scattered X-rays generate reflections. The scattered X-rays will be 
in phase whenever the path difference between the electron density planes is a 
whole number of wavelengths (λ)  
 
                                         n λ = 2d sinθ   39 
 
Where λ is the wavelength, d is the distance between the planes and θ is the 
angle of scattering.  
 
The crystallographic unit cell is described by the length of the a, b and c axes and 
the three inter-axial angles (α, β, γ). The unit cell with different dimensions gives 
rise  to  seven-crystal  systems.  These  crystal  systems  form  four  lattices  called 
primitive  and  non-primitive  e.g.  primitive  (P),  centred  (C),  face  centred  (F)  and 
body centered or internal (I), that form 14 different lattice types (7 primitive and 7 
non-primitive) called Bravais lattices. The different combinations of Bravais lattices 
with  symmetry  operations  include  reflection  planes,  rotation,  inversions  and 
improper rotation and constitute the 230 space groups. The good news is only 65 
space groups are allowed for protein crystallography due to the L-isomers of the 
amino acids.  
 
The  simple  2-D  Bragg  construction  allows  for  a  basic  understanding  of  the 
diffraction phenomenon but is not sufficient to reconstruct the electron density in 
the 3-D crystal from the diffraction pattern (Figure 3.9). A more complete analysis 
is  based  upon  the  determination  of  scattering  structure  factors  (shown  below), 
which  have  the  information  of  the  intensities  of  the  reflections  and  the  relative 
phases of the diffraction spots. 
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Figure  3.9  The  human  SAP-2  aminoethyl  phosphonic  acid  crystal  diffracted  to 
~1.4Å resolution. Total 370 images were collected with 0.5° oscillations at ESRF 
beam  line  ID  14-2  (λ=0.931Å)  on  an  ADSC  Q4  charge  coupled  device  (CCD) 
detector.  
 
 
The structure factor Fhkl for diffraction from planes with reciprocal Miller indices 
(h,k,l) relates the amplitude and phase of the diffracted spot to the electron density 
(ρ) in real space (x, y, z). 
 
Rearranging the equation to express the electron density in terms of the structure 
factors requires an inverse Fourier transformation: 
 
 
 
 
It is possible to determine the intensity of the reflection by integrating the area 
under  the  diffracted  spot  profile  but  it  is  not  possible  to  determine  the  relative   41 
phase.  Different  methods  have  been  developed  to  solve  this  so-called  phase 
problem of X-ray crystallography. 
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3.5 Data processing of SAP-2aminoethyl phosphonic acid (AEPA) 
 
X-Ray diffraction data of SAP-2aminoethyl phosphonate co-crystal complex were 
collected  to  1.5Å  resolution  at  ESRF,  Grenoble,  France  on  beam  line  ID  14-2 
(λ=0.931Å) using an ADSC Q4 charge coupled device (CCD) detector.  
 
MOSFLM (Leslie, 1992), which is supported by CCP4 (Collaborative Computing 
Project  Number4,  1994)  was  used  to  autoindex  the  data.  For  auto-indexing 
MOSFLM searches the intensity peaks of the reflections recorded by the detector. 
The coordinates of peaks are used to determine the inter-diffraction spot vectors 
and eventually assign the Miller indices (h, k, l) to each reflection. The determined 
inter-diffraction spot vectors are matched to those expected for different Bravais 
lattices  and  symmetries.  Ultimately  a  unit  cell  is  selected  which  is  the  most 
consistent with the pattern. A penalty function describes the goodness of fit of the 
measured spot positions to the predicted ones (Powell, 1999). 
 
In  MOSFLM,  I  selected  different  images  of  diffraction  and  the  program  first 
calculated  the  smallest  cell  with  least  symmetry  and  later  on  found  different 
possible Bravais lattices (Table 3.2).  
 
Before processing the data in the selected unit cell, the detector distance, beam 
centre, crystal orientation and mosaicity were refined. The output reflection MTZ 
file is a list of the indexed (hkl) spots, their integrated intensities and standard 
deviations. 
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Table  3.2  Auto-indexing  penalty  Table  for  the  SAP-2  aminoethyl  phosphonate 
complex data processed by MOSFLM showing the unit cells and space groups 
consistent with the data. 
 
The  data  were  scaled  (all  image  intensities  put  on  a  common  scale)  and  the 
intensities  of  equivalent  reflections  were  merged  using  SCALA  of  the  CCP4 
program suite. The quality of the data is assessed by the values of Rmerge or Rsym. 
During  data  collection,  the  same  (symmetry-related)  hkl  reflection  may  be 
measured several times (called Multiplicity) and Rmerge or Rsym is a reliability factor 
that reflects the deviation in the intensities of symmetry related reflections, which 
ideally should be identical on different images (Evans, 2006). An acceptable value 
for  the  overall  Rmerge  is  below  20%  to  demonstrate  successful  integration  and 
scaling up of the data (Table 3.3).  
 
The  averaged  intensities  were  converted  into  mean  structure  factor  amplitudes 
using the program TRUNCATE (French & Wilson, 1978) of the CCP4 suite. The 
validity  of  the  space  group  determination  was  confirmed  by  analysing  the 
diffraction pattern symmetry in HKLVIEW (Bailey, 1994). 
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Space group        P2  
Unit cell (Å) 
              (º) 
a = 94.96, b = 69.21, c = 105.0 and the, α 
= γ = 90.0, β = 92.3 
Low resolution (Å)  43.94 
 
High resolution (Å)  1.50 
 
Rmerge (%)  6.9 (47.5) 
 
Total number of reflections  1114638 (126106) 
 
Total number unique reflections  264739 (36654) 
 
Mean ((I)/sd(I))  13.1 (1.9) 
 
Completeness (%)  98.3  (93.5) 
 
Multiplicity  4.2 (3.4) 
 
 
Table  3.3  Data  processing  statistics  for  the  SAP-2-aminoethyl  phosphonate 
complex crystal, which was scaled with SCALA. The data were processed up to 
1.5Å resolution.  
 
HKLVIEW demonstrated the systematic absence of odd indexed reflections along 
the k axis (0, k, 0) resulting from a translation of half a unit cell characteristic of the 
P21 space group (Figure 3.10). The systematic absence of reflections indicates 
that a screw axis is present, which rotates the protein molecule 180° showing 2-
fold symmetry and translate it half a unit cell dimension. The data were scaled up 
in the P2 space group with cell dimensions of a = 95.0Å, b = 69.2Å, c = 105.8Å, α 
=  γ  =  90.0°,  β  =  92.3º.    The  Matthews  coefficient  suggested  a  55.8%  solvent 
content (Matthews, 1968), with the presence of one SAP pentamer (~125 kDa) in 
the asymmetric unit.  
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a) 
                     
b) 
 
 
 
Figure  3.10  A  pseudo-precession  picture  of  the  processed  SAP-2  aminoethyl 
phosphonate  complex  data.  a)  The  hk0  plane  b)  the  systematic  absence  of 
reflections along the reciprocal k axis characteristic of a two-fold screw axis along 
the real b axis, which validated the P21 space group (generated in HKLVIEW). 
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3.5.1 Molecular replacement for calculation of phases 
 
In this method the phases are “borrowed” from a structurally homologous structure 
(the “search model”). In this method, the model is correctly positioned and oriented 
with respect to the unknown structure within the new asymmetric unit (Rossmann 
& Blow, 1962). Several different molecular replacement programs are available 
e.g.  MOLREP  (Vagin  &  Teplyakov,  1997),  X-PLOR/CNS  (Brünger,  1990),  and 
PHASER (Read, 2001), all making use of the Patterson function (Patterson, 1934): 
€ 
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The Patterson function (determined from the diffracted intensities but without the 
phases) is similar to the electron density map but it generates a map of inter-
atomic  vectors  (u,  v,  w)  in  Patterson  space  (Tollin  &  Cochran,  1964).  The 
interatomic vectors may be intra-molecular or inter-molecular vectors. The intra-
molecular vectors are those between the atoms of the same molecule whereas the 
intermolecular vectors are between the atoms of neighbouring molecules related 
by  crystallographic  symmetry.  The  correct  positioning  and  orientation  of  the 
molecules  is  determined  by  rotation  and  translation  functions.  In  the  rotation 
function, the model Patterson is rotated until it superposes on that of the unknown 
structure  determined  from  the  diffracted  intensities  (Crowther,  1972).  Once  the 
correct  orientation  of  the  molecule  is  determined,  the  position  of  the  protein 
molecule in the asymmetric unit can be calculated from the translation function 
based on inter-molecular vectors.  
 
The  quality  of  the  final  structure  is  measured  by  the  reliability  factor  (Rfactor), 
which compares its calculated structure factor amplitudes with the observed ones 
(Brϋnger et al., 1992).  
 
                                   
€ 
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A good initial molecular replacement solution should yield an Rfactor between 
approximately 30 to 40%.   47 
3.5.2 PHASER 
 
PHASER  (Read,  2001)  uses  the  maximum  likelihood  method  for  rotation  and 
translation  function.  The  maximum  likelihood  represents  the  best  agreement 
between  the  observed  diffraction  data  and  the  model  used  for  the  molecular 
replacement  after  the  rotational  and  translation  search  functions.  In  PHASER, 
structure factors are calculated by fast Fourier transform (FFT). With advanced 
computers, the likelihood function is used to determine the full six dimensional 
searches for all possible orientation and positions of the obtained solutions. This 
technique is very effective to determine the protein structure of high symmetry in 
asymmetric unit. The merit of the PHASER solution is reflected in the Z score with 
high log likelihood gain (LLG) (Table 3.4). 
 
PHASER was used to calculate the initial phases for the SAP-aminoethyl complex 
crystal structures with 1SAC.pdb (Emsley et al., 1994) as the search model. The 
calcium ions and water molecules were removed from the pdb file before using it 
as a search model. The rotation search was conducted using reflections in the 
2.46 - 43.95Å resolution range in all of the possible space groups. 
 
Number               LLG         RFZ Score     
(Rotational) 
    TFZ score 
(Translational) 
1  6361.37  43.7  57.3 
2  6159.32  41.2  54.5 
3  5991.92  43.4  45.5 
4  5828.53  41.5  52.7 
5  5689.40  40.0  46.8 
 
Table 3.4 Molecular replacement solutions found by the PHASER program after 
rotational  and  translational  search  of  SAP  in  complex  with  AEPA.  PHASER 
generated five best solutions without any steric clashes in the P21 space group 
with the LLG of 6361.37 with RFZ and TFZ scores of 43.7 and 57.3 respectively. 
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3.5.3 The crystal packing study 
 
 
The correctness of the molecular replacement solution was checked by visualising 
the crystal packing with the NUcheck program (Feng et al., 1998). Two pentamers 
of human SAP were found at the equivalent positions in the unit cell (Figure 3.11) 
as expected. 
 
 
 
Figure 3.11 Crystal packing of the human SAP-2-aminoethyl phosphonate ligand 
complex in the primitive monoclinic P21 space group (a = 94.9Å, b = 69.2Å, c = 
105.0Å and the, α = γ = 90.0°, β = 92.3°) and there is one pentamer (depicted 
green) in asymmetric unit cell and the symmetry related pentamer is shown in red. 
The diagram was generated using NUcheck (Feng et al., 1998).   49 
3.5.4 Refinement and model building of SAP-2aminoethyl 
phosphonate 
 
 
The molecular replacement solution provides a structure (the search model) that 
fits  the  experimentally  determined  electron  density  map.  The  process  of 
refinement minimises the difference between the observed (from the diffraction 
experiment) and calculated structure factor amplitudes (from homologous model). 
Different programmes e.g. SHELXL (Sheldrick & Schneider 1997), CNS (Brünger 
et al., 1998) and REFMAC (Murshudov et al., 1997) can be used to refine the 
model, most of them using cycles of reciprocal space refinement. The refinement 
cycles conduct the positional correction of atomic coordinates in real space and 
adjustment of the temperature factors of the atoms etc.  
 
Protein molecules involve a large number of atoms and hence improvement in the 
observation to parameter ratio is required. This can be accomplished either by 
adding additional observations or reducing parameters. The observations can be 
increased in the protein macromolecular structure by the addition of bond length, 
bond angle and torsion angle restraints. On the other hand the parameters can be 
decreased by the imposing constraints (defined by specific values of the structural 
features) on the diffraction data (Moras et al., 1991).  
 
Each  SAP  pentamer  was  initially  treated  as  a  rigid  body  (constrained)  and 
subjected to 10 cycles of refinement with REFMAC. Later on restrained refinement 
was carried out. The progress of refinement was monitored by the reduction in an 
Rfactor.  To  avoid  over-refinement,  which  may  result  from  a  low  observation  to 
parameter  ratio,  5%  of  reflections  were  set  aside  (chosen  by  the  program 
DATAMAN). This Rfree is an independent set which is not used in the structure 
refinement (Brunger, 1992). If the Rfree value does not decrease along with an 
Rfactor  after  each  refinement  cycle  then  it  implies  that  over-refinement  of  the 
structure has occurred. REFMAC generates sigma-A weighted Fo-Fc and 2Fo-Fc 
electron  density  maps  which  were  visualised  in  the  graphics  program  COOT 
(Emsley & Cowtan, 2004). In the first round of model building the main chain and 
side  chain  atoms  of  SAP  were  moved  to  fit  better  into  the  electron  density. 
Subsequent refinement and improvement of the phases with REFMAC revealed   50 
electron density for the two calcium ions and a 2-aminoethyl-phosphonate (AEPA) 
ligand at the SAP binding site (Figure 3.12-3.13). In addition, electron density for 
the  long  sugar  chain  (NAG-NAG-MAN-MAN-NAG-GAL-SIA)  attached  to  Asn32 
was also visible in B protomer of SAP. The coordinate (pdb) and reflection (cif) 
files were generated for AEPA and the sugar moiety using the PRODRG program 
(van Aalten et al., 1996) The AEPA and sugar co-ordinates were imported using 
COOT  and  modelled  into  the  electron  density  of  the  structure.  The  sugar  was 
attached to the nitrogen atom of the side chain of Asn32 using REFMAC (CCP4 
suite) (Figure 3.14). After several more rounds of refinement in REFMAC, 1294 
water molecules were added to the model. The refinement statistics are shown in 
Table 3.5 below. 
 
Figure 3.12 The Fo-Fc electron density (contoured at 2.0 σ) at the calcium-binding 
site of the human SAP-2-aminoethyl phosphonic acid complex structure (in green). 
The two calcium ions are depicted in yellow. 
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Figure  3.13  The  2Fo-Fc  electron  density  map  generated  by  REFMAC  at  the 
contour level of 2.0 σ (depicted in blue) for ligand 2-aminoethyl phosphonic acid. 
The two calcium ions are shown as yellow balls and the labelled residues are part 
of the calcium-binding pocket.  
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Figure 3.14 The long sugar chain (NAG-NAG-MAN-MAN-NAG-GAL-SIA) 
covalently bound to Asn32 (2Fo-Fc map countered at 2.0 σ). 
 
Resolution (Å) 
 
42.0- 1.5 
Number of reflections used for refinement 
 
215897 
Number of reflections as Rfree  
 
10794 
Rfactor (%) 
 
17.6 
Rfree (%) 
 
20.2 
RMS bond length deviation (Å) 
 
0.012 
RMS bond angle deviation (°) 
 
1.54 
 
Table 3.5 Refinement statistics for the SAP-AEPA X-ray structure. 
 
 
The  stereochemistry  of  the  refined  SAP-AEPA  structure  was  checked  with 
PROCHECK (CCP4 suite) and incorrect torsion angles were amended in COOT.   53 
The structure was also validated using the MOLPROBITY server (www.duke.edu). 
The average B-factor for the SAP-AEPA structure was ~ 20Å
2 but higher B factors 
(~34Å
2)  were  encountered  around  the  sugar-linked  residue  Asn32.  The 
Ramachandran  plot  demonstrated  that  90.1%  of  the  residues  fell  in  the  most 
favourable region with 9.5% falling in the additionally allowed region and 0.5% 
falling in the generously allowed region (Figure 3.15) by PROCHECK (Laskowski 
et al., 1996) 
 
 
 
Figure 3.15 A Ramachandran plot for the SAP-2-aminoethyl phosphonic acid 
structure 
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3.6 The SAP-3-aminopropyl phosphonate complex 
 
X-ray  diffraction  data  on  the  SAP-3aminopropyl  phosphonate  were  collected  at 
ESRF,  Grenoble,  France  on  beam  line  ID  14-2  (λ=0.931Å)  using  an  ADSC 
detector. 370 images were collected with a 0.5º oscillation angle and the crystal 
diffracted to ~1.9Å resolution (Figure 3.16). The data of SAP-APPA complex was 
processed with MOSFLM (Leslie, 1992) in the P2 and P21 space groups with a 
unit cell of a= 95.72Å, b = 69.29Å, c = 105.93Å, α = γ = 90.0°, and β = 92.1° (Table 
3.6).  
 
               
 
Figure 3.16 A 0.5º oscillation diffraction image of the human SAP-3-aminpropyl 
phosphonic complex collected at ESRF, Grenoble, France. 
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Table 3.6 The MOSFLM auto-indexing penalty Table for the SAP-3-aminopropyl 
phosphonate complex.  
 
The  Matthews  coefficient  suggested  a  solvent  content  of  55.5%,  which  was 
consistent with the presence of one SAP pentamer in the asymmetric unit cell. The 
data were scaled with SCALA at 1.8Å resolution (Table 3.7). 
 
Space group         P2  
Unit cell (Å) 
              (º) 
a = 95.16, b = 68.99, c = 105.37 and the, 
α = γ = 90.0, β = 92.1    
Low resolution (Å)  52.63 
 
High resolution (Å)  1.8 
 
Rmerge (%)  5.9 (26.8) 
 
Total number of reflections  468001 (53549) 
 
Total number unique reflections  125554 (17413) 
 
Mean ((I)/sd(I))  16.9 (3.8) 
 
Completeness (%)  99.2  (95.0) 
 
Multiplicity  3.7 (3.1) 
 
 
Table  3.7  Data  processing  summary  for  the  SAP-3-aminopropyl  phosphonate.  
Values in brackets are for the outer resolution shell.   56 
The presence of systematic absences along the b (0k0) axis in HKLVIEW (Figure 
3.17) confirmed that the SAP-3-aminobutyl phosphonate complex crystallised in 
the  space  group  P21  that  was  confirmed  later  in  the  molecular  replacement 
solution.  
   a) 
 
 
                       
b) 
 
 
 
Figure  3.17  A  pseudo-precession  image  of  the  human  SAP-3-aminopropyl 
phosphonate X-ray data a) The hk0 plane and b) The systematic absence of oddly 
indexed reflections along the k axis, reflecting the presence of a two-fold screw 
axis along the b axis and confirming the space group as P21 (HKLVIEW).   57 
3.6.1 Molecular replacement of the SAP-3-aminopropyl 
phosphonate 
 
Molecular  replacement  was  performed  with  PHASER  using  the  SAP  pentamer  
(1SAC.pdb: Emsley et al., 1994) as the search model. The calcium ions and water 
molecules  were  removed  from  the  search  model  and  all  alternative  choices  of 
space groups were searched.  
 
For the rotation search, a resolution range from 2.46Å to 43.95Å was used and the 
position and orientation of the molecule were determined using the rotation and 
translation function. Furthermore, the packing function of the PHASER confirmed 
the absence of any atomic clashes obtained in all putative solutions. 
 
The PHASER programme automatically picked the solution with highest Z-score 
and log-likelihood-gain (LLG). The top solution was obtained in P21 with a LLG of 
10317  and  rotational  and  translational  Z-scores  of  57.6  and  84.9  respectively 
(Table 3.8). 
 
Number               LLG          Z Score 
(Rotational) 
Z score 
(Translational) 
1  10317  57.6  84.9 
2  9822  54.8  71.3 
3  9336  53.9  53.9 
4  8872  50.0  64.1 
5  8567  50.7  76.5 
 
Table 3.8. The top five molecular replacement solutions obtained for the SAP-3-
aminopropyl phosphonate co-crystal using PHASER. 
 
 
Crystal packing of the PHASER solution was viewed in PYMOL (Delano, 2002) to 
check for steric clashes (Figure 3.18). 
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Figure 3.18 Crystal packing of the human SAP-3-aminopropyl phosphonate 
complex (a = 95.1Å, b = 68.9Å, c = 105.3Å, α = γ = 90.0°, β = 92.1°). Two SAP 
pentamers are present at equivalent positions in unit cell. 
 
3.6.2  Refinement  and  model  building  of  the  SAP-3-aminopropyl 
phosphonic acid complex structure 
 
The program REFMAC (Murshudov et al., 1997) was used to refine the final model 
obtained from PHASER (Read, 2001) and 5% of reflections were set aside as a 
test set for calculation of the Rfree. 20 cycles of the rigid body refinement yielded 
an initial Rfactor of 37.4% and Rfree of 38.2%. The rigid body refinement was 
followed by 10 cycles of restrained refinement, which yielded an Rfactor of 17.7% 
and Rfree of 22.3%. 
 
As  for  the  SAP-2-aminoethyl  phosphonate  complex  structure  determination, 
sigma-A weighted Fo-Fc and 2Fo-Fc electron density maps were generated by 
PHASER  (Read,  2001)  and  viewed  in  COOT  (Emsley  &  Cowtan,  2004). 
Continuous and clear electron density was present for the main chain and side 
chain atoms and a few residues were manually adjusted into the positive electron 
density. After several refinement cycles, a model was obtained with clear positive   59 
difference  electron  density  present  for  the  3-aminopropyl  phosphonate  ligand 
(Figure 3.19) in each subunit and the long N-linked sugar moiety in the subunit B 
(Figure 3.20). The pdb files for the ligand and the sugar moiety were generated 
using PRODRG (van Aalten et al., 1996), imported using COOT and positioned in 
the respective electron density. The sugar was connected to the N atom of the 
side chain of Asn32 residue using REFMAC (CCP4 suite). Subsequently, 1180 
water molecules and two calcium ions were added and the model further refined 
by  REFMAC  using  ligand  and  sugar  dictionaries  (CIF  files)  generated  by 
PRODRG. The refinement statistics are shown in Table 3.9. 
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Figure 3.19 The positive difference electron density for 3-aminopropyl phosphonic 
acid (APPA) (in top view) and the 2Fo-Fc map contoured at 2.0σ (bottom) in which 
phosphonate head group interacts with two calcium ions and nitrogen of the alkyl 
chain forms hydrogen bond with Tyr64. After the complete refinement the map 
showed very clear electron density for the APPA in each subunit.    61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 N-acetyl glucosamine (NAG) covalently bound to the terminal nitrogen 
of Asn32 of the B-subunit of SAP protomer (2Fo-Fc map contoured at 2.0σ). 
 
 
Table 3.9 Refinement statistics for the SAP-APPA structure. 
 
The stereochemistry of the SAP-APPA structure was checked with PROCHECK 
and with the Molprobity server (www.duke.edu) after the generation of hydrogen 
atoms. The average B-factor of the SAP-APPA structure was ~ 20Å
2 but higher B 
factors (~34Å
2) were associated with the sugar-linked Asn32. The Ramachandran 
Resolution (Å) 
 
 34.6- 1.8 
Number of reflections used for refinement 
 
 119291 
Number of reflections as Rfree  
 
 5964 
Rfactor (%) 
 
 17.7 
Rfree (%) 
 
 22.3 
RMS bond length deviation (Å) 
 
 0.012 
RMS bond angle deviation (°) 
 
 1.50   62 
plot showed that 89.8% of the residues of SAP fell in the most favourable region 
with 9.8% falling in the additionally allowed region, 0.5% in the generously allowed 
region and none in the disallowed region (Figure 3.21). 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 The Ramachandran plot for the SAP-3-amino propyl phosphonic acid 
complex structure. 
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3.7 Results of SAP-4-aminobutyl phosphonate 
 
X-ray  diffraction  data  were  collected  on  the  SAP-4-aminobutyl  phosphonate 
complex  at  ESRF,  Grenoble,  France  on  beam  line  ID  23  (λ=0.931Å)  using  an 
ADSC Q315R detector. 370 images were collected at an oscillation angle of 0.5º 
at a resolution of 1.6Å resolution (Figure 3.22). The data were processed with 
MOSFLM (Leslie, 1992) and auto-indexed in P2/P21 space groups with a unit cell 
of a = 95.1Å, b = 69.8Å, c = 106.2Å with angles of α=γ= 90º, β = 92.3º (Table 
3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
Figure  3.22  The  human  SAP-4-aminobutyl  phosphonic  acid  complex  crystal 
diffracted  image  (0.5º  oscillation)  collected  at  1.6Å  resolution,  The  data  were 
collected at ESRF, Grenoble, France. 
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Table  3.10  The  auto-indexing  penalty  Table  for  the  SAP-4-aminobutyl 
phosphonate (MOSFLM). 
 
Finally,  the  data  were  processed  with  SCALA  program,  which  merged  and 
reduced the data in P2 space group. The resultant statistics of scaled up data is 
shown in Table 3.11 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.11 Data processing statistics for the human SAP-4-aminobutyl phosphonic 
acid complex. The data in brackets belongs to the high resolution shell. 
 
The clear absence of systematic reflections along the b (0k0) axis in HKLVIEW 
confirmed the space group as P21 (Figure 3.23).  
 
Space group         P2 or P21 
 
Unit cell (Å) 
              (º) 
a = 94.34, b = 69.44, c = 105.57 
 α = γ = 90.0, β = 92.4  
Low resolution (Å)  42.33 
 
High resolution (Å)  1.6 
 
Rmerge (%)  5.8 (48.4) 
 
Total number of reflections  677647 (99188) 
 
Total number unique reflections  175363 (25259) 
 
Mean ((I)/sd(I))  14.9 (2.4) 
 
Completeness (%)  97.8  (96.8) 
 
Multiplicity  3.9 (3.9) 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
b)  
 
 
 
 
 
Figure  3.23  A  pseudo-precession  analysis  of  the  human  SAP-4-aminobutyl 
phosphonate co-crystal complex a) the hk0 plane b) the presence of systematic 
absences along the k axis (HKLVIEW). 
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3.7.1 Molecular replacement of SAP-4-aminobutyl phosphonic 
acid (ABPA) structure 
 
Molecular  replacement  was  carried  out  with  PHASER  (Read,  2001)  using 
1SAC.pdb (Emsley et al., 1994) without calcium atoms and water molecules as the 
search  model.  All  alternative  space  groups  were  searched  and  3  possible 
solutions found (Table 3.12). 
 
Number               LLG          Z Score 
(Rotational) 
Z score 
(Translational) 
1  10717  64.6  80.2 
2  9410  58.6  68.3 
3  9367  55.8  53.5 
 
Table 3.12. The three molecular replacement solutions were obtained for the SAP-
4-aminobutyl phosphonate complex.  
 
The top solution showed that the protein was packed in the P21 space group with a 
LLG of 10717 (rotational Z-score of 64.6 and translational Z-score of 80.2) with 
one SAP pentamer molecule of approximately 125kDa in the asymmetric unit cell 
with 55.44% solvent contents. 
 
The  packing  diagram  showed  the  feasibility  of  the  solution  obtained  by  the 
molecular replacement. The crystal-packing diagram is shown below (Figure 3.24). 
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Figure 3.24 Sensible crystal packing of the human SAP-ABPA complex was seen 
in primitive monoclinic unit cell P21 (94.34Å, b= 69.44Å, c= 105.57Å, α = γ = 90.0º, 
β = 92.4º) (PYMOL). 
 
3.7.2 Refinement and model building 
 
The final model produced by molecular replacement was refined using REFMAC 
(Murshudov  et  al.,  1997)  with  5%  of  the  reflections  flagged  for  the  Rfree 
calculation. 20 cycles of rigid body refinement yielded an Rfactor of 38.3% and 
Rfree  of  38.6%.  This  was  followed  by  10  cycles  of  restrained  refinement 
(Rfactor18.0%, Rfree 21.7%). 
 
The 2Fo-Fc electron density maps were visualised in COOT (Emsley & Cowtan, 
2004)  The  Fo-Fc  map  showed  clear  electron  density  for  five  4-aminobutyl 
phosphonate ligands, ten calcium ions (Figure 3.25) and the long sugar linked to 
Asn32 residue of the B subunit of SAP (Figure 3.26). The pdb and cif files for the 
sugar and ligands were generated with PRODRG (van Aalten et al., 1996) and 
imported into the model using COOT. The long sugar chain was attached to Asn32 
using  REFMAC  (CCP4  suite).  After  several  cycles  of  model  refinement,  water 
molecules  and  calcium  ions  were  added  and  the  model  refined  again.  The 
refinement data are shown in Table 3.13.  
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Table  3.13  Refinement  statistics  for  the  SAP-4-aminobutyl  phosphonic  acid 
complex crystal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 The SAP-4-aminobutyl phosphonic acid (APBA) complex and the 2Fo-
Fc map at the ABPA binding site contoured at 2.0 σ.  
 
Resolution (Å) 
 
 31.0-1.60 
Number of reflections used for refinement 
 
 166463 
Number of reflections as Rfree  
 
 8323 
Rfactor (%) 
 
 18.0 
Rfree (%) 
 
  21.7 
RMS bond length deviation (Å) 
 
  0.012 
RMS bond angle deviation (°) 
 
  1.48   69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.26  The  2Fo-Fc  electron  density  around  the  NAG  covalently  bound  to 
Asn32 (contoured at 2.0σ). 
 
The SAP-ABPA complex stereochemistry was checked with PROCHECK and the 
Molprobity  server  (www.duke.edu).  The  average  B-factors  were  approximately 
22Å
2 but higher B factors (~34Å
2) were observed in the vicinity of Asn32. The 
Ramachandran plot showed that 89.1% of the residues fell in the most favourable 
region  with  9.6%  falling  in  the  additionally  allowed  region,  0.6%  falling  in  the 
generously allowed region and none in the disallowed region (Figure 3.27). 
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Figure 3.27 The Ramachandran plot for the SAP-4-aminobutyl phosphonic acid 
complex crystal. 
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3.8 Discussion and conclusion 
 
In this study, the three structures of SAP in complex with aminoethyl phosphonic 
acid (AEPA), aminopropyl phosphonic acid (APPA) and aminobutyl phosphonic 
acid (ABBP) have been determined at 1.5Å, 1.8Å and 1.6Å resolution respectively. 
The B face of SAP forms a hydrophobic cavity along the calcium-binding pocket, 
which  acts  as  ligand  recognition  site.  Previous  study  has  demonstrated  that 
different ligands with negatively charged head groups (phosphate or carboxylate) 
bind to SAP in a calcium-dependent manner (Emsley et al., 1994; Thompson et 
al., 2003 and Hohenester et al., 1997). 
 
Recently the SAP-PE complex structure was determined at high resolution (1.5Å) 
(Mikolajek, 2008). The alkyl phosphonate ligands (AEPA, APPA and ABPA) used 
in  this  study  are  structurally  similar  to  phosphoethanolamine  (PE)  except  the 
phosphorus is directly attached to the carbon of the alkyl main chain rather than 
oxygen  atom.  Replacement  of  a  phosphate  with  a  phosphonate  revealed  the 
geometrical importance of the phosphate orientation for the calcium dependent 
interaction  with  SAP.  In  addition,  the  importance  of  alkyl  chain  length  was 
evaluated for the optimal binding to SAP protein. 
 
In the SAP-PE complex structure, the phosphate group showed interactions with 
two calcium ions and the amine group made a hydrogen bond with Glu66 via a 
water molecule. The side chains of Tyr74 and Tyr64 were positioned on both sides 
of the PE amine group, but they were too distant to form hydrogen bonds with 
amine group (Figure 3.28).  
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Figure 3.28 The SAP-PE complex shows the phosphate of PE interacts with SAP 
in a calcium-dependent manner and the amine group forms the hydrogen bond 
with Glu66 via a water molecule. 
 
From the SAP-PE structure it was proposed that increasing the alkyl chain length 
of the ligand might displace the water molecule bridging the amine group of the 
ligand and Glu66 of SAP. It was suspected that this interaction might yield higher 
binding affinity of SAP for phosphonate ligands. 
 
In the SAP and 2-aminoethyl phosphonic acid (AEPA) structure the amine group 
of AEPA was 3.9Å from the bridging water molecule and more than 5Å from Glu66 
of SAP. Interestingly, the amine group formed a hydrogen bond with side chain of 
Tyr74, which was 2.8Å apart rather than Glu66 of SAP (Figure 3.29). 
 
In SAP-3-aminopropyl phosphonic acid (APPA) structure the phosphonate group 
occupied  a  similar  position  as  in  the  previous  structure  of  SAP-AEPA  but  the 
amine group of APPA was 4.6Å from Glu66 of SAP. Similar to previous structure 
of SAP-2-aminoethyl phosphonate, the amine group in majority of SAP subunits 
was hydrogen bonded with phenolic group of Tyr74 (2.8Å) not with Glu66 of SAP 
(Figure 3.30). 
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Figure  3.29  The  SAP-2-aminoethyl  phosphonic  acid  (AEPA)  complex  structure. 
The phosphonate head group interacts with SAP in a calcium dependent manner 
and the amine nitrogen is distant from Glu66 but close to Tyr74 (2.8Å) of SAP. 
However,  there  was  only  one  subunit  of  SAP  in  which  hydrogen  bonding  with 
water took place with NH group of AEPA ligand. 
 
In the case of SAP-4-amino butyl phosphonic acid (ABPA), the longer alkyl chain 
of the ABPA was expected to make the amine group available for direct hydrogen 
bonding with Glu66 of SAP. The distance between the amine group of ABPA and 
the  side  chain  (OH  group)  of  Glu66  was  4.8Å,  which  was  too  large  to  be 
considered as hydrogen bond. Surprisingly, the amine group of ABPA was twisted 
towards the side chain of Tyr74 (2.6Å) of SAP forming a hydrogen bond (Figure 
3.31).  In  the  majority  of  SAP  subunit,  the  water  molecule  was  still  hydrogen 
bonded with Glu66 while in one subunit, the displacement of water has been found 
by ABPA ligand. 
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Figure  3.30  The  diagram  shows  the  calcium  dependent  interactions  of  3-
aminopropyl phosphonic acid (APPA) with SAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31 The SAP and 4-aminobutyl phosphonic acid (ABPA) complex in which 
the phosphonate moiety interacts with SAP via two calcium ions and the amine 
group hydrogen bonded with Tyr74 of SAP.   75 
3.8.1 SAP-phosphonates binding study  
 
 
The  isothermal  titration  calorimetry  (ITC)  study  of  SAP-PE  was  conducted  to 
calculate  the  SAP  binding  affinity  for  PE.  The  PE  bound  to  SAP  calcium 
dependently with dissociation constant (KD) of 100µM. Similar ITC experiments 
were carried out with SAP and alkyl phosphonate ligands (AEPA, APPA, ABPA), 
which showed very weak binding affinities (discussed in ITC chapter 4). There are 
a number of possible mechanisms which could affect the binding affinity of SAP for 
phosphonate  ligands.  One  possibility  can  be  the  C-C-P  bond  angle  in  alkyl 
phosphonates.  This  angle  in  the  phosphonate  head  group  is  110-112°  as 
compared to 120-123° for the C-O-P of PE. This angle could be the binding affinity 
determining  effect  of  alkyl  phosphonates  to  SAP.  In  addition,  the  comparative 
structural  study  of  SAP-PE  and  SAP-AEPA  has  also  revealed  the  significant 
difference  in  angle  of  approach  of  the  oxygen  atoms  of  phosphate  and 
phosphonate head groups to the calcium ions. In SAP-PE structure, the angles 
between  phosphorus-oxygen-calcium  ions  were  147.7º  and129.0º  compared  to 
131.0º and 141.2º in SAP-alkyl phosphonates structure. This 6-8º angle difference 
in  SAP-alkyl  phosphonates  could  be  another  reason  for  its  weak  binding  as 
compared to SAP-alkyl phosphate complex (Figure 3.32). 
 
 The second possibility could be the disruption of hydrogen bonding between the 
amine groups of alkyl phosphonate ligands with Glu66 of SAP via water molecule. 
It was demonstrated that the replacement of a water molecule could change the 
binding affinity of the ligand from micromolar to millimolar (Homans, 2007).  
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Figure 3.32 The diagram represents the comparative study of SAP in complex with 
PE and AEPA. The angle of approach of the oxygen atoms of phosphate of PE 
and phosphonate of 2-aminoethyl phosphonate showed the significant differences.  
 
3.9 Conclusion 
 
In this chapter, the efforts were made to understand the interaction of different 
negatively charged head groups of alkyl phosphonates with SAP. Previous studies 
demonstrated  that  the  calcium-binding  pocket  of  SAP  prefers 
phosphate/carboxylate head groups but its specificity towards these head groups 
was not well understood. An ITC study revealed that alkyl phosphonic acid binds 
to SAP in millimolar affinity compared to micromolar for PE. This suggests that the 
calcium-binding site of SAP does prefer the phosphate head group rather than 
phosphonate. From the current structural study it seems that the conformation of 
the alkyl chain and the interaction of NH group of alkyl phosphonate ligands to 
Glu66 could be crucial for the tighter binding to SAP. The detailed study in this 
chapter  can  be  helpful  to  design  novel  compounds  with  different  negatively 
charged head group geometry, which may block amyloid recognition site of SAP 
more effectively. 
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Chapter 4 
 Serum amyloid P and chemical ligand interaction 
study by Isothermal titration calorimetry (ITC)   78 
4 Isothermal titration calorimetry (ITC) 
 
4.1 Introduction 
 
In this chapter, I described the use of ITC in the determination of binding affinities 
and  the  associated  thermodynamic  parameters  of  SAP  for  various  ligands  that 
interact with the amyloid recognition site. Isothermal titration calorimetry is a useful 
technique to determine the interaction of small molecules (ligands) with proteins. It 
is based on the heat evolved or absorbed due to intermolecular interactions like, 
hydrogen bonds, Van der Waals forces and displacement of water molecules, etc. 
ITC measures the change in heat during the interaction, which is called enthalpy 
(ΔH). It is the only technique that calculates the association constant (Ka), change 
in enthalpy and change in entropy (ΔS) on the basis of intermolecular interactions. 
The reviews of ITC cited in this chapter are as follows: Menke & Walmsley, 1976; 
Ababbou & Ladbury, 2004; Fisher & Singh, 1995; Indyk & Fisher, 1998; Chilom et 
al., 2004 and Pierce et al., 1999. 
 
In general, the protein-ligand complex has lower free energy than the unbound 
state, which is the main cause of the complex formation. 
 
    [P] + [L] -----------> [PL] 
 
The  Ka  value  is  the  ratio  of  concentration  of  protein-ligand  complex  to  the 
concentration of protein and ligand in the unbound state. 
 
                                       
€ 
Ka =
PL [ ]
P [ ] L [ ]
 M
-1                   (1) 
 
 
The binding affinity is most commonly quoted as the dissociation constant KD. 
                                       
€ 
D K =
1
ka
    M        (2) 
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The free energy change (ΔG) is related to the measured enthalpy change (ΔH) by 
the  second  law  of  thermodynamics.  The  Gibbs  free  energy  change  (ΔG)  (the 
energy available to do useful work) is given by: 
 
                                           
€ 
ΔG = ΔH −TΔS         (3) 
 
The Gibbs free energy of binding is related to the association constant and the 
absolute temperature as shown in equation 4
 
 
                                            
€ 
ΔG = −RTlnKa
         (4) 
 
     
                          
 
R   = Gas constant 
            T      = Temperature in Kelvin 
            Ka   = association constant 
               
It is clear from the above equations that the association constant (Ka), change in 
Gibbs  free  energy  (ΔG),  entropy ( ΔS),  enthalpy  (ΔH)  are  inter-dependent  at  a 
given temperature (T). The association constant is calculated using the interactive 
software of ITC, which uses equations 3 and 4. Entropy (S) is the dispersal of 
energy in a system at specific temperature to create disorder in the system. The 
units  of  entropy  are  Joules/Kelvin.  It  plays  an  important  role  in  the 
thermodynamics. At the molecular level, it is a quantitative measurement of the 
rearrangement or movement of components of a system. The greater the value of 
entropy, the more disordered is the system e.g. displacement of water molecules, 
etc. 
 
According to equation 3, the value of ΔG can be driven by a change in enthalpy 
(ΔH) or a change in entropy (ΔS). If the value of ΔG is negative, the reaction is 
spontaneous  i.e.  independent  of  an  exothermic  or  endothermic  process.  It  is 
possible that the feasibility of a reaction is driven by entropy (ΔS) or a change in 
enthalpy (ΔH).    80 
 
4.2 Advantages of isothermal titration calorimetry 
 
Isothermal titration calorimetry is a quite simple, reliable technique and is easy to 
use.  It  is  applied  for  the  reactants,  which  are  quite  soluble  in  water.  The  ITC 
machine takes a few minutes to reach equilibration at a given temperature. The 
machine is designed in such a way that there is no need to reload the sample 
avoiding repeated opening and closing of the adiabatic jacket to change samples. 
So once the sample is loaded, the completion of a reaction can be achieved. ITC 
is based on the change in enthalpy and the software calculates the association 
constant (Ka) directly, that is further used to calculate the change in Gibbs free 
energy (ΔG), change in entropy (ΔS) and stoichiometry (n) of interaction. ITC is a 
very sensitive technique and has the ability to determine KD from sub millimolar to 
nanomolar range.  
 
Alternative methods including, spectroscopy, nuclear magnetic resonance (NMR) 
and surface plasmon resonance are not only quite expensive but also complex 
techniques. Radio labelled ligand binding assay is another technique, which needs 
a radioactive element and reactant immobilization. As compared to ITC, none of 
the other techniques provide the information about the enthalpy change (ΔH) and 
entropy change (ΔS) and stoichiometry (n) and association constant Ka. 
 
 
4.3 Disadvantages of ITC 
 
 
ITC requires that the protein and ligand (and also their complex) are soluble. It is 
often the case that the chemical ligand must be solublized in an organic solvent, in 
which  case  the  determined  dissociation  constant  (KD)  does  not  reflect  the 
physiological environment. High concentrations of protein are also required for a 
precise estimation of the KD. If recombinant protein expression levels are low or if 
the  protein  aggregates  at  high  concentration  then  the  ITC  experiment  is  not 
suitable.  Similarly  the  protein  may  only  be  soluble  in  a  buffer  having  a  high 
enthalpy (due to heat sensitive protonation and deprotonation) yielding inaccurate 
data.   81 
 
4.4 General features of ITC 
 
 
The VP-ITC MicroCalorimeter (MicroCal, LLC; Northampton, MA, USA) was used 
to characterize serum amyloid P component interaction with different amino alkyl 
phosphonate ligands. The MicroCalorimeter consists of an adiabatic jacket that 
contains a reference cell and a sample cell. Each cell has the capacity of 1.4 ml 
reaction  mixture.  Two  thermocouples  are  present  in  the  cavity  of  an  adiabatic 
jacket. One thermocouple is between the reference and sample cell to maintain 
the temperature identical in both cells. Another thermocouple is located between 
the  reference  cell  and  the  adiabatic  jacket  to  detect  the  slightest  change  in 
temperature between them. 
 
The reference and sample cells are connected to their own two heaters allowing 
them  to  maintain  identical  temperature.  Heaters  are  activated  when  the 
temperature fluctuates in the ITC chamber. The main aim of these heaters is to 
keep the temperature difference (ΔT1) & (ΔT2) identical between each component 
of ITC (Wiseman et al., 1989). 
 
           
                             
€ 
ΔT 1 = TR −TS ≈ 0 
            TR =   Temperature of reference cell 
            TS =    Temperature of sample cell 
 
     
€ 
ΔT2 = TR −TJ ≈ 0 
           
            TR =   Temperature of reference cell 
            TJ =    Temperature of jacket cell 
 
 
The reference cell is filled with either milliQ water or protein buffer containing 0.1% 
sodium azide that prevents any microbial growth in the reference solution. The 
sample cell equilibrates within 10 mins by applying 1mW power to reference cell. 
The Origin 7.0 software generates the base line that is straight and horizontal in 
appearance. Different parts of ITC are shown in Figure 4.1. 
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Figure 4.1 The MicroCal consists of an adiabatic jacket, containing reference and 
the sample cells. Each cell is connected to an individual heater to maintain them at 
the  identical  temperature.  Depending  upon  the  nature  of  reaction  upon  adding 
ligand to the sample chamber, electrical energy is applied or withheld to maintain 
identical temperature in both cells (Pierce et al., 1999).  
 
 
The injection syringe is present to inject the ligand solution into the sample cell. 
The  injection  syringe  has  a  capacity  of  approximately  300µl  and  consists  of  a 
stirring motor at its top with a long stainless steel needle. The long needle has a 
small paddle at the tip, which helps to mix the ligand well while stirring. The needle 
is firmly seated on the opening of the sample cell and only a few centimetres of 
stainless  needle  can  protrude  in  the  sample  cell.  The  injection  time,  injection 
volume, stirring speed, are all set up in the interactive software called Origin 7.0 on 
the connected computer. The data obtained with each injection are automatically 
stored on a hard disk. The interactive software also offers to deconvolute the data 
and calculate the enthalpy change (ΔH), entropy change (ΔS), stoichiometry (n)   83 
and  association  constant  (Ka)  etc.  The  curve  fitting  may  be  performed 
automatically  or  manually,  which  provides  the  option  to  fix  or  float  different 
parameters. 
 
When  the  injection  needle  adds  the  ligand  to  the  sample  cell  containing  the 
protein,  an  exothermic  or  endothermic  reaction  occurs  which  is  directly 
proportional  to  the  extent  of  protein-ligand  complex  formation  or  any 
rearrangement in the protein or ligand conformations.  
 
                                   
Figure 4.2 To measure the precise value of association constant (Ka), the protein 
should be saturated with ligand at the end of the experiment. The ideal sigmoid 
isotherm  curve  is  shown  in  the  above  Figure  for  the  calculation  of  association 
constant. The curve represents the interaction of 2′-CMP and RNase (Spenser et 
al., 2002). 
 
With  the  addition  of  each  additional  injection,  the  protein  in  the  sample  cell 
becomes more and more saturated and the amount of heat evolved or absorbed 
decreases  with  further  addition  of  ligand  (Figure  4.2).  Ultimately  the  protein 
saturation point is reached and the change in heat becomes negligible (Chilom et   84 
al., 2006). The heat evolved after each injection can be described by the following 
equation (Pierce et al, 1999). 
 
 
 
                                    
   
                                         
€ 
Q=
V0ΔHb M [ ]tKa L [ ]
1+ Ka L [ ] ( )
 
 
                  V0   = Volume of sample cell 
          ΔH   = Enthalpy of binding per mole 
          Ka   = Association constant 
          [M]t  = Total protein concentration 
          [L]  = Free ligand concentration 
 
 
4.5 Importance of initial protein concentration 
 
 
The reliability of ITC is dependent on the C value, which in turns is dependent on 
the protein concentration (c), stoichiometry (n) and association constant (Ka):   
                                
€ 
C = Ka×c × n 
                                       
      
To measure the association constant accurately, the value of C must be adjusted 
between 1-1000 by varying the protein to ligand concentration ratio. If the change 
in  enthalpy  (ΔH)  is  plotted  against  the  protein-ligand  complex  concentration,  a 
sharp decrease in enthalpy gives the value of stoichiometry of the interaction. To 
fit the data, a sigmoid curve is very important (Figure 4.3). If the C value is very 
low (0.1), a very shallow curve is obtained which is not very useful to obtain the 
stoichiometry information and at high C value (>1000), the curve is too sharp that 
the transition points between the ligand binding and protein saturation cannot be 
obtained. In this case, the curve cannot be fitted accurately, yielding inaccurate 
values of association constant (Ka) and stoichiometry (n). 
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Figure 4.3 The change in heat versus the protein-ligand stoichiometry is plotted for 
different  values  of  C.  The  graph  shows  the  increase  in  enthalpy  directly 
proportional to C-value and sharp decrease in the enthalpy gives the information 
about the stoichiometric ratio of ligand to the protein (Wiseman et al., 1989). 
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4.6 Materials and methods 
 
Purified  SAP  was  provided  by  the  Centre  for  Amyloidosis  and  Acute  Phase 
Proteins (CAAPP), The Royal Free Hospital, University College, London. The 2-
amino  ethyl  phosphonate,  2-amino  ethyl  sulfate,  3-amino  propyl  sulfonate, 3 -
amino  propyl  phosphonate,  4-amino  butyl  phosphonate  and  O-
phosphoethanolamine ligands were purchased from Sigma-Aldrich. 
 
Since EDTA is a metal ion chelator it was removed from the SAP buffer (10mM 
Tris-HCl,  pH  8.0,  140mM  NaCl,  10mM  EDTA,  0.1%  sodium  azide)  by  dialysis 
against EDTA free buffer using dialysis tube (Medicell international Limited) of 10 
kDa MWCO. 
 
The stock SAP concentration was determined to be 275µM (extinction coefficient 
at  280nm  of  1.7  M
-1  cm
-1)  using  a  ND1000  nano-drop  spectrophotometer 
(NanoDrop Products, Wilmington, DE, USA) at 280nm. For the ITC experiment the 
protein concentration was diluted to 60µM SAP to use with 2mM ligand.  
 
4.6.1 Isothermal Titration Calorimetry operation 
 
The reference cell and the sample cell were washed using a 2.5ml syringe. The 
reference  cell  was  filled  with  milliQ  water  containing  0.1%  sodium  azide.  The 
sample cell was filled with 5% decon and then heated to 50°C for 2 hrs to remove 
any  aggregated  protein  left  from  previous  experiments.  The  sample  cell  was 
further washed with 400ml milliQ water and then 200ml of 10mM Tris-HCl (pH 
7.5), 140 mM NaCl, 200mM CaCl2, 0.1% sodium azide using a vacuum pump and 
at 35°C. Similarly, the ITC injection needle was washed with 5% decon 2-3 times 
followed by water and then the buffer described above.  
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4.6.2 Sample preparation 
 
The SAP sample (60µM in 2.1ml in 50mM Tris-HCl pH 8.0 and 140mM NaCl) was 
transferred  to  a  5ml  plastic  tube  containing  a  small  magnetic  stirrer  and  the 
chemical ligand (2mM in 600µl of the same buffer) to a small (800µl) glass tube.  
The protein sample was then placed in the vacuum pump rack with continuous 
stirring at a speed of 200rpm and degassed along with ligand solution for 20 mins 
at 35°C.  
 
Initially, degassed ligand was titrated into the buffer alone to ensure that the heat 
change could not be ascribed to ligand dilution or the buffer protonation effect. 
Only  a  negligible  amount  of  heat  was  generated  indicating  that  any  change  in 
enthalpy produced in subsequent ITC experiments could be due to the protein-
ligand interaction. 
 
Subsequently, the degassed protein sample was injected into the sample cell (in 
250µl pulses to avoid air bubbles) until it was filled. The injection syringe was filled 
with degassed ligand solution manually using a 2.5ml plastic syringe and mixed 
well  using  the  “purge”  functionality  of  the  microcalorimeter.  Finally,  the  ligand 
solution was injected into the sample cell ensuring that the needle fitted tightly into 
the seal on top of the adiabatic jacket.  
 
4.6.3 Experimental parameters 
 
The ligand was injected into the protein solution in 37 injections. The volume of 
first injection was 1µl with duration of 2.4sec, separated from other injections by 
280sec. The rest of the injections were 8µl each with 19.2 sec duration separated 
by  delay  of  280sec.  The  stirring  speed  of  injection  needle  was  set  up  to 
310rpm/min to mix the ligand and protein solution well. The file was automatically 
saved on the computer hard disk. 
 
Similar operations have been conducted with SAP-2-aminoethyl sulfate, 3-amino 
propyl sulfonate, 3-amino propyl phosphonic and 4-amino butyl phosphonic acid   88 
ligand interactions. All the experiments were performed in the 5mM calcium with 
700mM NaCl or 200mM CaCl2 alone in order to ascertain the effect of high salt 
upon  ligand  binding.  To  compare  with  the  above  experiments  the  SAP-
phosphoethanolamine  (PE)  interaction  experiment  was  performed  using  5mM 
calcium  in  high  NaCl  concentration  with  55  injections  of  PE  ligand  into  SAP 
protein. 
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4.7 Results and discussion 
 
The protein ligand binding interactions involved measuring the heat absorbed or 
evolved in terms of change in enthalpy. But the enthalpy change in the adiabatic 
system is not only due to the ligand binding to protein. There are other factors 
responsible for the change in enthalpy. 
 
                               
€ 
ΔH = ΔHbind + ΔHconf + ΔHion 
 
Certain proteins change their conformation upon ligand binding. The change in 
enthalpy  due  to  this  conformational  rearrangement  is  called  enthalpy  of 
conformation (ΔHconf). The enthalpy of ionization (ΔHion) of buffer and reactants are 
an important consideration too. Certain buffers like Tris-HCl produces significant 
amount of heat due to protonation effects.  
 
To minimize the ΔHion, the buffer composition in the sample cell and in the needle 
must be identical and at constant temperature. For all the experiments conducted 
in this research, a control base line was measured with ligand against buffer to 
compensate for ΔHion at constant temperature.  
 
4.7.1 The driving force for protein-ligand complex formation 
 
The second law of thermodynamics states that all the systems tend to disorder. 
Interestingly, ligand and protein in free form have more translational, rotational and 
torsional degrees of freedom. The interaction of ligand with protein is formed at the 
cost  of  entropy,  as  the  ligand  loses  its  rotational  and  translational  degrees  of 
freedom  although  this  is  offset  by  the  increase  in  entropy  due  to  water 
displacement.  
 
The above restrictions of movement oppose the protein-ligand complex formation 
but why do proteins still form complexes with ligands? Clearly, the loss of entropy 
upon  complex  formation  must  be  compensated  by  forces  arising  from  different 
interactions. It had been determined that there are balancing forces which make   90 
the protein-ligand complex formation feasible (Murphy et al., 1994, Janin et al., 
1990).  The  loss  of  entropy,  which  is  related  to  the  degrees  of  freedom,  is 
compensated by the intra and intermolecular interaction of protein and ligands. 
Such  interactions  can  be  hydrogen  bonding,  electrostatic  and  most  importantly 
hydrophobic interactions (Tamura et al., 1997).  
 
4.7.2 SAP solubility 
 
For ITC studies, the solubility of SAP protein in the presence of calcium was a big 
obstacle.  The  natural  propensity  of  SAP  to  aggregate  in  the  presence  of  a 
physiological concentration of calcium (~3mM) leads to precipitation. It has been 
demonstrated that SAP precipitation did not require any other serum constituent 
but calcium ions (Baltz et al., 1982).  The precipitation of SAP is caused by the 
stacking of pentamer molecules on each other due to the Glu167. This acts as a 
ligand, on the A face of SAP pentamer that interacts calcium-dependently with the 
binding site of adjacent SAP molecules (Emsley et al., 1994). At >1mM (Ca
2+) SAP 
precipitation may be reversed by the addition of the metal chelator EDTA. 
 
 After years of study, it was discovered that SAP could stay in solution in high 
calcium  concentration  of  200mM.  In  high  calcium  chloride  concentration,  the 
chloride ions still interact with calcium ions in the SAP binding pocket and prevent 
the  stacking  process  of  SAP  pentamers  (Pepys  et  al.,  2002).  So  high  calcium 
chloride concentration has allowed the determination of the binding affinities of 
different ligands to SAP in a calcium dependent manner. 
 
More recently, SAP solubility was alternatively improved by adding high sodium 
chloride (700mM) to prevent the SAP precipitation in the presence of physiological 
concentration of calcium (Alun R. Coker unpublished). 
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4.7.3 Effect of high salt on the SAP-ligand interactions 
 
It is quite obvious that in a high sodium chloride concentration, there might be a 
competition  between  chloride  ions  and  chemical  ligands.  To  make  sure  the 
isotherms produced by the binding of ligand to SAP, the ITC experiments of SAP-
PE and amino-alkyl phosphonate were performed in the presence of high sodium 
chloride concentration as well as high calcium chloride salt. The results of both 
ITC experiments yielded the similar binding affinity for PE (KD =100 µM). 
 
4.7.4 SAP and small chemical ligand study 
 
Previous study demonstrated that SAP interacts with phosphoethanolamine (PE) 
in a calcium dependent manner via the phosphate moiety. In addition, the amine 
group of PE interacts with Glu66 of SAP via a water molecule. 
 
The two aims of this work were, to establish the effect of replacing the phosphate 
moiety of PE with a phosphonate (replacement of the phosphate P-O bond with P-
C) (Figure 4.4) and secondly to ascertain if it is possible to extend the alkyl chain 
to allow direct interaction of the amine group of the ligand with Glu66 (i.e. without 
the need for bridging water coordination) to give tighter binding. In addition, I also 
investigated  alkyl  sulphate  and  sulfonate  (also  called  Taurines).  Interestingly, 
Taurines have recently been used to block the amyloid beta aggregation in vitro 
and have been used in large clinical trials. As they are PE analogues, I have also 
investigated their binding affinity for SAP.  
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Figure 4.4 Small chemical ligands have been studied for their ability to block the 
amyloid recognition site of SAP protein. A) 2-aminoethyl phosphonic acid (AEPA) 
is shown which is shorter than O-phosphoethanolamine (PE) and the head group 
of phosphate has been replaced by phosphonate as compared to B. C) represents 
3-aminopropyl  phosphonic  acid  (APPA).  D)  The  length  of  the  main  chain  was 
increased from propyl to butyl in 4-aminobutyl phosphonic acid (ABPA). It was 
assumed that the length of the main chain of the ligand could make the binding 
affinity tighter than PE due to the direct interaction of the amine group with the 
(Glu66) of SAP, E) The sulphate analogue of PE and F) sulfonate have also been 
used as potential SAP ligands due to similar geometry of sulfate with phosphate.  
                                          
4.7.5 Ligand properties 
 
4.7.5.1 Phosphonates as drugs 
 
The phosphonates are widely employed as drug constituents, for example alpha 
aminophosphonic  acid  is  an  analogue  of  alpha-amino  acids  and  is  used  as  a 
peptide  mimic  enzyme  inhibitor,  which  is  an  effective  drug  in  cancer   93 
chemotherapy. The polymers of phosphonates are excellent carriers of drugs. The 
bisphosphonates  has  been  tested  to  cure  osteoporosis  in  which  bisphosphate 
inhibits  the  calcium  phosphate  crystal  formation  in  bones  and  ceases  bone 
resorption (Fleisch, 1993). 
 
The 2-amino ethyl phosphonic acid, the only phosphonate occurring naturally in 
human, was first discovered and isolated from ciliated protozoa (Alhadeff et al., 
1971). The 3-amino propyl phosphonic acid was first discovered 30 years ago as a 
flame-retardant and is also the most potent known GABAB agonist. 4-aminobutyl-
phosphonic acid is two carbons longer than PE and is assumed to bind Glu66 of 
SAP directly rather than via a water molecule, which might increase the binding 
affinity to SAP.  
 
To compare the effect of the phosphonate head group and the length of the alkyl 
main  chain,  a  control  ITC  experiment  of  SAP-PE  was  conducted.  In  control 
experiment of SAP-PE in the presence of 5mM calcium, a large amount of heat 
(ΔH) change was observed due to an exothermic reaction. In the beginning of the 
experiment a large amount of heat was evolved and subsequently decreased due 
to the saturation of protein with ligand. The final value of ΔH was -11430 ± 620 
cal/mol, with KD of 100µM and stoichiometry (n) of 1.  The SAP-PE isotherm is 
shown in Figure 4.5  
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Figure  4.5  An  ITC  isotherm  of  the  SAP-PE  interaction  in  the  presence  5mM 
calcium  represents  the  complete  saturation  of  protein  towards  the  end  of  the 
reaction. This interaction was exothermic which shows as a negative value up to 1 
µcal/sec.  
 
4.7.6 SAP-chemical ligands interaction study 
 
The isotherm obtained from the ITC experiments showed that the binding affinity 
of  amino-alkyl  phosphonates  to  SAP  is  very  weak.  The  binding  of  SAP-PE  in 
which the binding reaction is exothermic but interestingly, changing the oxygen of 
phosphate to carbon in propyl and butyl phosphonates changed the entire reaction 
to endothermic.  
However,  in  the  case  of  2-aminoethyl  phosphonic  acid-SAP  binding,  the  small 
exothermic signal of interaction could not be measured with microcalorimeter and   95 
after  a  few  injections  of  ligand  the  experiment  was  abandoned  to  prevent  the 
wastage  of  expensive  SAP  protein.  The  used  SAP  was  recovered  with  20mM 
EDTA solution to sequester the calcium ions from the protein solution. The ITC 
isotherm of the SAP-2-amino alkyl phosphonate interactions is shown in panel A of 
Figure 4.6. 
  
The 3-aminpropyl-phosphonic acid absorbed heat from environment when titrated 
against  SAP  protein.  The  change  in  enthalpy  was  significant  but  the  protein 
saturation point was not attained with the subsequent addition of ligand. The ITC 
diagram of the interaction is shown in panel B in the following Figure 4.6. 
 
As the length of the main chain is increased in 4-aminobutyl phosphonate, the 
more heat was absorbed from the environment. But once again the point of protein 
saturation could not be found. The complete saturation of protein with ligand is 
very important to calculate the precise value of association constant. Surprisingly, 
there was no binding at all with the 2-aminoethyl sulfate, which is a PE analogue 
and  3-aminopropyl  sulfonate.  It  implies  that  the  phosphate  head  group  is  very 
specific for the interaction with SAP calcium dependently.  
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Figure 4.6 The effects of phosphorus-carbon bond and change in length of the 
alkyl main chain of aminoalkyl phosphonates on SAP binding were determined by 
ITC. It has been analysed that the oxygen linkage of phosphorus to the alkyl chain 
is critical for the interactions. Panel A, SAP interaction with 2-aminoethyl, panel B, 
with 3-aminopropyl and C, 4-aminobutyl phosphonic acid.  
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The Figure 4.6 demonstrates the weak endothermic binding of alkyl phosphonates 
to SAP. It is possible that the binding is entropy driven, with SAP expanding to 
accommodate the alkyl phosphonate ligands. Alternatively, the alkyl phosphonate 
ligands might displace the ordered waters at the hydrophobic surfaces of the SAP 
binding pocket.  
 
4.7.7  Comparative  study  of  amino  alkyl  phosphates  and 
phosphonates  
 
4.7.7.1 Bond angle of head group  
 
The X-ray structural analysis of SAP-alkyl phosphonate reveals that SAP binds 
negatively charged chemical ligands via two calcium-binding sites. There are two 
adjacent calcium ions on the B face of SAP. One calcium ion posseses pentagonal 
bipyramidal  geometry,  interacting  with  Asn59,  Glu136,  Gln137,  Asp138,  Asp58 
and  the  head  group  of  phosphate/phosphonates  of  the  chemical  ligand.  The 
second  calcium  ion  makes  tetrahedral  co-ordination  geometry,  interacting  with 
Glu136,  Asp138,  Gln148,  two  water  molecules  and  once  again 
phosphate/phosphonates head group of chemical ligand (McPhalen et al., 1991). 
The oxygen atoms of phosphate interact with the SAP calcium dependently and 
the amine group of the ligand makes a hydrogen bond with Glu66 via a water 
molecule. So it is important to analyse the way the phosphate or phosphonate 
head  groups  approach  the  binding  pocket  of  SAP.  In  the  case  of  the  SAP-PE 
interaction, the bond angle of the P−O−C in PE is ~123° while in phosphonates 
this is significantly smaller i.e. between 110-114°. This difference in bond angle 
could be a significant factor in weak binding of the phosphonate head group to 
calcium pockets of SAP compared to a phosphate group. So, replacing an ester 
oxygen with carbon affects the angle of approach of the phosphonate head group 
to the SAP bound calcium ions. 
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4.7.7.2 Conformational effect of the alkyl side chain of phosphate/ 
phosphonates 
 
O-phosphoethanolamine (PE) is a well-known constituent of phospholipids of the 
cell membrane and its levels are reduced in Alzheimer’s disease patients. Initially, 
it  was  proposed  that  PE  might  interact  with  the  GABAB  receptor  due  to  its 
structural similarity to 3-aminopropyl phosphonic acid, which is a GABAB agonist. 
The 3-aminopropyl phosphonate used in this research, is similar to PE but the 
ester oxygen is replaced by an αCH2 group. It has since been shown that PE, 
even in millimolar concentration, is unable to bind the GABAB receptor.  
 
The  NMR  and  crystallographic  studies  of  PE  and  3-aminopropyl  phosphonate 
show that βC− γC bond of 3-aminopropyl phosphonates is predominantly in an 
extended  conformation.  On  the  other  hand,  βC−  γC  of  PE  is  in  a  gauche 
conformation (Klunk et al., 1994). This extended conformation might be the cause 
of  the  decrease  in  the  binding  affinity  of  alkyl  phosphonates  as  compared  to 
phosphates of PE in SAP interaction. It may also be due to the disruption of the 
amine group hydrogen bonding with Glu66 through a water molecule, which has 
been demonstrated by structural studies. The loss of one water molecule involved 
in  the  ligand  interaction  can  change  the  affinity  of  a  ligand  to  protein  from 
micromolar to millimolar (Homans, 2007). 
 
4.8 Conclusion 
 
The ITC experiments represented in this chapter demonstrated that the change in 
the  phosphate  head  group  to  phosphonate  decreases  the  binding  affinity  from 
micromolar  to  millimolar.  The  structural  investigation  of  SAP-alkyl  phosphonate 
complexes revealed the importance of the phosphate head group geometry, which 
seems  very  strict  for  the  binding  to  SAP  calcium  dependently.  Secondly,  the 
conformation  of  the  side  chain  to  which  the  amine  group  is  attached  could  be 
crucial and may indirectly affect the binding affinity of small ligands to SAP. The 
previous structural study of SAP-PE showed that the amine group of PE interacts   99 
with  the  Glu66  of  SAP  through  hydrogen  bonding  (via  water  molecule).  In  this 
study we tried longer alkyl side chains of phosphonate ligands to replace the water 
molecule  between  the  amine  group  of  ligands  and  Glu66  of  SAP.  Due  to  the 
structural configuration of the alkyl side chain of the ligands, the water molecule 
replacement was not analysed in all three structures. It may be the cause of the 
weaker binding affinity of SAP for all the alkyl phosphonate ligands studied in this 
research. This study showed that it is very crucial to understand the head group 
geometry as well as the side chains conformation of the chemical ligands of SAP 
for the future anti-amyloid drug design. 
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Chapter 5 
 Review of literature on Transthyretin   101 
5 Transthyretin (TTR) or Prealbumin 
 
5.1 General background 
 
Transthyretin (TTR) was originally called prealbumin because it ran just in front of 
albumin on denaturing SDS-PAGE. It was first sequenced in the early seventies 
(Kanda et al., 1974). TTR binds thyroid hormone as well as retinol-binding protein 
(RBP). The dual function of TTR well reflects its name “Transthyretin”, which was 
coined  by  Robbins  (Robbins,  1976).  Transthyretin  is  composed  of  a  single 
polypeptide of 127 residues with a molecular weight of ~14kDa. It belongs to the 
thyroxine binding globulin protein family. It is also a thyroid hormone transporter in 
addition to a thyroxine binding globulin (TBG) (Larsson et al., 1985). The thyroid 
hormone  is  a  mixture  of  3,  5,  3,  and  5,  tetraiodo-L-thyronine  (T4)  and  3,  5,  3, 
triiodo-L-thyronine  (T3)  (Figure  5.2)  (Johnson  et  al.,  1980)  both  of  which  are 
essential for growth and development in vertebrates. T4 is secreted by the follicular 
cells of the thyroid gland and deiodinated in the tissues to active tri-iodothyroxine 
(T3).  
 
 TTR has a higher affinity for T3 than for T4 in the human and TBG is the main 
transporter of T4 but interestingly, TTR is the main transporter of T4 in rodents. In 
humans, TTR is mainly produced in the choroid plexus and liver (Oppenheimer et 
al., 1975) but the human foetus also produces TTR in the pancreas and in the 
gastrointestinal  mucosa  (Grey  et  al.,  1985).  The  TTR  molecule  (~  14  kDa)  is 
secreted extracellularly into the blood plasma by liver and into the cerebrospinal 
fluid by choroid plexus where it forms metastable tetramer of ~55kDa (Blake et al., 
1974). The normal concentration of TTR in the circulation is ~ 300mg/l with a half-
life of 2 days (Power et al., 2000) although it is a negative acute phase protein 
(Costa et al, 1986). TTR degradation is poorly understood but the liver, kidney and 
muscle  are  prominent  sites  for  its  degradation  (Makover  et  al.,  1988).  TTR 
production and degradation is schematically illustrated in Figure 5.1.   102 
 
 
Figure 5.1 The TTR (depicted in blue) produced by the choroid plexus as well as 
the  liver  forms  tetramers,  which  in  turns  binds  to  retinol  binding  protein  (RBP 
depicted in green). Ultimately, the liver and kidneys degrade TTR. 
 
In vitro studies have revealed the degradation pathways of TTR in the human and 
the rat. The in vitro study demonstrated that TTR binds to the hepatoma cells lines 
(KD  =  15µM  at  37°C)  and  the  internalization  of  I
125TTR  to  hepatocytes,  renal 
adenocarcinoma and neuroblastoma was also demonstrated (Divino & Schussler, 
1990). It was also observed that the conversion of T4 to T3 decreases when TTR 
expression  is  down-regulated  (Wartofsky  et  al.,  1982).  It  was  discovered  that 
addition of TTR to culture media increases the absorption of T4 by hepatoma cells 
(Divino & Schussler, 1990) and TTR internalisation by rat hepatocytes is directly 
proportional to the ambient T4 concentration. So, it has been proposed that TTR is 
internalized not only free but also in complex with T4 (Azimova et al., 1984). The 
Figure 5.2 shows the structural composition of thyroid hormones. 
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Figure 5.2 The two constituents of thyroid hormone: triiodo-L-thyronine (T3) and 
tetraiodo-L-thyronine (T4) 
 
 
A functional TTR tetramer, which transports thyroid hormone, is composed of two 
non-covalently bound TTR dimers, which form a large hydrophobic central channel 
at  their  interface.  The  central  channel  of  the  tetramer  binds  two  molecules  of 
thyroxine (Wojtczak et al., 2001) and as previously discussed, the TTR tetramer 
also binds to one molecule of retinol binding protein (RBP) (Naylor & Newcomer, 
1999). RBP is well known as a vitamin A transporter and TTR protects it from 
removal by the kidney (Monaco et al., 1995). In addition, retinol binds more tightly 
to RBP when RBP is in complex with TTR (Goodman & Raz, 1972). 
 
5.2 TTR as thyroxine transporter in the brain 
 
The blood-brain barrier keeps the cerebrospinal fluid (CSF) of the nervous system 
physically separate from the blood circulation. TTR is mainly produced by liver and 
choroid plexus. The choroid plexus secretes the CSF. [
14C]- Leucine labelled TTR 
injected  intravenously  in  mice  was  detected  in  the  CSF  (Dickson  et  al.,  1987; 
Schreiber et al., 1990), suggesting that thyroid hormone maybe transported into   104 
the  brain  by  TTR.  Gerhard  and  co-workers  in  1990  proposed  a  model,  which 
suggested the TTR mediated transfer of T4 based on studies with I
125 T4. When 
radio-iodinated T4 was injected intravenously into mice, maximal radioactivity was 
detected in the epithelial cells of the choroid plexus with some being detectable in 
the CSF after several hours. In the proposed model, T4 is initially absorbed by the 
fenestrated capillaries, stroma of the choroid plexus and then by the epithelial cell 
layer.  The  choroid  plexus  then  secretes  the  TTR-T4  complex  into  the 
subarachnoidal and perivascular space and finally into brain tissue (Figure 5.3). 
 
Figure  5.3  The  model  shows  the  transport  of  thyroxine  across  the  blood-brain 
barrier  by  TTR.  The  TTR-T4  complex  enters  into  the  choroid  plexus  and  is 
secreted into the ventricle and delivered into brain tissues (Schreiber et al., 1990). 
 
5.2.1 The genetics of TTR 
 
The transthyretin gene in human is located on chromosome 18 where it exists as a 
single copy comprised of four exons of ~200 bps each and separated by 3 introns. 
The first exon encodes the N-terminal signal peptide and also the first three amino 
acids of TTR. The remainder of the molecule is coded for by the 2nd, 3rd and 4th 
exons  (Sasaki  et  al.,  1985)  (Figure  5.4).  TTR  gene  expression  is  regulated  by 
splicing of the 5′ hnRNA.  
   105 
 
 
 
Figure 5.4 The operon of human TTR gene shows four exons (Benson et al., 
1996) 
 
Organisation of the TTR gene is very similar in the human, rat and mouse. It is 
speculated  that  gene  expression  is  regulated  by  cis  and  trans-acting  factors 
approximately  2000  bps  upstream  of  the  translation  initiation  site  (Yan  et  al., 
1990). TTR is composed of 127 residues in the human and rat (Dickson et al., 
1985) but pig, lizard, chicken and teleost fish TTR each possess 130 residues 
(Duan et al., 1995; Achen et al., 1993; Santos et al., 1999). TTR sequences from 
several mammalian species are aligned in Figure 5.5. 
 
 
Figure 5.5 The Multialign programme was used to align several mammalian TTR 
sequences. Sequence identity is depicted in red (High consensus sequences in 
red, low consensus in blue and neutral in black).  
 
In  the  human  TTR  gene,  more  than  100  point  mutations,  resulting  in  a  single 
residue substitution, have been sequenced. Some of these mutations are non-
pathogenic and others cause misfolding, aggregation and ultimately amyloidosis 
(Power  et  al.,  2000).  Interestingly,  some  of  the  mutations  resulting  in  human 
amyloidosis  do  not  cause  any  known  harm  in  other  species.  For  example, 
Val30Leu and Ile84Ser are amyloidogenic in human but in the sea bream these 
mutations are non-amyloidogenic. Furthermore, study revealed that some of the 
single residue substitutions in humans are actually conserved in other species, like 
sea bream and skunk TTR.   106 
 
So, why are the same TTR mutations pathogenic in humans but harmless in other 
species? There might be some compensatory mutations present in other species. 
Obviously, factors other than TTR structure must contribute to amyloid formation 
and these might differ between species (Power et al., 2000). For example, the 
chemical properties of a substituted residue may depend on its microenvironment. 
 
5.2.2 Comparative physiology of TTR 
 
TTR is mostly expressed in the choroid plexus and in the liver in human, rat, pig 
and sheep (Dickson & Schreiber, 1986; Schreiber et al., 1990; Duan et al., 1995; 
Costa et al., 1989, Yan et al., 1990). TTR expression has also been detected in 
the human pancreas (Jacobsson et al., 1990). Interestingly, TTR is predominantly 
expressed in the brain of lizards and turtles; expression by the liver is so low that it 
is not easily detected (Achen et al., 1993). In sea bream TTR is predominantly 
expressed  by  the  liver  and  in  intestines  and  heart  (Santos  &  Power,  1999). 
Furthermore,  TTR  expression  has  also  been  detected  in  the  eyes  of  certain 
mammals like sheep and cattle (Martone, 1998; Cavallaro et al., 1990; Dwork et 
al., 1990). Significant expression levels of TTR protein have also been detected 
during  the  developmental  stages  of  different  species.  For  example,  TTR  is 
expressed in the yolk sac of the rat foetus (Soprano and Goodman, 1990), in early 
developmental rat eye tissue (Mizuno et al., 1992) and in the developmental heart 
cells of the chicken (Barron et al., 1998). However, the exact developmental role of 
TTR is as yet unknown.  
 
 
5.2.3 The three-dimensional structure of transthyretin 
 
X-ray  structural  studies  of  human  transthyretin  were  initiated  in  1966  in  the 
laboratory  of  Haupt  and  Heide  (Haupt  &  Heide,  1966).  TTR  crystals  were  first 
obtained by using ammonium sulphate as a precipitant and the protein crystallized 
in  the  P21212  space  group  with  two  monomers  in  the  asymmetric  unit  cell 
possessing two fold rotational symmetry (Haupt & Heide, 1966). X-ray structure of 
human TTR was first determined to 1.8Å resolution in the Blake group at Oxford   107 
(Blake  et  al.,  1971).  The  X-ray  structures  of  chicken  and  rat  TTR  were 
subsequently determined at 2.9Å and 2.5Å resolution respectively (Power et al., 
2000).  TTR  tetramer  in  complex  with  two  molecules  of  retinol  binding  protein 
(RBP) was also determined in 1990 as shown in Figure 5.7 (Cowan et al., 1990). 
Each monomer of TTR consists of 8 β-strands (labelled A to H) and a short α-
helix, which is positioned between strands E and F. The β-strands hydrogen-bond 
to form two β-sheets, one involving strands D, A, G & H and the another involving 
strands C, B, E & F, which are separated by approximately 10Å and form a β-
barrel structure. The β-sheet structure involves 68 residues (55%) whereas the 
seven helical residues account for only 5% of the TTR structure. The range of 2 to 
15 residue loops connect β-strands B to F. The nine residues at the flexible N-
terminus  and  the  four  at  the  carboxyl  terminus  are  both  disordered  in  all  TTR 
crystal structures.  
 
Two  TTR  monomers  form  a  dimer  when  strands  H  and  F  hydrogen  bond  to 
strands H′ and F′ respectively of an adjacent monomer (Blake et al., 1971).  This 
extensive H-bonding makes the TTR dimer very stable and robust under drastic 
conditions (Jaarsveld et al., 1973). Two dimers further self-associate to form the 
functional TTR tetramer by hydrophobic interaction of the A, B, G & H loops of one 
dimer with the A′ B′ and G′ H′ loops of the second dimer. 
 
The X-ray structure of the T4-bound TTR tetramer (Blake & Oatley, 1977) reveals 
the  presence  of  three  halogen-binding  pockets  at  the  monomer-monomer 
interfaces  of  two  dimers  of  the  tetramer.  The  pockets  are  named  as  P1 
(outermost), P2 and P3 (innermost). The side chains of Met13, Lys15 and Thr106 
residues  contribute  to  the  P1  pocket.  The  P2  pocket,  which  is  hydrophobic,  is 
made  up  of  the  side  chains  of  Lys15,  Leu17,  Ala109  and  Leu110.  It  is  also 
contributed to by the carbonyl groups of Ala108, Ala109 and Lys15. The innermost 
pocket (P3) is made up of the side chains of Ala108, Leu110, Ser117, Thr119 and 
also carbonyl and amide groups of Ala108, Ala109, Leu110 and Thr118 (Blake & 
Oatley, 1977; Wojtczak et al., 2001) (Figure 5.6).    108 
                      
 Figure 5.6 The three halogen-binding pockets of TTR involve the three pockets 
called P1, P2 and P3 of TTR (Wojtczak et al., 2001). 
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Figure 5.7 A) The TTR dimer with the monomers (each containing 8 β-strands) is 
depicted in red and blue. B) The TTR tetramer with two thyroxine molecules (cyan) 
bound at the monomer-monomer interfaces of each substituent dimer. C) The TTR 
tetramer in complex with two molecules of retinol binding protein (in green) each 
bound to a retinol molecule (in cyan) (Wojtczak et al.,1996; Naylor & Newcomer, 
1999). 
 
5.2.4 The TTR-retinol binding protein complex 
 
As  previously  discussed,  the  TTR  tetramer  binds  to  two  molecules  of  retinol 
binding protein (RBP). RBP is a ~21 kDa protein, composed of eight β-strands (1-
8) forming a β-barrel structure and a short carboxyl terminal α-helix (Cowan et al., 
1990).  The  human  TTR-RBP  complex  was  first  co-crystallised  and  its  three-  110 
dimensional structure determined in 1995 (Figure 5.7; Monaco et al., 1995). The 
loop regions connecting β-strand 5, 6, 7 and 8 of RBP interact hydrophobically 
with the α-helix (residues 80-86) of TTR (Rask et al., 1971).  
 
5.2.5 TTR amyloid 
 
The involvement of TTR in amyloidosis was first discovered in Costa’s lab in 1978 
(Costa  et  al.,  1978).  Later  on,  the  same  group  discovered  that  different  TTR 
hereditary mutants are more susceptible to amyloidogenesis (Costa et al., 1978). 
Amyloid  is  the  end  product  of  TTR  mis-folding  and  the  aggregation  product  is 
ultimately  deposited  in  the  different  tissues  of  the  body.  The  native  (wild-type) 
transthyretin has the propensity to form amyloid in an age dependent manner but 
the inherited mutant TTR is far more amyloidogenic. The majority of the mutant 
TTR proteins bind to thyroxine less tightly than native TTR and destabilize the TTR 
tetramer, making it more prone to amyloid formation. More than 100 mutations in 
human TTR gene have been identified to date and ~10,000 people worldwide are 
suffering inherited TTR amyloidosis (Pepys, 2006).  
 
In  this  study  I  aim  to  structurally  characterize  V30M  and  L55P  human  TTR  in 
complex with Mds84 bivalent ligand. The V30M TTR mutation is very common in 
the  population  of  England,  Brazil,  Sweden,  Portugal,  Greece,  and  the  United 
States and causes familial amyloidotic polyneuropathy (FAP) (Terry et al., 1993). 
On the other hand, L55P TTR is far more rare and found only in the United States 
and  Taiwan  but  is  the  more  pernicious,  causing  cardiomyopathy  and  death, 
sometimes  before  the  age  of  40  (Benson  et  al.,  1996).  The  protein  backbone 
structures of wild-type and L55P TTR are structurally identical, but in V30M TTR 
the bulky methionine substituent disrupts the β-sheet formed by β-strands D, A, G 
and H. This shift changes the shape of the thyroxine binding cavity resulting in 
lower  binding  affinity.  The  whole  process  ultimately  destabilizes  the  tetramer 
(Hamilton  et  al.,  1992)  and  forms  amyloid  (Hamilton  et  al.,  1993).  The  lower 
thyroxine-binding affinity of L55P TTR is harder to explain. The surface exposed 
CD loop of L55P containing the mutation has a structure identical to that in wild-
type TTR (Yang et al., 2003) but it can affect the conformational flexibility.   111 
Different  types  of  amyloidosis  are  associated  with  wild  type  and  specific  TTR 
mutations. Furthermore, whereas some amyloids are organ specific, others are 
generalized. Senile systemic amyloidosis (SSA) is caused by the deposition of wild 
type TTR amyloid in the heart and liver in people older than 80 years of age. Both 
full length and N-terminal truncated wild-type TTR sequences are found in amyloid 
and  most  of  them  are  cleaved  between  residues  46  and  52  (Sunde  &  Blake, 
1998).  
 
The  discovery  of  SSA  resulting  from  aggregation  of  wild-type  TTR  implies  the 
existence of a mutation-independent (but perhaps mutation-accelerated) pathway 
of amyloid formation. Approximately 25% population of over 80 years is affected 
worldwide by SSA (Cornwell et al., 1983; Pitkanen et al., 1984).  
 
Familial amyloidotic polyneuropathy (FAP) disease is caused by a single residue 
substitution in the TTR sequence. It was first discovered in Portugal (Andrade, 
1952), and was later on found in the US population as well  (Falls et al., 1955). 
The  first  TTR  mutant  FAP  associated  amyloidosis  was  discovered  due  to  the 
mutation  of  valine  to  methionine  (V30M).  The  first  FAP  mutation  sequenced 
(V30M) is very common in Sweden, Japan, Portugal and Brazil (Suhr et al., 2003; 
Dwult & Benson, 1983) whereas L55P is much rarer (McCutchen et al., 1995).  
 
 In addition to SSA and FAP, there is another type of organ specific amyloidosis 
called Familial amyloidotic cardiomypathy (FAC). It results from TTR mutations 
such as A45S, L111M and V122I (Jacobson et al., 1996, Janunger et al., 2000). 
FAC is most prevalent in Denmark and Sweden and amongst African-Americans 
and the amyloids are deposited mainly in the heart. 
 
5.2.6 The proposed mechanism of TTR amyloid formation 
 
The process of TTR amyloid formation is not well understood but several different 
mechanisms  have  been  proposed.  TTR  generally  exists  as  a  stable  tetramer 
under physiological conditions but it has been speculated that the tetramer might 
dissociate  into  TTR  monomers  under  certain  conditions.  These  unstable   112 
monomers  might  form  non-native  structures,  which  are  more  prone  to  amyloid 
formation rather than tetramer reformation. Tetrameric TTR is known to dissociate 
into  monomers  and  form  amyloid  at  acidic  pH.  Additionally,  FAP-linked  TTR 
mutants are more susceptible to amyloid formation at acidic pH compared to wild 
type TTR (Johnson et al., 2005; Hurshman et al., 2004) (Figure 5.8). The mutant 
TTR forms amyloid fibrils approximately 100 times faster than wild type (Jiang et 
al., 2001; McCutchen et al., 1993). 
              
Figure  5.8  The  schematic  diagram  shows  the  pH  dependent  formation  of  TTR 
amyloid pathway (Kelly et al., 1997). 
 
It  has  also  been  proposed  that  the  exposed  Cys10  makes  disulphide  bridges 
between  V30M  TTR  dimers.  This  could  favour  aggregation  and  subsequent 
amyloid formation (Felding et al., 1985; Terry et al., 1993). Interestingly, V30M 
TTR tetramer binds thyroxine less tightly hence it is less stable. This compromised 
TTR tetramer stability shifts equilibrium towards its monomeric form and ultimately 
misfolding.  Different  models  have  been  proposed  based  on  the  combination  of 
experimental  observations  and  computational  modelling  to  understand  the 
progression of TTR led amyloid fibres formation (Figure 5.9).  
 
In  the  case  of  the  L55P  variant,  another  mechanism  has  been  proposed  to 
account for amyloid formation. It has been observed that L55P TTR extracted from 
amyloid is cleaved between residues 36-66. The monomer of the amyloidogenic 
intermediate  has  exposed  C  and  D  strands  and  the  proline  substitution  in  this 
region is not conductive to β-sheet structure (Figure 5.10). As a result, this region   113 
becomes  more  susceptible  to  proteolytic  cleavage.  However,  it  is  not  clear 
whether the protein is cleaved prior to or after amyloid formation (Westermark et 
al., 1990). 
            
 
Figure 5.9 A schematic representation of proposed model of the TTR protofilament 
formation which is based on the combination of experimental observations and 
computational modelling to understand the progression of amyloid fibre formation 
(Correia et al., 2006). 
 
Figure 5.10 The native TTR dimer and the exposed C & D strands of L55P TTR 
(dark line) (Kelly & Lansbury et al., 1994). 
 
5.2.7 In vitro versus in vivo fibril formation 
 
The in vitro study of TTR misfolding and amyloid fibre formation is informative but 
is  not  possible  at  physiological  conditions.  The  physiological  pH  of  the  living 
system  is  almost  neutral  whereas  fibril  formation  in  vitro  has  been  studied  at 
unrealistically low pH. It seems that some other mechanisms must be there in vivo 
which destabilise functional TTR tetramer and ultimately leads to the formation of 
amyloid fibrils (Figure 5.11).   114 
 
Figure 5.11 A proposed model for TTR subunit exchange is shown in the diagram 
and the subsequent amyloidosis after partial denaturation of the TTR monomer 
(Johnson et al., 2005). 
 
 
5.2.8 TTR subunit exchange model 
 
Experiments  with  the  human  and  rhesus  monkey  TTR  heterotetramer  first 
demonstrated  subunit  exchange  at  physiological  pH  (Bernstein  et  al.,  1970).  A 
later study demonstrated that the equilibrium shifted from tetrameric to monomeric 
TTR  at  physiological  pH  but  it  is  only  possible  when  the  TTR  concentration  is 
below  the  physiological  concentration  (Quintas  et  al.,  1999).  Interestingly,  the 
expression of TTR in certain individuals who are suffering from amyloidosis is very 
low  (Skinner  et  al.,  1985).  Different  models  for  the  TTR  tetramer  dissociation 
mechanism have been suggested. In the 1
st and 2
nd mechanisms the two dimers 
of the tetramer dissociate first whilst the 3
rd proceeds via the formation of trimers 
(Figure 5.12).   115 
 
 
Figure 5.12 The different mechanisms proposed for TTR tetramer dissociation to 
monomers,  which  ultimately  leads  to  mis-assembly  and  amyloid  fibril  formation 
(Foss et al., 2005). 
 
To monitor subunit exchange of human TTR tetramer in vitro, wild type and V30M 
TTR  were  independently  mixed  with  recombinant  N-terminal  tagged 
(DYKDDDDKDYKDDDDK) TTR (Schneider et al., 2001). TTR heterotetramer were 
analysed by the anion-exchange chromatography. It was found that both wild type 
and V30M TTR exchange subunits at 37°C but with V30M the subunit exchange is 
comparatively  slow  and  incomplete  (according  to  an  equilibrium  study).  The 
exchange of subunit was found to increase with increasing concentrations of TTR 
(Schneider et al., 2001).  
 
A related mass-spectrometric study on L55P TTR subunit exchange showed that 
monomer exchange in this variant is 12.5 times faster than that of wild type and 
exchange of the variant dimer is 22 times faster. The suspected disulfide bond 
formation between monomers was not observed as the experiment was performed 
under  reducing  conditions.  It  implies  that  the  L55P  mutation  disrupts  the 
hydrophobic interactions within the TTR tetramer (Keetch et al., 2005). It seems   116 
that it might be possible that the heterotetramer of L55P is very unstable and it 
rapidly ends up in the amyloid formation pathway. 
 
5.2.9 TTR as a potential therapeutic target 
 
There are several strategies used to treat TTR-related amyloidosis (Figure 5.13).  
 
                                                      
 
Figure 5.13 Possible approaches to treat TTR-related amyloidosis at different 
stages (Saraiva, 2002). 
 
Currently  the  most  effective  treatment  is  liver  transplantation.  The  newly 
transplanted  liver  degrades  the  mutant  TTR  from  the  blood  plasma.  It  also 
prevents  the  deposition  of  variant  TTR  amyloid  in  the  organs  of  FAP  patients 
(Holmgren  et  al.,  1991).  Because  the  root  cause  of  TTR  amyloidosis  is  the 
mutation in the TTR gene, gene therapy could be an exciting possibility in the   117 
future.  More  recently,  efforts  have  been  made  to  stabilise  TTR  with  chemical 
ligands, which also trigger its clearance from the body. 
 
Several different TTR-related amyloid disrupter drugs have been studied both in 
vivo and in vitro. 4′-deoxy-4′-iododoxorubicin (IDOX) has been tested in vitro and 
proved  to  be  a  potential  TTR-related  amyloid  disrupter  but  is  unfortunately 
cardiotoxic. An analogue of IDOX with no side effect could be considered as a 
potential therapeutic drug (Sebastiao et al., 2000). More recently, doxycycline was 
demonstrated to disrupt V30M TTR-related amyloid fibril formation in mice with no 
known toxicity (Cardoso & Saraiva, 2006).   
 
Another possibility is to stabilize the TTR to prevent amyloid formation by small 
chemical compounds. The binding of chemical compounds to the thyroxine binding 
sites not only stabilizes the TTR tetramer but also inhibits subunit exchange, which 
is thought to be the rate-limiting step in amyloidosis (Kelly, 1997). 
 
Over the past decade, attempts have been made to design structure based drug 
compounds to stabilize the tetrameric form of TTR. Small chemical inhibitors like, 
Diclofenac were shown to stabilize the tetrameric form of mutant TTR (Bares et al., 
1999). Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) and most of 
this  class  of  drugs  cause  gastrointestinal  ulcers.  This  property  of  Diclofenac 
abandoned its use for the treatment of FAP (Oza et al., 2002).  
 
Different  bis-aryl  compounds  have  been  used  up  to  now  to  stabilize  the  TTR 
tetramer in Kelly’s lab (Johnson et al., 2005) and still efforts are going on to make 
more potent TTR stabilizers. A single bivalent inhibitor that binds to both thyroxine-
binding sites in the tetramer very tightly (with nanomolar affinity) could glue the two 
dimers together to form a stable tetramer and inhibit subunit exchange processes 
(Hammarstrom et al., 2003). The linker of the bivalent compound is designed to be 
rigid and its length optimized according to the length of the central cavity of the 
tetramer (Figure 5.14). 
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Figure 5.14 Design of a bivalent inhibitor of the TTR tetramer. The two outer and 
inner halogen-binding sites are occupied by the head groups (yellow and blue) and 
the length of the linker is 7-10Å (Green et al., 2003). 
 
The binding of different bivalent inhibitors to TTR has already been characterized 
by mass spectrometry and X-ray crystallography (Klabunde et al., 2000). But these 
compounds only bind to TTR when it is denatured in 6M urea (Green et al., 2003). 
A bivalent class of inhibitors has recently been studied for lung tryptase (alkyl-
linked  benzamidine;  Burgess  et  al.,  1999),  acetylcholinesterase 
(bistetrahydroaminacrine; Pang et al., 1996) and CPHPC for SAP (Pepys et al., 
2002). 
 
5.3 Aim of research 
 
The wild type transthyretin and its mutants are well known as amyloid forming 
proteins and cause different types of amyloidosis. The structural study of the wild 
type and mutant TTR is already well characterized. In this study I focused on the 
structural stability of L55P and V30M TTR mutants. A number of different drug 
compounds have already been characterized to stabilize the tetrameric structure 
of TTR. In this study I have complexed the L55P and V30M TTR mutants with a 
novel and bivalent ligand called palindromic dichloro bisaryl compound (Mds84) 
and crystallized the complex. 
 
X-ray crystallography is used to determine the three dimensional structure of the 
complexes at atomic resolution and the structural effect of the ligand binding to the 
TTR mutants has been analysed.    119 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 The structures of L55P and V30M TTR in complex 
with Mds84 (a TTR super-stabilizer)   120 
6  Introduction 
 
Transthyretin  is  a  plasma  protein  and  it  transports  thyroid  hormone.  It  has  the 
potential  to  form  amyloid  deposits  in  different  tissues  of  the  human  body. 
Worldwide,  over  10,000  individuals  suffer  from  amyloidosis  resulting  from 
mutations in the TTR gene (Pepys, 2006). Amyloid deposition of wild-type TTR 
fibrils in elderly patients results in senile systemic amyloidosis (SSA) which affects 
~  25%  of  over  80-year-olds  worldwide  (Cornwell  et  al.,  1983;  Pitkanen  et  al., 
1984). 
 
Additionally, more than 100 TTR gene variants have been identified that result in 
hereditary  transthyretin  amyloidosis  e.g.  FAP  (familial  amyloid  polyneuropathy) 
and FAC (familial amyloid cardiopathy). Patients with TTR amyloidosis have life 
spans of 5-15 years. The most effective treatment for TTR related amyloidosis is 
liver transplantation, which slows disease progression in younger patients. But in 
case of older patients, the liver transplant is not very successful. 
 
Recently,  efforts  have  been  made  to  develop  drugs  to  treat  the  TTR-related 
amyloidosis.  It  has  been  established  that  small  compounds  binding  at  the 
thyroxine binding site of TTR can stabilise the tetrameric form of protein (Johnson 
et  al.,  2005)  and  prevent  amyloid  formation.  In  this  research  the  transthyretin 
tetramer has been stabilised with the bivalent, palindromic compound Mds84 (2,2’-
(4,4’-(heptane-1,7-diylbis(oxy))bis(3,5-dichloro-4,1-phenylene))-bis-(azanediyl)  di-
benzoic acid)) (Figure 6.1). 
 
Mds84 possesses two identical head groups linked via a seven-carbon linker. The 
head group possesses two chlorine atoms designed to interact with the thyroxine 
binding site of the TTR tetramer and the linker length is optimized to span the 
central cavity of the tetramer. In this study I have made efforts to stabilise the 
L55P  TTR  (rare  but  most  toxic)  and  V30M  TTR  (the  most  common)  tetramers 
using Mds84. 
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Figure 6.1 The structure of the palindromic, bivalent TTR super stabilizer mds84 
(2,2’-(4,4’-(heptane-1,7-diylbis(oxy))bis(3,5-dichloro-4,1-phenylene))-bis-
(azanediyl) di-benzoic acid)). 
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6.1 Materials and methods 
 
6.1.1 Reagents 
 
All reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK) and Fisher 
Scientific  (Loughborough,  UK).  Mds84  was  kindly  provided  by  Professor  Steve 
Wood, Lab of Crystallography, Centre for Amyloidosis and Acute Phase Proteins, 
University College London, UK. 
 
6.1.2 Media preparation 
 
Luria-Bertani (LB) medium (10g tryptone, 5g yeast extract, 10g NaCl, 5 gram Agar 
(15g) in 1L pH 7.0) was prepared and autoclaved at 121°C/15 psi for 20 mins. 
Ampicillin  was  filter  sterilized  through  a  0.2  µm  disposable  filter  and  added  to 
molten  LB  agar  (100µg/ml)  once  it  had  cooled  to  50˚C.  LB  agar  plates  were 
prepared under sterile conditions, sealed with parafilm and stored at 4˚C for up to 
6 weeks. The pET11a plasmids containing the L55P TTR and V30M mutant genes 
were  kindly  provided  by  Professor  Carol  Robinson,  Department  of  Chemistry, 
Cambridge University, UK (Figure 6.2). 
 
                  
Figure 6.2 Restriction map of pET11a (Novagen)  
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6.1.3 Transformation of E. coli 
 
BL21 (DE) pLysS E.coli competent cells (Invitrogen) were transformed with the 
pET11a plasmid containing TTR gene, plated on LB-Amp plates and incubated 
overnight at 37˚C. 
 
6.1.4 Small-scale preparation of starter culture (100ml) 
 
Four single colonies were picked into the four vials of autoclaved LB medium (pH 
7.0) (10ml each) containing ampicillin (100µg/ml) and grown overnight at 37˚C with 
shaking at 220 rpm. 
 
6.1.5 Large-scale cell culture for L55P and V30M TTR mutant 
protein expression 
  
For  large-scale  cell  culture  and  expression  of  recombinant  TTR,  4  litres  of  LB 
medium (pH 7.0) was prepared in separate 1L flasks and autoclaved at 121°C/15 
psi for 20 mins. The LB broth was allowed to cool to room temperature and filter-
sterilized ampicillin (100µg/ml) was added under sterilised conditions. The flasks 
were  then  inoculated  with  10  ml  of  starter  culture  and  incubated  at  37°C  with 
shaking at 220rpm. The cells were grown to an OD600 of 0.60 and the culture 
induced  with  2mM  (final  concentration)  filter  sterilized  IPTG  under  sterilised 
conditions.  
 
The  IPTG  induced  cells  were  grown  for  further  5  hrs  and  harvested  by 
centrifugation at 8,000g for an hour. The wet cell weight of the cell pellet was 
determined and the cells stored at -20°C. 
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6.1.6 Cell lysis 
 
The cell pellet was resuspeded in 50 ml of cell lysis buffer (50 mM Tris pH8.0, 140 
mM NaCl). The cells suspension was sonicated (Soniprep 150) with 30 sec on and 
40 sec off cycle for 5 mins and the lysate was centrifuged at 15,000 g for 25 mins. 
 
6.1.7 SDS-PAGE 
 
10  µl  of  lysate  and  a  small  quantity  of  pellet  were  suspended  in  2  x  Laemmli 
loading buffer (including 5% β-mercaptoethanol) and denatured by boiling for 5 
min.  A  12%  SDS-poyacrylamide  gel  was  prepared  containing  stacking  and 
separating gels using a Bio-Rad SDS-PAGE gel system. 
 
The  separating  gel  consisted  of  3  ml  of  30%  w/v  acrylamide:  0.8%  (W/V)  bis-
acrylamide  stock  solution  (Flowgen  Bioscience),  1.87  ml  4X  Tris-HCl  SDS 
separating buffer pH 8.8, 2.6 ml distilled water, 50µl of 10% (freshly prepared) 
APS and 10 µl of TEMED.  
 
The stacking gel consisted of 0.65 ml of 30% (W/V) acrylamide: 0.8% (W/V) bis-
acrylamide  stock  solution  (Flowgen  Bioscience),  1.25ml  4X  -Tris-HCl-SDS 
separating  buffer,  pH  6.8,  3.05ml  distilled  water,  50µl  of  10%  ammonium 
persulfate (APS) and 10 µl of TEMED.  
 
The  denatured  lysate  and  the  inclusion  bodies  in  Laemmli  loading  buffer  were 
loaded on the 12% SDS polyacrylamide gel and electrophoresed at 24mA for 1 
hour.  The  gel  was  stained  with  Coomassie  blue  solution  (30%  methanol,  10% 
acetic acid and 2% Coomassie Brilliant Blue R-250) for 30 mins and destained 
(30% methanol, 10% acetic acid) until the protein bands were visible. The gel was 
photographed on a Doc 2000 transluminator (BIO RAD) system. 
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6.1.8  L55P  variant  TTR  purification  by  anion  exchange 
chromatography 
 
Anion  exchange  chromatography  separates  a  mixture  of  proteins  according  to 
their charge. L55P TTR is negatively charged at pH 8.0 so a Q-Sepharose (50ml 
volume)  fast  flow  (Amersham  Pharmacia  Biotech)  anion  exchange  column 
equilibrated in Tris-HCl (pH 8.0) buffer was used for its purification. The column 
was  attached  to  the  Akta  Prime  FPLC  Chromatography  System  (Amersham 
Pharmacia Biotech). 
 
The cell lysate containing L55P protein was dissolved in 10mM Tris-HCl, pH 8.0 
(loading  buffer),  and  loaded  onto  the  column  at  the  flow  rate  of  1ml/min.  The 
column was washed with loading buffer to remove any non-specific proteins bound 
on  the  column.    Then  the  bound  TTR  mutant  protein  was  eluted  with  linear 
gradient of NaCl from 0 to 1M (total volume, 600ml) (Olofsson et al., 2001).  
 
6.1.9 Gel filtration of L55P TTR. 
 
Gel  filtration  (size  exclusion  chromatography)  separates  a  mixture  of  proteins 
according  to  their  size.  Proteins  larger  than  the  matrix  pore  size  elute  in  the 
exclusion volume whereas small protein molecules permeate the pores and take a 
longer time to elute from the column. Proteins of intermediate size are fractionated 
accordingly.  A  Superdex75  gel  filtration  column  (of  80ml  volume)  (Amersham 
Pharmacia  Biotech)  was  equilibrated  in  10mM  Tris-HCl  (pH8.0),  140mM  NaCl. 
L55P TTR was concentrated to 18mg/ml with a 30,000 MWCO centricon (Viva 
science) and 1ml of concentrated protein was loaded with flow rate of 1ml/min. 
Purified L55P TTR tetramer was eluted after 84min. The V30M TTR mutant was 
purified with a similar strategy except that V30M TTR was eluted after 47min from 
Superdex75 column. 
 
Purified protein was re-concentrated to 12mg/ml with a 30,000 molecular weight 
cutoff (MWCO) centricon (Viva science) and 0.01% sodium azide was added to 
prevent any bacterial growth.    126 
6.2 Mass-spectrometry 
 
In mass spectrometry, a mixture of gas phase ions are separated by magnetic 
fields according to their mass/charge ratio.  
 
6.2.1 Electrospray ionization (ESI) 
 
ESI  is  the  method  of  choice  for  protein  analysis  because  it  produces  multiple 
charged  ions  (Figure  6.3).  The  sample  is  loaded  straight  from  the  HPLC  line, 
which is connected to the electrospray probe. The tip of the electrospray probe is 
bathed in a nitrogen flow. A high voltage is applied between the probe tip and the 
sampling cone. Nitrogen is used for spray stability at higher flow rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Schematic diagram of the electrospray source of a mass spectrometer 
(http://chemwiki.ucdavis.edu). 
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The  surface  of  the  sample  becomes  charged  and  the  solvent  in  the  droplet 
evaporates  when  it  passes  through  the  warm  stream  of  inert  gas  and  its  size 
decreases, increasing the surface charge density until repulsive forces disintegrate 
the  drop.  The  charged  protein  fragments  are  then  detected  on  the  quadrupole 
analyser (Hoffmann & Stroobant, 2002). 
L55P  and  V30M  TTR  mutant  proteins  were  desalted  using  Pharmacia  Biospin 
columns and dissolved in acetonitrile/H2O/formic acid (1:1:0.01) at a concentration 
of 10-50 pmol/ml. The samples were analysed by positive ion electrospray mass 
spectrometry on a Micromass Quattro II triple quadrupole mass spectrometer by 
Dr N Rendell (UCL Medical School).  Data were then deconvoluted by Micromass 
Masslynx 4.0 software to produce molecular ion spectrum. 
 
6.3 Co-crystallisation of L55P and V30M TTR with Mds84  
 
The L55P and V30M TTR mutant protein concentrations were adjusted to 12mg/ml 
in Tris-HCl buffer (pH 8.0), 140mM NaCl. 100µl of 10mM sodium acetate (pH 5.0) 
was added to 2mg of Mds84 dissolved in 200µl DMSO. The pH of the solution was 
adjusted to 5.0 with acetic acid and the solution was then incubated at 60°C for 
3hrs. The sample was then centrifuged and the 50µl of solublized mds84 fraction 
was mixed with an equal volume of 12mg/ml TTR (10:1 molar ratio). The mixture 
was incubated at room temperature for approximately 3hrs and then centrifuged 
again  at  13,000  g  for  5  mins.  The  supernatant  of  the  mixture  was  used  for 
crystallisation. 
 
Crystallisation trays were set up in 70mM sodium acetate buffer (pH 4.0, 4.5 & 
5.0), 100 mM NaCl and 25-32% (v/v) PEG550 (Table 6.1). 0.01% sodium azide 
was routinely added to well solutions to prevent microbial growth. Mds84-mutant 
TTR  complexes  were  crystallized  using  the  hanging  drop  (vapour  diffusion) 
method. 3 µl of protein-ligand mixture and 3 µl of well solution were mixed and the 
drop suspended from siliconised cover slips, sealed over the respective well. The   128 
plates  were  incubated  at  room  temperature  and  crystals  appeared  at  28% 
PEG550, 70mM sodium acetate (pH 5.0), 100 mM NaCl after two weeks. 
 
 
                         PEG 550  (%) 
           25         28        30        32 
 
 
4.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.0 
 
 
 
 
Best 
crystals  
 
 
 
 
 
 
 
6.0 
 
 
       
 
 
 
 
 
70mM 
Sodium 
acetate 
(pH) 
 
 
 
 
 
 
 
 
 
 
                 
        100mM NaCl +10 times molar excess of Mds84 
 
Table 6.1 Crystallisation trial conditions for the L55P-Mds84 and V30M TTR -
Mds84 mutants. 
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6.4 Results 
 
6.4.1 Protein expression and purification 
 
L55P TTR was expressed in E. coli BL21 (DE3)pLysS (Invitrogen Ltd). SDS-PAGE 
demonstrated that the protein was well expressed with the majority in soluble 
fraction (Figure 6.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.4  Reduced  and  denatured  L55P  TTR  electrophoresed  on  12%  SDS-
PAGE. Lane 1, broad range protein marker (Promega Corp.) and lane 2, soluble 
protein in the cell lysate. 
 
6.4.2 Purification of L55P TTR mutant 
 
L55P  TTR  was  purified  by  anion-exchange  chromatography  followed  by  gel 
filtration chromatography. A single peak ~ 56kDa in size corresponding to the TTR 
tetramer was obtained (Figure 6.5). Purity of the protein was assessed by 12% 
denaturing SDS-PAGE (Figure 6.6). 
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Figure 6.5 Gel filtration chromatography of L55P TTR. A single peak of tetrameric 
L55P TTR eluted at 82mls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Reducing SDS-PAGE of L55P and V30M TTR after anion exchange 
and gel filtration chromatography. M: broad range protein marker (Fermentas Ltd). 
The lane 1 is L55P and lane 2 shows V30M TTR mutant. 
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6.4.3 Mass-spectrum of L55P and V30M TTR mutant        
 
The mass spectra of L55P (Figure 6.7) and V30M (Figure 6.8) yielded expected 
masses of 13876.80 Da and 13925.15 Da respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Mass spectra of L55P TTR (mass/charge ratio (top) and deconvoluted 
data (bottom).   132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Mass spectra of V30M TTR (mass/charge ratio (top) and deconvoluted 
data (bottom). 
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6.4.4 Co-crystallisation of L55P and V30M TTR with MDS84. 
 
Crystals of L55P and V30M in complex with Mds84 appeared within two weeks at 
room temperature by the hanging drop method (Figures 6.9 and 6.10). 
 
                        
 
Figure 6.9 A crystal of L55P TTR co-crystallised with Mds84 and the best crystals 
were obtained at 28% PEG550, 70mM sodium acetate (pH 5.0), 100 mM NaCl.  
 
                         
Figure 6.10 A crystal of V30M TTR in complex with Mds84 was obtained with the 
same conditions discussed above for L55P-Mds84 crystallization.  
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6.5 Structure of L55P TTR in complex with Mds84 
 
6.5.1 Crystal freezing and X-ray data collection of L55P-Mds84 
complex 
 
L55P TTR-mds84 crystals were frozen in a cryostream (Oxford Cryosystems) and 
transported  to  the  Diamond  Light  Source,  Oxford  under  liquid  nitrogen. X -ray 
diffraction data were collected on beam line I04 (λ=0.970Å) using an ADSC Q315 
charge coupled device (CCD) detector. 150 images were collected at 1º oscillation 
(Figure  6.11)  and  the  data  were  processed  with  iMOSFLM  (CCP4  suite). 
Autoindexing  revealed  that  the  following  were  possible  space  groups:  P222, 
P2221, P2122, P2212, P21212, P2212, P21221, P212121 with unit cell dimensions of 
a= 43.27Å, b = 65.33Å, c = 85.07Å, α = β = γ =90°  (Table 6.2).  The Matthews 
coefficient  showed  the  presence  of  one  TTR  dimer  in  the  asymmetric  unit 
(Matthews, 1968) with 42% solvent content. The data were then scaled to 1.7Å 
resolution using SCALA (CCP4 suite) (Table 6.3). The overall Rmerge of the scaled 
data was 4.7% with an overall completeness of 98.8%.   Then the scaled data 
were re-indexed (h=-h, k=l, l=k) to get the molecular replacement solution in the 
conventional space group P21212.  
                             
Figure 6.11 A representative diffraction image collected (using 1º oscillation) from 
the L55P-Mds84 crystal at the Diamond Light Source, Oxford, UK. 
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Table 6.2 iMOSFLM penalty Table for the L55P TTR –mds84 complex. The data 
were initially processed in space group P222.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3 SCALA processing statistics for the L55P TTR-Mds84 complex. 
 
Pseudo-precession images were generated using HKLVIEW along the axes (h, k, 
l) and data were searched for the systematic absences of reflections (Figure 6.12-
14). There were systemic absence of reflections along h and l axes.   
 
 
Space group        P222  
Unit cell (Å) 
 
              (º) 
a = 43.14, b = 
65.13, c = 84.82   
α = β = γ = 90.0,  
Low resolution (Å)  43.41 
 
High resolution (Å)  1.70 
 
Rmerge (%)  4.7 (20) 
 
Rmeas (%)  5.4 (23.3) 
 
Total number of reflections  121923 (17810) 
 
Total number unique 
reflections 
31825 (4601) 
 
Mean ((I)/sd(I))  18.9 (5.7) 
 
Completeness (%)  98.8  (99.9) 
 
Multiplicity  3.8 (3.9) 
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Figure  6.12  A  pseudo-precession  picture  of  L55P-mds84  reflection  image  a) 
created by HKLVIEW showed the hk0 plane and b) in close up view, systematic 
absences of reflections along h axis were detected. 
   137 
 
 
 
 
 
 
Figure 6.13 A pseudo-precession image of L55P-mds84 reflection image created 
using HKLVIEW (CCP4 suite) showed in panel a) 0kl plane and b) the close up 
view without clear systematic absences along the k axis. 
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Figure  6.14  a)  The  0kl  plane  of  the  L55P  TTR  -mds84  data.  b)  Systematic 
absences were visible along the l axis. 
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6.5.2 Molecular replacement of the L55P TTR-Mds84 structure. 
 
Phases  for  the  L55P  TTR-Mds84  structure  were  determined  by  molecular 
replacement  using  PHASER  (Read,  2001).  The  human  TTR  structure  1DVQ 
(Klabunde et al., 2000) was used as the search model without water molecules. 
PHASER  searched  for  a  molecular  replacement  solution  in  all  possible  P222 
space groups. The best solution found was in space group P21212 and showed 
LLG of 2627 with RFZ of 29.9 and TFZ 50.5 respectively. The crystal packing of 
the PHASER solution was viewed in NUcheck (Figure 6.15). 
 
Figure 6.15 Crystal packing of the four L55P TTR-Mds84 dimers at the equivalent 
positions in the P21212 unit cell (a= 43.14Å, b= 84.82Å, c= 65.13Å; α = β = γ = 
90.0º) (NUchek; Feng et al., 1998).  
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6.5.3 Refinement of the L55P-Mds 84 structure  
 
The  L55P-mds84  PHASER  solution  was  manually  rebuilt  in  COOT  (Emsley  & 
Cowtan, 2004) and refined with REFMAC (Murshudov et al., 1997). To minimise 
model bias 5% of the reflections (Rfree) were initially put aside using FREERFLAG 
(CCP4 suite) and their degree of fit to the model was also determined (Brunger et 
al.,  1992).  The  rigid  body  refinement  yielded  an  Rfactor  of  27.7%  with  Rfree 
27.8%.  Ten  further  cycles  of  restrained  refinement  were  carried  out  using 
REFMAC  including  temperature  factor  refinement.  Well-defined  2Fo-Fc  density 
was  visible  for  the  Mds84  head  group  at  the  thyroxine  binding-site  along  the 
crystallographic symmetry axis. All four chlorine atoms of the head group of Mds84 
occupied  the  inner  most  binding  pocket  at  the  interface  of  the  TTR  dimers. 
Additionally, continuous 2Fo-Fc density for the 7-carbon linker was present along 
the central channel of the TTR tetramer and the positive electron density for the 
mutated residue Leu55 to Pro55 was also seen. 
 
After  few  rounds  of  model  building  and  refinement  the  Leu  55  side-chain  was 
mutated to a proline (Figure 6.16). Subsequently pdb and cif files were generated 
for Mds84 using PRODRG (van Aalten et al., 1996) and the ligand was modelled 
to the 2Fo-Fc density map (Figure 6.17). The occupancy of Mds84 ligand was set 
to 0.5 as it was lying on the 2-fold symmetry axis. After further model building and 
refinement 183 water molecules were added and the final structure yielded an 
Rfactor of 17.7% and Rfree of 21.8% (Table 6.4)   141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16 2Fo-Fc electron density in the vicinity of the L55P mutation (contoured 
at 2σ). Molecular replacement and refinement with L55 (WT) TTR (top) and the 
mutation to a Pro followed by refinement (bottom). 
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Figure 6.17 Modelling and refinement of mds84 at the thyroxine-binding site of 
L55P  TTR  (2Fo-Fc  electron  density  contoured  at  2σ).  The  7-carbon  linker 
traverses the central cavity of the TTR tetramer (top view) and Mds84 (with 0.5 
occupancy) is shown (bottom view).  
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6.5.4 The interaction of Mds84 with L55P TTR 
 
X-ray structure of the L55P TTR-Mds84 complex revealed that the molecule is 
positioned on the two-fold crystallographic axis of the tetramer. The head groups 
of Mds84 are positioned in the inner binding pocket of the TTR tetramer and the 7-
carbon long linker traverses the central cavity. The chlorine atoms were in van der 
Waals contact with the side-chains of Ser117 and Thr118 of β-strand H and the 
side-chains of Ala108, Ala109 and Leu110 of β-strand G (Figure 6.18) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18 The interactions of the chlorine atom of Mds84 with the L55P TTR at 
the thyroxine binding site. 
 
The  anthranilic  acid  moiety  of  Mds84  interacts  with  Leu17  of  β-strand  A.  The 
carboxylate group of anthranilic acid is hydrogen-bonded with Lys15 via a water 
molecule.  
 
The stereo-chemical properties of the refined L55P-Mds84 complex structure were 
checked  using  PROCHECK  (CCP4  suite).  The  MOLPROBITY  (www.duke.edu) 
online server was used to investigate any steric clashes between the residues. 
The residue average B factors were close to 20-24Å
2 (average B factor: CCP4 
suite). The Ramachandran plot showed that 92.3% of residues fell in the most   144 
favourable region, 7.5% fell in the additionally allowed region and none fell in the 
generously disallowed regions (Figure 6.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19 The Ramachandran Plot for the L55P TTR-mds84 X-ray structure 
(PROCHECK). 
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Resolution (Å) 
 
 35.9- 1.7 
Number of reflections used for refinement 
 
 25193 
Number of reflections used for Rfree  
 
 1259 
Rfactor (%) 
 
 17.7 
Rfree (%) 
 
 21.8 
RMS bond length deviation (Å) 
 
 0.012 
RMS bond angle deviation (°) 
 
 1.56 
 
Table 6.4 Refinement statistics of L55P TTR-mds84 X-ray structure. 
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6.6 Structure of the V30M TTR-Mds84 complex 
 
6.6.1 Data collection and processing 
 
X-ray data were collected on frozen V30M TTR-mds84 crystals at the Diamond 
Light  Source,  Oxford  UK  on  beam  line  I04  (λ=0.970Å)  using  an  ADSC  Q315 
charge  coupled  device  (CCD)  detector.  The  crystal  was  diffracted  to  ~  2.0Å 
resolution and 180 images were collected at 1º oscillation (Figure 6.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
      
Figure 6.20 A representative 1º oscillation diffraction image of the V30M-Mds84 
crystal. The V30M-Mds diffraction data were collected at Diamond light source, 
Oxford.  
 
 
The data were processed in P222 with iMOSFLM (CCP4) with unit cell dimensions 
of a= 43.13Å, b = 63.65Å, c = 85.64Å, α =90º β =90º γ =90º (Table 6.5). The 
Matthews coefficient suggested the presence of a TTR dimer in the asymmetric 
unit (Matthews, 1968) with a solvent content of 42.23%.  
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Table 6.5 The iMOSFLM penalty Table for unit cell determination and space group 
assignment for the V30M TTR-Mds84 crystal. 
 
Pseudo-precession  pictures  generated  in  HKLVIEW  demonstrated  systematic 
absences along the h, and l axes (Figure 6.21). 
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Figure 6.21 The HKLVIEW (CCP4) created pseudo-precession image along 0kl 
planes of V30M-mds84 (top) and the close up view (bottom) show the systematic 
absences along h and l axes.  
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The  data  were  scaled  using  SCALA  (CCP4  suite)  and  processed  in  the  P222 
space group. The processed data at 2.1Å resolution showed an overall Rmerge of 
6.2% with 98% completeness. The statistics produced after the scaling process, 
are shown in Table 6.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.6 The scaling and data processing statistics of human V30M-Mds84. The 
high-resolution data is shown in bracket. 
 
 
The scaled data were re-indexed (h=-h, k=l, l=k) using SORTMTZ (CCP4 suite) to 
obtain  the  final  molecular  replacement  solution  in  conventional  P21212  space 
group. 
 
 
 
 
 
Space group  P21212 
 
Unit cell (Å) 
              (º) 
a = 43.12, b = 63.64, c = 85.64 and 
α = β = γ = 90.0 
 
Low resolution (Å)  38.51 
 
High resolution (Å)  2.1 
 
Rmerge (%)  6.2  (26.3) 
 
Rmeas  (%)  7.3 (31.3) 
 
Total number of reflections  46041 
 
Total number of unique reflections  13933 
 
Mean ((I)/sd (I))  11.3 (3.7) 
 
Completeness (%)  98.1 (92.5) 
 
Multiplicity  3.3 (3.2) 
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6.6.2 Molecular replacement  
 
 
The  structure  of  V30M-Mds84  was  determined  by  the  molecular  replacement 
method  using  PHASER  (Read,  2001).  The  human  TTR  coordinate  file  1DVQ 
(Klabunde et al., 2000) without water molecules was used as a search model. The 
PHASER  job  was  conducted  with  all  choices  of  alternative  space  groups. 
PHASER found the best solution in the P21212 space group. The authenticity of 
the solution was confirmed by the high value of log likelihood gain (2627) with 
rotational function Z-scores (22.1) and translational function Z-scores (34.6). The 
crystal packing of V20M-Mds84 solution was generated by PHASER was analysed 
with Pymol (Figure 6.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.22 Crystal packing of V30M TTR in complex with Mds84 in P21212 space 
group (a=43.12Å, b=85.64Å, c=63.64Å; α = β = γ = 90.0º) was generated with 
Pymol,  which  showed  the  dimer  in  the  asymmetric  unit  (shown  in  green). 
Symmetry related molecules are shown in blue, lemon and cyan.    151 
6.6.3 Refinement and model building of V30M TTR-Mds84 
complex at 2.1Å resolution 
 
 
The program REFMAC (Murshudov et al., 1997) was used to refine the V30M-
Mds84 structure at 2.1Å resolution. A randomly selected fraction of 5% reflections 
were flagged as the Rfree set using FREERFLAG (CCP4 suite) to judge the final 
quality of the structure after each refinement cycle in an unbiased manner. The 
model  generated  using  PHASER  was  refined  by  20  cycles  of  rigid  body 
refinement. Then restrained refinement was carried out which yielded an Rfactor 
26.3% and Rfree to 27.8% respectively.  
 
The  electron  density  maps  (Fo-Fc  and  2Fo-Fc)  were  generated  by  FFT  after 
REFMAC.  The  maps  were  visualised  using  the  graphics  programme  COOT 
(Emsley & Cowtan, 2004). Maps revealed continuous electron density for the main 
chains and side chains of the model. The initial positive electron density for the 
mutated residue methionine 30 (V30M) was also very prominent (Figure 6.23) in 
the 2Fo-Fc map. The difference maps showed well-defined electron density for the 
Mds84 ligand at the symmetry axis of two dimers (Figure 6.24). All four chlorine 
atoms of the head group occupied the inner binding pocket. Continuous electron 
density was seen for the seven-carbon linker passing though the central cavity of 
the TTR tetramer. After each subsequent refinement round, electron density maps 
were generated and model building was carried out. 
 
Finally,  the  previously  created  pdb  and  cif  files  of  Mds84  were  imported  and 
merged  into  the  V30M  TTR  model.  Then  the  residue  Val30  was  mutated  to 
methionine  using  COOT  and  modelled  into  the  well-defined  positive  electron 
density map. Subsequently, 106 water molecules were added in the model for final 
refinement. The refined structure yielded an Rfactor of 19.8% with Rfree of 23.9%. 
The refinement statistics are shown in Table 6.7 below. 
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Resolution (Å) 
 
 34.6- 2.1 
Number of reflections used for refinement 
 
 13220 
Number of reflections as Rfree  
 
 661 
Rfactor (%) 
 
 19.8 
Rfree (%) 
 
 23.9 
RMS bond length deviation (Å) 
 
 0.011 
RMS bond angle deviation (°) 
 
 1.36 
 
Table 6.7 The refinement statistics of the V30M-Mds84 complex structure. 
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Figure 6.23 The mutation of V30M was confirmed by the electron density of the 
side chain of methionine (top view) contoured at 2σ. Val30 was replaced with Met 
(bottom view) and the side chain of Met was modelled into the electron density 
map (bottom view). The Pymol program was used to draw this diagram. 
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Figure 6.24 The 2Fo-Fc electron density countered at 2 σ shows the prominent 
electron  density  for  the  Mds84  ligand.  The  head  groups  are  situated  in  the 
thyroxine-binding sites and the linker is passing through the central cavity of TTR 
tetramer  (top  view)  and  the  symmetry-related  Mds84  is  also  generated  with 
graphics program Pymol (bottom view). 
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6.6.4 V30M TTR and Mds84 interaction 
 
The three dimensional structural study of V30M-Mds84 complex showed similar 
interactions involved in L55P-Mds84 structure. The ligand was positioned on the 
two-fold  symmetry  axis  in  a  manner  that  is  similar  to  the  previous  structure  of 
L55P-Mds84.  The  binding  study  demonstrated  the  presence  of  Van  der  Waals 
interactions between the chlorine atoms of the Mds84 head group and residues of 
G, H strands of the thyroxine binding sites of TTR. The chlorine atoms showed 
Van der Waals interactions with main and side chain of Ser117, Thr118 of strand 
H and residues Ala108, Ala109 and Leu110 of the G strand (Figure 6.25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.25 The diagram shows the binding of Mds84 to V30M via Van der Waals 
interactions with the side chain and main chain groups of residues Ala108, Ala, 
109, Leu110 of G strand and Ser117 and Thr119 of thyroxine binding site. 
 
6.6.5 Stereo-chemistry of V30M-Mds84 structure 
 
The geometric analysis of the refined V30M-Mds84 structure was carried out using 
PROCHECK  (CCP4  suite)  and  Molprobity  online  server  (www.duke.edu)  to 
analyse any steric clashes. The average B factors were approximately 20 to 24Å
2, 
calculated with B-average (CCP4 suite). The Ramachandran plot was produced   156 
using PROCHECK program, which showed that 92.0% of the residues were in the 
most favourable regions with 8.0% in additional allowed regions and none in the 
generously disallowed regions (Figure 6.26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.26 The Ramachandran plot shows most of the residues are in the most 
favourable region (PROCHECK). 
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6.7 Discussion 
 
6.7.1 Structural study of L55P-Mds84 complex versus wild type 
TTR  
 
The crystals of L55P TTR mutant in complex with Mds84 (bivalent ligand) were 
obtained at acidic pH and the X-ray structure was determined at 1.7Å resolution in 
the P21212 space group. The structure of L55P-Mds84 was compared with wild 
type  TTR  (WT  TTR)  crystallised  in  acidic  pH  with  the  same  space  group 
(1DVQ.pdb  Klabunde  et  al.,  2000).  The  structural  study  demonstrated  that  the 
single substitution of proline at position 55 in L55P-Mds84 caused irregularities in 
strand  D.  This  disturbance  leads  to  the  disruption  of  the  hydrogen  bonding  of 
neighbour residues, which may affect the stability of the tetrameric form of L55P 
TTR mutant. 
 
In wild type TTR, there are two hydrogen bonds (2.6Å and 2.8Å) between the main 
chain of Leu55 (strand D) and Val14 (stand A), which are shown in Figure 6.27 
below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.27 A diagram showing the two hydrogen bonds between the main chain 
of Leu55 and Val14 (1DVQ.pdb) of wild type TTR (WT TTR). (Diagram was 
generated using Pymol). 
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On the other hand, the substitution of Pro55 disrupted these two hydrogen bonds 
in L55P-Mds84 structure. As shown in Figure 6.28 below, the distances between 
the O55 (Pro55) and N14 (Val14), O14 (Val14) and N55 (Pro55) are too long (4.1Å 
and  5.6Å  respectively)  to  be  considered  as  hydrogen  bonds  in  L55P-Mds84 
complex (Figure 6.28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.28 In the L55P-Mds84 structure, the distances between the main chain 
atoms of Pro55 and Val14 are approximately 5.4Å and 5.6Å, which are too long to 
be considered as hydrogen bonds.  
 
In comparison to WT TTR, the L55P TTR mutant structure has disordered electron 
density for the side chain of His56 in the B subunit only but the continuous electron 
density has been seen in subunit A (Figure 6.29). 
 
 
6.7.2 V30M structural comparison with WT TTR 
 
 
The structure of V30M-Mds84 complex structure was determined at acidic pH in 
space group P21212 and the structure was compared with the structure of wild 
type TTR (1DVQ.pdb Klabunde et al., 2000). The comparative structural study 
showed high overall similarity in both the structures except for a few significant   159 
differences. In wild type TTR, the side chain of a Val14 was approximately 4.3Å 
apart from the side chain of Val30 residue (Figure 6.30). 
 
 
Figure 6.29 The diagram shows the disordered side chain of His56 of B monomer 
in L55P-Mds84 structure (on right hand side) and continuous electron density for 
His56 of subunit A (on left hand side) (Pymol).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure 6.30 The wild type TTR showed no steric clashes between the side chains 
of Val30 and Val14 (1DVQ.pdb) (Pymol) 
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It was speculated that the substitution of Met30 in the V30M TTR mutant could 
lead  to  the  steric  clashes  with  Val14  of  β-strand  A.  Furthermore,  these  steric 
clashes  might  contribute  towards  the  instability  of  TTR  tetramer.  In  the  V30M 
structure, the mutation of Val30 to the bulkier Met30 caused a shift of its α-carbon 
(approximately 0.9Å) to accommodate its long side chain. Interestingly, the side 
chain of Met30 was separated from the side chain of Val14 by 4.0Å, which could 
provide  the  Van  der  Waals  repulsion  that  might  be  responsible  for  the  extra 
stability of V30M in the presence of Mds84 bivalent ligand (Figure 6.31). 
 
The structural alignment study of wild type TTR (1DVQ.pdb) and V30M-Mds84 
showed that the substitution of Met30 caused the shift in its α-carbon (0.9Å) to 
accommodate its long side chain (Figure 6.32). It seems that this shift caused the 
rearrangements of residues 10-14 and 56-58 in V30M TTR structure (Terry et al., 
1993). 
 
 
Figure 6.31 A diagram showing the Van der Waal interaction (4.0Å) between the 
side chains of Met30 residue of the B strand and Val14 of strand A of V30M-
Mds84 complex. The diagram was produced using Pymol. 
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Figure 6.32 A structural alignment study of wild type TTR (1DVQ.pdb) and V30M-
mds84 showing the 0.9Å shift in the position of α-carbon of Met30. 
  
The previous structural study revealed that the V30M TTR mutation caused the 
disruption of a hydrogen bond between the Cys10 and Gly57 as compared to wild 
type TTR (which showed the hydrogen bond to have a distance of 3.4Å between 
the terminal sulphur atom of Cys10 and NH group of main chain of Gly57). This 
could lead to the exposure of Cys10 to the surface, which was speculated to form 
the intermolecular disulfide bond formation between the adjacent TTR tetramer 
(Terry et al., 1993). However, no such disruption was seen in the V30M-Mds84 
structure. The Cys10 in the structure was well defined with continuous electron 
density and the terminal sulphur was approximately 3.4Å apart from the N atom of 
the main chain of Gly57 (Figure 6.33). It could be another reason by which Mds84 
bivalent ligand stabilises the V30M mutant. 
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Figure 6.33 Structure of V30M-Mds84 structure showed the presence of hydrogen 
bond between the terminal sulphur atom of Cys10 and the N atom of main chain of 
Gly57 of V30M-Mds84 complex (The diagram was generated by Pymol). 
 
6.7.3 Mds84 bivalent ligand as a super-stabilizer of TTR mutants 
 
In our group, a binding study of Mds84 ligand to WT TTR as well as mutant TTR 
has been conducted. It was revealed that Mds84 has the ability to displace the 
bound thyroxine from wild type TTR as well as from L55P and V30M TTR mutants. 
TTR  binds  Mds84  in  1:1  ratio  (confirmed  by  mass  spectrometry  conducted  on 
native intact TTR tetramer, unpublished work) and the binding is so stable that a 
10  times  higher  concentration  of  thyroxine  could  not  displace  the  Mds84  from 
TTR-Mds84 complex even after the incubation of 6 days (Mark Pepys unpublished 
work). Unfortunately, the binding affinity of Mds84 to transthyretin could not be 
measured by isothermal titration calorimetry (ITC) due to its very low solubility in 
water (MDS84 is only soluble in DMSO). Furthermore, the stability assay of L55P 
and  V30M  mutants  was  conducted  by  measuring  the  subunit  exchange  study. 
Normally, TTR is well known to be involved in a subunit exchange process, which 
might  be  the  cause  of  TTR  tetramer  dissociation  and  ultimately  the  formation 
amyloid fibrils (Keetch et al., 2005). The binding of Mds84 to TTR (both wild type   163 
and mutants TTR) prevented all intermolecular subunit exchange due to the extra 
stability of the tetramer. The melting temperature (Tm) of WT TTR and L55P TTR 
mutant  has  been  determined  by  differential  scanning  calorimetry  (DSC).  The 
results demonstrated that binding of Mds84 to wild type TTR and L55P increases 
their  melting  temperature  (Tm)  by  approximately  6°C,  which  further  shows  the 
enhancement in stability of wild type as well as mutant TTR (Pepys unpublished 
work). 
 
6.7.4 Mechanism of binding of Mds84 to TTR mutants 
 
The binding of the bivalent inhibitors to TTR was tested in a previous study by 
mass spectrometry and X-ray crystallography (Klabunde  et al., 2000). Different 
bivalent inhibitors have already been studied like R-1-[6-[R-2-carboxy-pyrrolidin-1-
yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC). CPHPC is a palindromic 
compound  designed  to  cross  link  serum  amyloid  P  component  protein  (Pepys, 
2002). 
 
One  important  question  in  TTR  stabilization  with  a  bivalent  inhibitor  is,  how  a 
single  bivalent  ligand  can  bind  to  both  thyroxine-binding  pockets?  Different 
mechanisms have been suggested. One of the suggested mechanism is called the 
“threading mechanism” in which a bivalent chemical compound squeezes through 
the  hydrophobic  cavity  of  the  TTR  tetramer  (Green  et  al.,  2003).  In  this 
mechanism, it is assumed that Mds84 head group with chlorine atoms enters in 
the outer halogen pocket of TTR then moves forward to the inner pocket, pushing 
the anthranilate of Mds84 through the central of cavity of TTR.  
 
Another possibility is the binding of the bivalent head of Mds84 to the thyroxine 
binding pockets simultaneously during the process of subunit exchange in TTR 
tetramer  (Schneider  et  al.,  2001).  It  might  be  possible  that  TTR  monomers 
assemble  around  the  dumbbell  shaped  head  groups  of  the  bivalent  inhibitors 
(Hammarstrom et al., 2003).  
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It could also be possible that the TTR exists in dimeric and tetrameric form at 
equilibrium  and  the  bivalent  compounds  bind  to  dimer  and  then  the  tetramer 
formation takes place. 
 
6.8 Conclusion 
 
The study in this chapter suggested that the bivalent chemical ligand Mds84 is a 
super-stabiliser of amyloidogenic L55P and V30M TTR mutants. The structures of 
L55P and V30M TTR mutants in complex with Mds84 showed very little difference 
compared  to  the  structure  of  wild  type  TTR.  From  the  structural  point  of  view 
Mds84  showed  glue  like  properties,  which  keeps  the  TTR  tetramer  intact 
essentially  irreversibly  due  to  the  interactions  of  chlorine  atoms  with  its  inner 
thyroxine binding pockets. Furthermore, the binding study of TTR-Mds84 showed 
that Mds84 is capable to displace the bound thyroxine molecules from the wild 
type TTR. The differential scanning calorimetry study revealed that the mutants as 
well as WTTR in complex with Mds84 have higher melting temperature (~6°C) as 
compared to transthyretin alone. The present data demonstrated that this bivalent 
ligand provides extra-stability to tetrameric form of mutant transthyretin and this 
classic  structural  approach  could  lead  to  novel  methodologies  to  treat  different 
types of amyloidosis caused by wild type as well as mutant transthyretin protein.   165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
Structural study of Burkholderia invasion protein D 
(BipD) 
 
     166 
 
7 Introduction of Burkholderia invasion protein D (BipD) 
 
BipD  protein  is  produced  by  the  gram-negative  bacterium  Burkholderia 
pseudomallei.  It  consists  of  a  single  polypeptide  chain  of  310  residues  with 
molecular weight of approximately 33 kDa. Burkholderia is a saprophytic, gram-
negative, non-spore forming bacterium that consists of more than 30 species. The 
B. pseudomallei and B. mallaei are the most pathogenic members of this genus 
causing melioidosis in human and glanders disease in horses respectively. BipD is 
a component of the type III secretion system in which B. pseudomallei transfers 
effector proteins into the host cell in an ATP dependent manner (He et al., 2004; 
Mecsas  &  Strauss,  1996).  The  effector  proteins  subsequently  affect  host  cell 
signalling which allows the bacterium to escape the endocytic vacuoles and enter 
the  cytoplasm  of  the  host  cell.  The  internalized  B.  pseudomallei  induce 
polymerization of actins to form membrane protrusions, which further helps the 
bacterium to spread into adjacent cells. The infection mechanism of the bacterium 
is shown in Figure 7.1 
 
B. pseudomallei is commonly found in wet soil, especially in the paddy fields of 
Southeast Asia (Wuthiekanun et al., 1995) and Australia (Wiersinga et al., 2006). It 
can infect humans and animals through injured skin or via air born inhalation and 
is the cause of approximately 40% deaths of treated patients in Thailand. The 
most  common  disease  caused  by  infection  of  B.  pseudomallei  is  melioidosis, 
which is characterized by the abscess formation in the lungs, liver, spleen and 
skeletal  muscles  (White,  2003).  The  predominantly  affected  organ  is  the  lung 
where it causes pneumonia. B. pseudomallei has been called “the great mimicker” 
as  it  is  difficult  to  recognize  its  involvement  in  disease  and  sometimes  takes 
prolonged  time  to  develop  clinical  symptoms.  In  some  cases  infection  has  not 
been diagnosed until after 62 years (Ngauy et al., 2005).    167 
             
  
Figure 7.1 The mechanism of B. pseudomallei infection and its life cycle, a) the 
BSA (Burkholderia secretary apparatus), similar to the type III secretary system 
(T3SS)  helps  the  entry  of  the  bacterium  into  the  host  cell.  b)  The  bacterium 
escapes  the  endosome.  c)  Cell  to  cell  bacterial  transfer.  d)  Multiplication  of 
bacteria in the adjacent cell (Wiersinga et al., 2006). 
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7.1 Review of literature 
 
7.1.1 Bacteriology of B. pseudomallei 
 
B.  pseudomallei  has  recently  been  classified  as  a  category  B  agent  (potential 
biological terrorist weapon) by the United States of America. It can cause death 
from  septic  shock  within  48  hours  of  infection  (Mathew  et  al.,  2004).  This  has 
attracted worldwide interest in genomic studies of the bacterium B. pseudomallei 
K96243 (from Thailand), which contains two chromosomes, one 4.07Mbp in size 
and the other 3.17Mbp in size (Holden et al., 2004) shown in Figure 7.2. 
 
 
 
Figure  7.2  Chromosomes  1  (~4.07Mbp)  and  2  (~3.17Mb)  of  B.  pseudomallei 
K96243, each possesses 16 genomic islands (GI) (Holden et al., 2004).  
 
The chromosome 1, which is the bigger in size, encodes proteins involved in the 
metabolic activities, cell growth, amino acid and nucleic acid biosynthesis. The 
small sized chromosome 2 encodes fewer proteins which play an accessory roles 
like  cell  survival  and  adaptation  in  host  cell.  Approximately  14%  variation  is 
detected  between  the  genomes  from  different  B.  pseudomallei  K96243 
subspecies.  This  variable  component  of  the  genome  is  called  the  accessory 
genome and possesses a number of genomic islands (GI) displaying anomalies in   169 
GC  contents.  The  GI  have  the  capability  to  excise  themselves  from  the 
chromosome  and  transfer  to  another  chromosome  in  the  same  manner  as  the 
transposons. GI’s are thought to be involved in pathogenesis as mutations result in 
reduced microbial adherence to host cells. There is evidence that the dynamic 
nature  of  B.  pseudomallei  genome  is  adaptive  for  different  environmental 
conditions (Sim et al., 2008).  
 
7.1.2 Burkholderia pseudomallei and the type III secretion system 
 
B. pseudomallei infection starts with the translocation of bacterial proteins into the 
host cell. There are six secretary pathways in gram-negative bacteria named as I-
VI (Bingle et al., 2008). The type III secretary system (T3SS) is the most common 
in  B.  pseudomallei,  Shigella  flexineria,  Salmonella  typhimurium,  Pseudomonas 
aeruginosa and Yersinia enterocolitica (Espina et al., 2007).  
 
The T3SS is also called the “needle and syringe” system, which protrudes from the 
bacterial cell wall. The T3SS needle (injectisome) is a hollow tube of 45-80nm in 
length depending upon the species, approximately 25Å in internal diameter and 
composed of 20-30 different proteins (He et al., 2004; Yip & Strynadka, 2006). The 
base of the needle is supported by the inner and outer membranes of the bacterial 
cell wall and the narrow tip points out into the extracellular space (Moraes et al., 
2008).  A  ring-like  structure  called  the  “translocon”  is  present  at  the  tip  of  the 
needle and forms a pore through which effector proteins are injected into the host 
cell (Blocker et al., 2000). The translocator proteins, which form the translocon, are 
secreted when the bacterial needle comes in contact with host cell (Pettersson et 
al., 1996). Furthermore, the translocon seems to form pores in host cell membrane 
to facilitate the transfer of effector proteins into host cell cytosol. 
 
The BipD protein belongs to the translocon category and is attached to the needle 
tip  by  its  conserved  C-terminus  sequence.  An  in-vivo  study  has  revealed  that 
mutations in the BipD gene significantly reduced virulence in mice (Stevens et al., 
2002; 2004). 
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BipD  possesses  sequence  and  structural  similarity  with  other  gram-negative 
bacterial translocon proteins such as IpaD of Shigella (26% sequence and 36% 
structural)  and  sequence  homology  with  SipD  of  Salmonella  species  (as  the 
structure is not known). The sequence alignment of BipD with IpaD and SipD is 
shown in Figure 7.3. 
 
The  T3SS  locus  of  the  B.  pseudomallei  genome  (also  called  the  Burkholderia 
secretary apparatus (BSA) is similar to that of Shigella flexneri and Salmonella 
typhimurium (Stevens et al., 2002; Rainbow et al., 2002; Attree & Attree, 2001; 
Wiersinga et al., 2006). It has been proposed that BipD also acts as an extra-
cellular chaperone which helps its own refolding and assists other hydrophobic 
translocators to enter the host cell. 
 
Figure 7.3 A sequence alignment of Burkholderia BipD with IpaD of Shigella and 
SipD of Salmonella species demonstrating the C-terminus conserved DNLKVLS 
consensus sequence. 
 
7.1.3 The Structure of BipD 
 
The  crystal  structure  of  SeMet  BipD  has  recently  been  determined  at  2.1Å 
(Erskine et al., 2006) and at 2.8Å resolution (Johnson et al., 2007). The structure 
of BipD has eight, long antiparallel α-helices and eight short β-sheets present at 
the ends of the α-helix bundles. The electron density of the N-terminal 30 amino 
acids  and  residues  111-  127  residues  was  poorly  defined.  A  far  UV  circular 
dichroism spectrum confirms the predominance of α-helical structure. Remarkably, 
the C- terminal α-helix is some 50 residues in length, and is approximately equal 
to the length of the whole BipD molecule (Erskine et al., 2006).   171 
BipD  appears  to  exist  in  a  dimeric  form  in  the  crystal  whereas  gel  filtration 
demonstrates that in solution it exists as a monomer (Erskine et al., 2006). In the 
crystal BipD monomers interact with each other at the interface between helix 4 
and helix 8. Helix 8 possesses some of the most conserved C-terminal residues of 
BipD. The structure of BipD is shown in Figure 7.4. 
 
 
 
 
Figure  7.4  The  diagram  shows  the  crystal  structure  of  BipD  depicting  the 
antiparallel α-helical bundle and two short-stranded β-sheets on either sides of the 
α-helices. 
 
It  is  possible  that  dimerisation  is  important  for  BipD  function.  The  homologous 
IpaD protein forms a pentameric plug-like structure with the T3SS forming proteins 
to control the secretion of different proteins from the tip of the needle. A mutational 
study of BipD in Burkholderia by inserting the suicide plasmid caused the rise in 
the  secretion  level  of  T3SS  effector  proteins.  It  is  possible  that  BipD  plays  as 
regulatory  role  in  the  secretion  of  T3SS  effector  proteins  into  the  extracellular 
environment (Erskine et al., 2006). Furthermore, the first 20 residues of IpaD, a 
BipD homologue, seem to be a signal peptide as the deletion of these residues 
prevents IpaD secretion and ultimately invasiveness of the organism (Picking et 
al., 2005). T3SS proteins are associated with different types of chaperone activity 
but none has been identified in the case of BipD. The α-helical C-terminal domains 
of both BipD and IpaD share a high sequence homology with the chaperones of 
T3SS filament forming proteins (White, 2003). It has been suggested that the N-  172 
terminal region of BipD might have chaperone activity (Johnson et al., 2007). BipD 
may partially unfold during transport to the tip of the needle and refold into the 
native conformation once it is reached there. Both SipD and IpaD have already 
been suggested to possess a chaperone activity (Johnson et al., 2007), which may 
have a role in joining the needle with the translocon pore. In addition they may 
also guide the translocator protein into the host cell. BipD may play a similar role in 
the BSA system and help in actin rearrangement to facilitate in bacterial invasion. 
 
7.2 The aim of the research 
 
In this chapter I present the high-resolution (1.5Å) X-ray crystal structure of BipD. 
The model presented displays a number of the previously unseen amino acids 
including C-terminal residues, which are highly conserved.  
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7.3 Materials and methods 
 
7.3.1 Reagents 
All reagents used were purchased from Sigma-Aldrich (Poole, Dorset, UK) and 
Fisher Scientific (Loughborough, UK). 
 
7.3.2 L.B Media preparation 
 
10g tryptone, 5g yeast extract and 10g NaCl (with an additional 15 gram Agar for 
plates) per L was made to pH 7.0 and autoclaved at 121°C with 15 psi for 20 mins. 
The  ampicillin  was  filter-sterilized  through  a  0.2  µm  disposable  filter.  Ampicillin 
(100µg/ml) was added to the molten LB agar once it was cooled to 50˚C.  
 
7.3.3 Transformation of E. coli 
 
BL21  DE3  pLysS  competent  cells ( Invitrogen  Ltd)  were  transformed  using  the 
supplied  transformation  protocol  with  the  IPTG  inducible  pGEXBipD  plasmid 
(kindly provided by Professor Jon Cooper). The pGEX vector expresses BipD as a 
glutathione-S-transferase (GST) fusion protein. Transformed cells were plated on 
LB plates containing ampicillin antibiotic and incubated at 37˚C overnight. 
 
7.3.4 Starter culture preparation  
 
A  single  colony  of  transformed  BL21  DE3  pLysS  cells  was  picked  into  5  vials 
containing 10 ml of autoclaved LB broth media (10g tryptone, 5g yeast extract, 10g 
NaCl, in 1L pH 7.0) containing filter sterilized ampicillin (100µg/ml). The cells were 
grown overnight at 37˚C with shaking at 220 rpm. 
 
 7.3.5 5 L High Density Cell Fermentation 
5 L of terrific medium was sterilized by autoclaving at 15 psi and 125°C for 20 
minutes  and after cooling the 100µg/ml  of filter-sterilized ampicillin was added.   174 
Each flask was inoculated with 10 ml of overnight starter culture and fermentation 
was carried out at 37˚C with shaking at 220rpm. The culture was grown to mid-log 
phase (OD600 ~0.6) and then induced with filter sterilized IPTG (1mM final). The 
culture was grown for a further 12 hours and the cells pelleted at 8,000g for 30 
mins and the supernatant discarded. The 5 L cell culture yielded 12g (wet-weight) 
of cell mass. 
 
7.3.6 Cell lysis 
 
The cell pellet was resuspeded in 50 ml of cell lysis buffer (50 mM Tris pH8.0, 150 
mM NaCl). 5mM PMSF was added to the cell lysis buffer to prevent proteolysis by 
serine  proteases  and  5mM  EDTA  was  also  added  to  inhibit  metal-dependent 
protease  activity.  The  cell  suspension w as  sonicated  using  a  Soniprep  150 
sonicator with 30 sec on and 40 sec off for 10 mins and the lysate centrifuged at 
15,000g for 25 mins. 
 
7.3.7 SDS-PAGE 
 
A 12% SDS-poyacrylamide gel was prepared as described in chapter 5. Two 10 µl 
samples  of  purified  BipD  after  GSTrap  and  Benzamidine  column  affinity 
chromatography were added to an equal volume of 2 x Laemmli loading buffer 
(containing 5% β-mercaptoethanol) and denatured by boiling for 5 min. The 10 µl 
of samples and 10ul broad range protein marker (Promega Ltd) were loaded on 
the 12% SDS polyacrylamide gel and electrophoresed at 24mA for 1hr. 
 
Protein bands were stained with Coomassie blue solution (30% methanol, 10% 
acetic acid and 2% Coomassie Brilliant Blue R-250) for 30 mins and destained 
(30% methanol, 10% acetic acid) until the protein bands were visible.  
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7.3.8 Protein purification 
 
GST-tagged BipD was purified from the cell lysate using GSTrap column (Sigma-
Aldrich Ltd) according to the protocol suggested by the company. The column was 
washed with 10mM phosphate buffer (pH 7.3)/200mM NaCl. The GSTrap column 
is  loaded  with  BipD  and  unbound  protein  washed  off  with  binding  buffer. 
Approximately 15 units of thrombin (Novagen, Ltd.) were used to cleave the GST 
tag on the column. Thrombin recognizes the Leu-Val-Pro-Arg-Gly-Ser sequence 
and cleaves between the arginine and glycine residues to release intact BipD. 
 
7.3.9  Further  purification  of  BipD  by  benzamidine  affinity 
chromatography 
 
The  residual  thrombin  was  removed  by  further  affinity  chromatography  on  a 
benzamidine  column  (GE  Healthcare  Ltd.).  The  0.5M  NaCl  was  added  to  the 
purified BipD preparation from the GSTrap column to prevent non-specific binding 
and loaded onto the column. Non-bound BipD was collected as the flow-through 
and the thrombin was bound to the column. The serine protease inhibitor 4-(2-
aminoethylbenzenesulphonyl fluoride-HCl) (AEBSF) was added at 1 mM to the 
purified  BipD  protein  to  protect  it  from  any  thrombin  degradation.  BipD  was 
concentrated  with  Viva-spin  column  of  10kDa  molecular  weight  cutoff  (Viva 
science). The final concentration of BipD (in 10mM Tris-HCl, 140mM NaCl, pH 7.5) 
was determined to be 6mg/ml (with extinction coefficient of 30940M
-1cm
-1) by a 
nanodrop spectrophotometer (Nanodrop ND1000) at 280nm.  
 
7.4 SDS-PAGE of purified BipD 
 
The purity of purified BipD was assessed by SDS-PAGE as described before in 
section 7.23. 
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7.4.1  Sample  preparation  for  mass-spectrometry  and  data 
collection 
BipD protein was desalted using Pharmacia Biospin columns and then dissolved in 
acetonitrileN/H2O/formic acid (1:1:0.01) at a concentration of 10-50 pmol/ml. The 
samples  were  analysed  by  positive  ion  electrospray  mass  spectrometry  on  a 
Micromass  Quattro  II  triple  quadrupole  mass  spectrometer  by  Dr  N  Rendell 
(University  College  London,  Medical  School).   Data  were  deconvoluted  using 
Micromass  Masslynx  4.0  software  to  generate  a  transformed  molecular  ion 
spectrum. 
 7.4.2 Co-crystallization of BipD with phosphocholine 
A preliminary ITC study demonstrated that BipD bound to phosphocholine (PC), 
which is a constituent of the outer cell membrane of host cells. Attempts were 
made  to  co-crystallize  the  BipD-PC  complex  using  the  Molecular  dimensions 
crystallisation  kit  (Molecular  Dimensions  Ltd)  and  hits  were  obtained  with  PEG 
4000, and cacodylate buffer and glycine. The best crystals grew in PEG 4000 (25-
35%),  100mM  glycine,  20mM  EDTA,  60mM  cacodylate  buffer  (pH  5.0  to  6.5) 
(Table 7.1). 
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                             PEG 4000  (%) 
           25         30        35 
 
 
5.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.0 
 
 
 
 
 
 
 
Best crystals 
 
 
60mM 
cacodylate 
(pH) 
 
 
 
 
 
 
 
 
 
 
 
6.5 
     
                                          100mM glycine, 20mM EDTA 
                                       10mM Phosphocholine 
 
Table 7.1. Optimization of BipD-PC complex crystallization at varying precipitant 
concentrations (25-35% PEG4000) and buffer PH (pH 5.5-6.5 cacodylate) using 
the hanging drop method. 
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7.5 Results 
 
7.5.1 Protein expression and purification 
 
SDS-PAGE of GST-tagged BipD protein expressed in E. coli demonstrated that 
the majority of the protein was soluble. The GST-tag was removed from the BipD 
protein  with  thrombin  and  residual  thrombin  activity  eliminated  by  benzamidine 
column chromatography. BipD was more than 95% pure when assessed visually 
(Figure 7.5). 
 
 
 
 
Figure 7.5 SDS-PAGE of purified BipD. A) 1-6: eluted fractions after the GST-tag 
cleavage  with  thrombin,  B)  1-3:  purified  BipD  after  benzamidine  column 
purification. 
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7.5.2 The mass-spectrometry of BipD 
  
The mass-spectrum of the purified BipD displayed and a peak at 33,045 Da was 
detected which was close to calculated mass of BipD protein (Figure 7.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 The molecular mass spectrum of the purified BipD indicating a mass of 
33045 Da. 
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7.5.3 Crystallization of BipD 
 
The best single crystals of BipD were obtained with 35% (w/v) PEG4000, 100mM 
glycine,  20mM  EDTA,  60mM  cacodylate  buffer  (pH  6.0)  and  10mM 
phosphocholine (Figure 7.7). 
 
 
 
Figure  7.7  A  single  crystal  of  BipD  (~  60µm)  grown  using  the  hanging  drop 
method. 
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7.5.4 Data collection and processing of BipD protein 
 
X-ray diffraction data from the BipD crystal were collected at Diamond light source, 
England,  UK  on  beam  line  I02    (λ=0.971Å).  The  crystal  diffracted  to  ~1.4Å 
resolution and 360 images were collected with an oscillation angle of 0.5° (Figure 
7.8). The data were processed with iMOSFLM (CCP4 suite) in the C2 space group 
with cell dimensions of a = 51.25Å, b = 60.42Å, c = 90.41Å, α = 90.0º, β = 96.1º, γ 
= 90.0º. The penalty Table statistics are presented in Table 7.2. 
 
 
 
                   
 
Figure  7.8  A  0.5º  oscillation  X-ray  diffraction  image  of  the  BipD  crystal  which 
diffracted to ~1.4Å resolution.  
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Table  7.2  The  penalty  Table  for  BipD  crystal  data  processing  in  the  different 
possible space groups (iMOSFLM). 
 
 
The Matthews coefficient (Mathews, 1967) suggested the presence of only one 
BipD molecule in the asymmetric unit with 42% solvent content. The data were 
scaled  at  1.51Å  resolution  (overall  and  outer  shell  Rmerge  of  4.3%  and  55.3% 
respectively) with SCALA. The scaling statistics are presented in Table 7.3. 
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Space group                       C2 
Unit cell (Å) 
              (º) 
a = 51.15, b = 60.42, c = 90.41 
α = 90.0, β= 96.0, γ = 90.0 
Low resolution (Å)  38.90 
 
High resolution (Å)  1.51 
 
Rmerge (%)  6.7 (55.6) 
 
Total number of reflections  218736 (21565) 
 
Total number unique reflections  42898 (6210) 
 
Mean ((I)/sd(I))  13.7 (2.0) 
 
Completeness (%)  98.3  (99.4) 
 
Multiplicity  5.1 (3.5) 
 
 
Table 7.3 Scaling statistics for the BipD crystal at 1.51Å resolution in space group 
C2. 
 
Pseudo-precession  images  of  the  hk0,  0kl,  h0l  planes  displayed  no  axial 
systematic absences consistent with the absence of any screw axis (Figure 7.9-
11).  
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Figure 7.9 A pseudo-precession image of the (top) 0kl planes of the BipD crystal 
(top) and in close up and (bottom). In C2 space group the entire rows of spots are 
systematically absent (The diagram was created using HKLVIEW).    185 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 The diagram of a pseudo-precession image of the (top) h0l planes of 
the BipD crystal (top) and in close up (bottom) without systematic absences along 
the l axis (HKLVIEW). 
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Figure 7.11 A pseudo-precession image of the (top) hk0 planes of the BipD crystal 
and  in  close  up  (bottom)  demonstrating  the  systematic  absences  of  reflections 
(HKLVIEW). 
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7.5.5 Molecular replacement of BipD 
 
The  scaled  BipD  reflection  file  was  used  for  molecular  replacement  using 
PHASER (Read, 2001) with the BipD monomer (2IZP: Erskine et al., 2006) with all 
waters removed as the search model. All possible alternative space groups were 
searched yielding only one solution in C2 (rotational Z-score 16.7, translational Z-
score 13.6, LLG 1788) demonstrating the presence of only one BipD monomer in 
the asymmetric unit. Visualization of the crystal packing for this solution (NUcheck) 
showed that the molecules pack with reasonable crystal contacts (Figure 7.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12 Crystal packing of BipD viewed in the monoclinic C2 space group 
with cell dimensions, a = 51.15, b = 60.42, c = 90.41 and angles of α = 90.0, β= 
96.0, γ = 90.0 with four equivalently positioned BipD monomers in the unit cell. 
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7.5.6 Refinement and model building 
 
The model obtained from PHASER was refined with REFMAC (Murshudov et al., 
1997) and 5% reflection set was used as Rfree to give an unbiased check on the 
progress of the refinement. The first 10 cycles of restrained refinement yielded an 
Rfactor  28.12%  with  Rfree  of  31.15%.  Sigma-A  weighted  Fo-Fc  and  2Fo-Fc 
electron density maps were generated and viewed in COOT (Emsley & Cowtan, 
2004). No electron density was visible for the first 30 N-terminal residues and for 
residues 114-124 but the continuous electron density was present for the rest of 
the  protein.  A  few  residues  were  out  of  electron  density,  which  were  rebuilt 
manually (Figure 7.13) and 265 water molecules were added. After several rounds 
of  model  building  and  refinement,  an  Rfactor  of  16.1%  and  Rfree  19.8%  were 
obtained (Table 7.4).  
 
Resolution (Å) 
 
 34.7- 1.51 
Number of reflections used for refinement 
 
 40761 
Number of reflections as Rfree  
 
 2038 
Rfactor (%) 
 
 16.1 
Rfree (%) 
 
 19.8 
RMS bond length deviation (Å) 
 
 0.012 
RMS bond angle deviation (°) 
 
 1.26 
 
Table 7.4 The refinement statistics for the BipD structure  
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Figure 7.13 Representative 2Fo-Fc electron density for the BipD model contoured 
at 2 σ.   
 
The stereochemistry of the refined BipD structure was checked (PROCHECK) and 
several  torsion  angles  corrected  and  closely  contacting  water  molecules  were 
removed in COOT. The geometry of the refined structure was further checked with 
MOLPROBITY (www.duke.edu). The average B-factor of the BipD structure was 
approximately 20Å
2 but higher B factors were exhibited at N-terminus side-chains 
31-33  (~60Å
2)  and  around  the  C-terminus  (~40Å
2).  The  Ramachandran  plot 
showed that 96.5% of the residues were in the most favourable region, 3.0% in the 
additionally allowed region and 0.4% in generously allowed region (Figure 7.14). 
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Figure  7.14  The  Ramachandran  plot  for  the  BipD  structure  showing  95.7% 
residues  falling  in  the  most  favourable  region,  3.8%  in  the  additionally  allowed 
region and 0.4% in the disallowed region. 
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7.6 Discussion  
 
 
The  X-ray  structures  of  BipD  have  been  independently  determined  in  this 
laboratory  at  2.1Å  (Erskine  et  al.,  2006)  and  else  where  at  2.7Å  resolution 
(Johnson et al., 2007). In this research, the first high resolution structure of BipD 
has  been  determined  at  1.5Å.  BipD  consists  of  eight-antiparallel  α-helices  and 
seven beta strands. (Figure 7.15). 
 
Figure 7.15 BipD is composed of eight antiparallel α-helices and seven β-sheets.  
 
BipD  is  predominantly  of  α-helical  structure  with  α4  being  the  second  longest 
secondary structure composed of 42 residues and the C-terminal α8 being the 
longest involving 50 residues that run through the whole length of the molecule. 
The sequence of α8 is highly conserved in the BipD protein family, suggesting its 
important  role  in  the  type  III  secretary  system.  The  residues  involved  in  the 
secondary structure are shown in the Table 7.5. 
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Secondary structure  Residues involved (in number) 
α1  41-43 
α2  47-63 
α3  81-110 
α4  128-170 
α5  184-197 
α6  213-216 
α7  233-241 
α8  252-302 
β1-β2  68-75 
β3  172-175 
β4  179-182 
β5  197-203 
β6  220-230 
β7  233-241 
β8  247-250 
 
Table 7.5 The Table represents the residues involved in the secondary structure of 
BipD. 
 
 
In this study I presented the high resolution structure of BipD at 1.5Å resolution in 
the new C2 space group, which contains only one monomer in the asymmetric 
unit.  The  first  30  residues  were  not  visible  as  the  electron  density  was  poorly 
defined but after several cycles of refinement residues 30-34 were modelled into 
the improved electron density map. Another disordered region was encountered 
from Gly112 to Gly122, which seems to form a long loop. There was very poor 
electron density in this region but the rest of the structure had well defined electron 
density. 
 
This is first time the disordered residues 122-128 in previous structure have been 
modelled in this high resolution structure (Figure 7.16). However, the first 30 N-  193 
terminal residues, the C-terminal as well as Gly112-Gly122 of BipD which may 
have biological importance, are still not seen in the structure. 
 
 
 
Figure 7.16 2Fo-Fc electron density map round residues 122 to 128 of a loop 
which was disordered in the previous BipD structures 
  
7.6.1 Comparative study of BipD 
 
The previous structural study in this laboratory (Erskine et al., 2006) revealed a 
dimer of BipD in the asymmetric unit of space group P21 whereas the monomeric 
form presented by gel filtration study is more physiologically relevant (Erskine et 
al.,  2006).  The  high  resolution  structure  of  BipD  is  similar  to  the  previous 
structures (Erskine et al., 2006) but with small yet significant differences. In the 
high resolution structure, the two BipD monomers are related by crystallographic 
rather than non-crystallographic symmetry. The total surface accessible area of 
each  monomer  was  determined  by  (PISA)  provided  by  the  European 
Bioinformatics Institute (www.ebi.ac.uk) and compared with the earlier crystal form 
(Erskine et al., 2006). The total surface accessible area of each monomer that is 
buried at the putative dimer interface (1271Å
2) is larger than the previous crystal   194 
form (970 Å
2). This apparent strengthening of the dimer interface appears to stem 
from the improved definition of the residues in the range of 122-128 which form 
more extensive contacts in the new crystal form. 
 
Further more, the structural superposition of the high and lower resolution BipD 
structures  (Figure  7.17)  reveals  a  1.5Å  shift  of  the  α-carbon  positions  of  α4 
(residues 128-135). This seems to be a very flexible area of the BipD, which could 
be helpful for the transport of BipD to the tip of the secretion needle. On the other 
hand in the low resolution structure of BipD this helix is slightly twisted towards α8, 
which may be required to interact with another BipD molecule to form a dimer.  
 
 
 
 
 
 
 
Figure  7.17  Structural  superposition  of  the  high-resolution  (in  green)  and  low 
resolution  (in  yellow)  structures  of  BipD  demonstrating  that  the  high-resolution 
structure showed the absence of β5 and displacement of α4. 
 
Structural superposition of the high resolution BipD structure on IpaD of Shigella 
flexneria  (26%  sequence  and  36%  structural  homology)  was  carried  out.  It 
demonstrates that both structures possess the central coiled coil structure but that 
the N-terminal conformations are different (Figure 7.18). 
 
The N-terminal conformation of BipD is very different from that in the homologous 
protein  possibly  suggesting  a  unique  biological  role  for  this  region  in  B. 
pseudomallei. It has been proposed that BipD is present at the tip of the secretary 
needle of T3SS. It is also proposed that the N-terminal region of BipD has self-
chaperone activity, which helps the protein to refold following translocation through 
the secretion needle (Johnson et al., 2007). In contrast the conserved C-terminii of   195 
IpaD and BipD possess similar conformations and the deletion of a few C-terminal 
residues in IpaD eliminates host cell invasiveness (Picking et al., 2005). A similar 
function has been proposed for the C-terminal region of B. pseudomallei (Erskine 
et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18 The diagram shows the structural alignment of BipD (in green) of B. 
pseudomallei   and IpaD  (in yellow) of Shigella flexneria. The alignment study 
revealed the different N-terminal conformations. 
 
7.7 Conclusion 
 
The high resolution and more complete X-ray structure of monomeric BipD at 1.5Å 
is presented in the new space group C2 in this study but the electron density for 
co-crystallised  phosphocholine  (PC)  could  not  be  visualised.  However  the 
improved resolution structure of BipD will contribute significantly to the study of 
structure based drug design and understanding of the functional properties of this 
T3SS component. Previous structural studies revealed the dimeric form of BipD 
and it is possible that BipD may exist in different forms to perform multi functional 
tasks in the B. pseudomallei. 
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Chapter 8 
Cloning, expression and purification of ATJ11 co-
chaperone   197 
8 Introduction 
8.1 ATJ11 as a DnaJ protein  
ATJ11 is a chloroplast co-chaperone belonging to the group III DnaJ family. It was 
isolated  from  Arabidopsis  and  it  is  the  eleventh  member  of  the  DnaJ  family 
(Kroczynska  et  al.,  2000).  The  ATJ11  precursor  protein  is  composed  of  161 
residues (Mwt of 17.8kDa) including 63 residues of the transit peptide at its N-
terminus. The mature protein is processed to remove the transit peptide yielding a 
mature protein of 125 residues (Mwt of 14.3kDa). The N-terminal transit peptide 
targets the protein to the stroma of chloroplasts in a manner similar to that of the 
nuclear encoded small subunit of Rubisco. 
Mature  ATJ11  is  composed  of  an  80  residue  central  J  domain  containing  the 
conserved His-Pro-Asp tripeptide with a further 21 and 27 residues at N and C 
terminus respectively (Orme et al., 2001). The J-domain of ATJ11 interacts with 
and stimulates the ATPase activity of the molecular chaperone DnaK (Hsp70) via 
its tripeptide (His-Pro-Asp). The ATPase activity of DnaK is essential for its binding 
to nascent polypeptide chains. The J domain is also thought to be essential in the 
recruitment of Hsp70 in the protein refolding process. 
The single copy of the ATJ11 gene is located on chromosome 4 of the A. Thaliana 
genome  and  it  is  expressed  in  all  parts  of  the  plant  (Orme  et  al.,  2001).  The 
sequence alignment of ATJ11 with DnaJ of E.coli (Figure 8.1) demonstrated the 
presence of the conserved tripeptide sequence His-Pro-Asp. 
 
 
 
 
Figure  8.1  Sequence  alignments  of  ATJ11  of  Arabidopsis  and  E.coli 
(MULTIALIGN)  (High  consensus  sequences  in  red,  low  consensus  in  blue  and 
neutral in black).  
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8.1.1 Review of literature of DnaJ domain family 
8.1.2 DnaJ co-chaperone family 
DnaJ co-chaperone is present in prokaryotes and a homologue (Hsp40) is also 
found  in  eukaryotes.  Only  six  prokaryotic  DnaJ  co-chaperones  have  been 
identified to date whereas many more eukaryotic Hsp40 homologues are known. 
For example, P. falciparium posseses 10 Hsp40 molecules, yeast possesses 22 
and  humans  with  41.  In  Arabidopsis  Thaliana  there  are  89  Hsp40  equivalent 
proteins, which have been further sub-divided into 51 families according to the 
presence or absence of the conserved J-domain and ATJ11 is one of them (Walsh 
et al., 2004). These J-domain proteins are distributed throughout all organelles of 
the plant cell (Qiu et al., 2006). 
8.1.3 Molecular chaperones and their discovery 
Molecular chaperones are proteins that interact non-covalently with other proteins 
to assist in their folding but without taking an active part in their biological functions 
(Ellis  &  Hemmingsen,  1989).  In  the  early  1960’s  when  Ron  Laskey  of  The 
Genetics Institute of Pavia was researching into the formation of the nucleosome 
after fertilization of the amphibian egg, he observed the non-specific aggregation 
of histones. Interestingly, these histones were unable to dissociate even in the 
presence of high salt concentrations. Laskey analysed the power of Xenopus egg 
homogenate  to  prevent  this  non-specific  aggregation  and  isolated  the  active 
component,  with  an  acidic  nuclear  protein,  which  he  named  nucleoplasmin. 
Nucleoplasmin was essential for nucleosome assembly in vivo but was not itself a 
component of the nucleosome. However dialysis studies later demonstrated that 
nucleosome  assembly  could  indeed  proceed  in  vitro  in  the  absence  of 
nucleoplasmin. The basic function of nucleoplasmin seems to be to overcome the 
mutual  repulsion  of  the  positively  charged  histone  monomers  and  promote  the 
correct  interaction  with  the  negatively  charged  DNA  backbone  to  facilitate   199 
assembly of the nucleosome (Ritossa, 1996; Ellis, 2006). Lasky coined the term 
molecular  chaperone  to  describe  proteins  such  as  nucleoplasmin.  Molecular 
chaperones are also called heat shock proteins as their expression levels increase 
with temperature (Ritossa, 1996). 
8.1.4 The discovery of DnaJ 
DnaJ was originally discovered as the protein, which inhibited genomic DNA and 
bacteriophage λ replication in the GroPC250 E. coli mutant, but at that time the 
exact mechanism was not known. The size of DnaJ was determined to be 37kDa 
(Georgopoulos et al. 1977) and its gene located adjacent to the DnaK gene on the 
same  operon  (Yochem  et  al.,  1978)  lying  between  the  Thr  and  Leu  loci.  The 
presence  of  DnaJ  and  DnaK  genes  on  the  same  operon  provided  the  first 
evidence for their co-transcription (Saito & Uchida, 1978).  
In the late 1970’s, three laboratories worked independently on the isolation of E. 
coli mutants of DnaJ, DnaK, GrpD and GrpE, all suspected to be involved in the 
inhibition of DNA replication in bacteriophage λ (Georgopoulos et al., 1980). The 
sizes of three of these proteins were determined (DnaJ: 37kDa; DnaK: 93kDa; and 
GrpE:  24kDa)  (Saito  et  al.,  1978).  It  had  already  been  established  that  DnaJ, 
DnaK and GrpE worked together as a team (Liberek et al., 1991). This idea gave 
further encouragement when the cooperation of GroEL/GroES with DnaJ, DnaK 
and  GrpE  was  observed  in  the  prevention  of  the  aggregation  of  a  number  of 
different proteins. A schematic diagram of the co-operational pathway of molecular 
chaperones in sequential protein folding is shown below (Figure 8.2). 
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Figure 8.2 The co-operation of co-chaperones (DnaJ), chaperones (DnaK, GrpE) 
in the sequential process of protein folding (www.mpimf-heidelberg.mpg.de). 
8.1.5 Structure and organization of DnaJ 
All DnaJ proteins possess a conserved J domain of 72 residues composed of four 
α-helices and a conserved tripeptide (HPD) loop (Qian et al., 1996). As previously 
stated,  DnaJ  proteins  have  been  divided  into  three  groups  according  to  the 
presence or absence of conserved sequences (Cheetham et al. 1998): 
1) The Group I DnaJ proteins consist of a conserved J domain, a Gly/Phe -rich 
region and a Cys-rich region (zinc-finger domain). 
2) The Group II DnaJ proteins consist of a conserved J domain, Gly/Phe-rich 
region or a Cys-rich region (zinc-finger domain) 
3) The Group III DnaJ proteins consist only of the conserved J domain. 
The structures of the three types of DnaJ protein are illustrated schematically in 
Figure 8.3.   201 
 
 Group I                       
       
 
J domain           G/F rich region           Cys-rich region        C- terminus 
Group II 
 
 J domain          G/F rich region                C- terminus 
Group III 
 
   J domain                 C- terminus 
 
Figure 8.3 A schematic diagram of the three DnaJ/Hsp40 protein groups. 
8.1.6 Conservation of the J domain of DnaJ and its structure 
The J domain of DnaJ is composed of 4 alpha helices, which are made up of 72 
residues. Site-directed mutagenesis studies demonstrate that the conserved HPD 
tripeptide loop between helix II and III interacts with the ATPase domain of DnaK 
(Tsai et al., 1996; Qui et al., 2006). Helix II of the J domain is rich in positively 
charged amino acids and may interact electrostatically with the negatively charged 
residues of the ATPase domain of DnaK. The 17 residues of the J domain have 
charged  functional  groups  and  5  of  these  are  present  in  helix  II  which  are   202 
conserved in all DnaJ types. A second sequence (QKRAA) conserved in all DnaJ 
types has also been identified in helix IV of the J domain and this is also involved 
in the interaction with DnaK. Further studies on related chaperones also showed 
the importance of the Lys and Arg amino acids (Hennessy et al., 2000) and their 
substitution  by  site-directed  mutagenesis  has  been  demonstrated  to  inhibit  the 
interaction between DnaJ and DnaK (Suh et al., 1999). The X-ray structure of the 
J domain of DnaJ (C. elegans) is depicted in Figure 8.4. 
 
 
 
 
 
 
 
 
Figure 8.4 The X-ray structure of the J domain of DnaJ from C. elegans at 1.8 Ǻ. 
The conserved HPD peptide loop links α-helices II & III. H is depicted in green, P 
in yellow and D in red. The conserved Lys and Arg residues of α-helix IV are 
depicted in blue and yellow respectively (Osipiuk et al., 2007). 
8.1.7 Structure of the cysteine-rich domain of DnaJ 
The cysteine-rich domains of type I and II DnaJ proteins contain the CXXCXGXG 
consensus sequence which is also found in zinc finger proteins (Ohki et al., 1986). 
DnaJ has been shown to have a strong affinity for zinc and mutagenesis studies 
showed  that  the  Cys-rich  region  is  important  for  DnaK  ATPase  stimulation 
(Banecki et al., 1996) and the NMR structure of the Cys-rich region of DnaJ has 
been determined (Martinez-Yamout et al., 2000) (Figure 8.5). 
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 Figure 8.5 The diagram shows the solution structure of the Cys-rich region of 
DnaJ (Martinez-Yamout et al., 2000). The zinc (in red) binding the Cys-rich (in 
yellow) β-sheet structures (in blue) are also shown. 
 
8.2 Aim of the research 
 
More  recently  ATJ11,  a  plant  J  domain  protein  showing  homology  with  the  J 
domain of DnaJ was discovered. This protein has been proposed to be involved in 
Rubisco refolding and assembly (Orme et al., 2001). The aim of this study was to 
express  it  in  E.coli  cells  and  purify  it.  Furthermore,  the  main  target  was  to 
crystallize and determine the X-ray structure of recombinant ATJ11 protein. Many 
efforts  were  made  to  refold  the  protein  and  although  crystallization  trials  were 
unsuccessful,  biophysical  studies  allowed  the  determination  of  the  secondary 
structural composition of ATJ11 by circular dichroism. 
 
8.3 Materials and methods 
 
 8.3.1 Reagents 
All reagents used in this work were purchased from Sigma-Aldrich (Poole, Dorset, 
UK) and Fisher Scientific (Loughborough, UK). 
 
 
 
Zn2 
β-hairpin 
N 
C 
Zn
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8.3.2 Media preparation 
Luria-Bertani (LB) medium (10g tryptone, 5g yeast extract, 10g NaCl, 5 gram agar 
in 1L pH 7.0) was prepared and autoclaved at 121°C/15 psi/ for 20 mins. The 0.2 
µm disposable filter sterilised ampicillin (100µg/ml) and kanamycin (30µg/ ml) were 
added  to  molten  LB  agar  once  it  was  cooled  to  50˚C.  LB  agar  plates  were 
prepared under sterile conditions, sealed with parafilm and stored at 4˚C for up to 
6 weeks. 
 
8.3.3 Plasmid sequencing 
The pJ8H plasmid pET16-B was kindly provided by Dr A. Coker (containing the 
cloned Arabidopsis ATJ11 gene). It was sequenced using T7 forward and reverse 
primers (The Sequencing Service, University of Dundee) to confirm the correct 
sequence and orientation of the ATJ11 gene insert.  
 
8.3.4 Transformation of E. coli 
BL21 (DE)pLysS cells (Invitrogen) were transformed with the pJ8H plasmid using 
the supplied transformation protocol. Transformed cells were plated on LB plates 
containing kanamycin and ampicillin and incubated at 37˚C overnight. 
 
8.3.5 Starter culture preparation (1 L) 
 
A single colony of pJ8H transformed BL21 cells was picked into a 100ml baffled 
flask  of  autoclaved  LB  containing  filter  sterilised  ampicillin  (100µg/ml)  and 
kanamycin (30µg/ml). The cell culture was grown overnight at 37˚C with shaking at 
220 rpm. 
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8.3.6 High-density cell fermentation 
 
10 L of LB medium was sterilized in a BIOSTAT ED fermenter (Braun + Diessel 
Biotech  GmbH)  and  after  cooling  the  appropriate  quantities  of  filter-sterilized 
ampicillin and kanamycin were added. The fermenter was inoculated with 100ml of 
overnight grown starter culture along with 5ml of antifoam 289 (Sigma-Aldrich). 
Fermentation  was  carried  out  at  37˚C  with  10  L/min  aeration  and  stirring  at 
300rpm. The culture was grown to mid-log phase (OD600 ~ 0.6) and then induced 
with filter sterilized IPTG (2 mM final). The culture was grown for another 5 hours. 
The harvested cells were pelleted at 8,000 g for 30 mins and the supernatant was 
discarded. A yield of 32 g (wet-weight) was obtained from the 10 L fermentation. 
 
8.3.7 Cell lysis 
The cell pellet was resuspeded in 200 ml of cell lysis buffer (50 mM Tris pH8.0, 
140  mM  NaCl).  To  prevent  proteolysis  by  serine  proteases,  50mM  PMSF  was 
added to the cell lysis buffer. The resuspended cells were lysed using a French 
press at 15Kpsi and the lysate centrifuged at 15,000 g for 25 mins. 
 
8.3.8 SDS-PAGE 
10 µl of lysate and a small quantity of pellet were added to 2 x Laemmli loading 
buffer  (5%  β-mercaptoethanol),  denatured  by  boiling  for  5  min  and 
electrophoresed using a12% SDS-poyacrylamide gel for an hour at 24mA. 
 
8.3.9 ATJ11 purification by Ni-NTA column chromatography 
ATJ11  inclusion  bodies  were  solubilised  in  50mM p hosphate  buffer  (pH  7.0) 
containing 6M guanidine-HCl at 37˚C for 1 hr. A Ni-NTA column (Pharmacia Ltd) 
was  equilibrated  with  2L  of  degassed  8M  urea  dissolved  in  50mM  phosphate 
buffer (pH 7.0). The solubilised ATJ11 inclusion bodies were loaded onto the Ni-
NTA column at 3ml/min. The column was washed with phosphate buffer (pH 7.0) 
containing  5mM  imidazole  to  elute  non-specifically  bound  proteins.  The  bound   206 
denatured ATJ11 protein was eluted with a 0-200 mM imidazole gradient in 50mM 
phosphate buffer (pH 7.0) containing 8M urea. 
 
8.4 ATJ11 refolding by dialysis 
 
Solubilised ATJ11 using 8M urea in 50mM phosphate buffer (pH7.0) was refolded 
by  successive  step  dialysis  using  a  3,500  molecular  weight  cutoff    (MWCO) 
benzylated dialysis tube (Sigma-Aldrich Ltd) against 2 L volumes each of 6M, 4M, 
2M urea in 50 mM phosphate pH 5.0/100mM NaCl/5mM EDTA/ 5mM DTT/10% 
glycerol at room temperature in 4 hours steps. 
 
8.4.1 Cation exchange chromatography  
 
To facilitate efficient refolding partially purified ATJ11 was further purified by cation 
exchange chromatography using a mono-S column (Pharmacia) equilibrated with 
2M urea in 50mM phosphate pH 5.0. Dialysed ATJ11 was loaded onto the column 
at a flow rate of 1 ml/min and the bound protein was eluted with a gradual gradient 
of 86% (0.43 M) of NaCl dissolved in 2M urea using 50mM phosphate buffer (pH 
5.0). 
 
8.4.2 Optimisation of protein refolding 
8.4.2.1 pH optimisation 
To determine the optimal pH for refolding of ATJ11, the protein was refolded at pH 
5.0, 6.0 & 7.0 in 100mM NaCl, 50mM phosphate buffer, 5mM EDTA, 5mM DTT 
and 10% glycerol.  
 
8.4.2.2 Optimisation of salt concentration 
 
ATJ11 was refolded at different concentrations (0.5 mg/ml, 0.7mg/ml and 1mg/ml) 
and at different salt concentrations (100mM, 300mM and 500mM NaCl) in 50 mM 
phosphate pH 7.0, 5mM EDTA, 5mM DTT and 10% glycerol.    207 
8.4.3 Circular dichroism of ATJ11 
 
Circular  dichroism  is  a  variation  of  absorption  spectroscopy  that  measures  the 
difference  in  absorption  between  left  and  right  circularized  polarized  light  as  a 
function of wavelength for a chiral compound. Since proteins are made of L-amino 
acids the spectrum can give an indication of secondary structure (backbone amide 
transitions occur in the far UV 180-250 nm) and tertiary structure (aromatic residue 
cloud transitions in the near UV 250-320 nm). In the far UV the CD of α-helical, β-
sheet and random coil structures give rise to characteristic spectra and the CD 
spectrum  maybe  decomposed  into  the  relative  proportions  of  these  structures 
present. In the near UV any conformational changes upon ligand binding can be 
monitored if in the vicinity of tryptophan, tyrosine or phenylalanine residues (~275 
nm). In addition a strong 250 nm disulphide band may be present, it’s sign and 
strength representing the hand and strain of the disulphide bond. 
 
CD measurements were carried out on the ATJ11 (3mg/ml) protein solubilised in 
50mM phosphate, 20mM NaCl (pH5.0) using a JASCO spectro-polarimeter J-720. 
The spectral bandwidth was 1.5 nm and the temperature was 25°C. 3 scans were 
averaged for each measurement to increase the signal to noise ratio. Data were 
collected at 0.2 nm intervals in the near UV and at 0.2 nm intervals in the far UV. 
The background spectra arising from the buffer alone were subtracted from the 
measurements.  The  absolute  sample  concentration  of  ATJ11  was  determined 
from its extinction coefficient. 
 
8.4.4 Sample preparation and mass spectrometry 
 
Purified 10 µl of 1mg/ml ATJ11 in 8M urea/50 mM phosphate pH 8.0 in150 mM 
NaCl,  1mM  DTT,  was  desalted  on  a  POROS  R2  20  µm  Self  Pack®  Media 
reversed-phase micro-column (50 µl bed volume). The column was washed with 3 
x  50  µl  of  double  distilled  water  and  the  protein  eluted  with  50  µl  of  40% 
acetonitrile in 5% formic acid.   208 
The samples were analysed by positive ion electrospray mass spectrometry on a 
Micromass  Quattro  II  triple  quadrupole  mass  spectrometer  by  Dr  J.N.  Wright 
(Southampton  University,  UK).   Data  were  deconvoluted  using  the  Micromass 
Masslynx 4.0 software to generate a transformed molecular ion spectrum. 
 
8.4.5 Removal of the ATJ11 His-tag 
 
A  review  of  the  DnaJ  literature  reveals  that  recombinant  ATJ11  protein  may 
become  soluble  if  the  His-tag  is  removed  (Wall  et  al.,  1994).  Accordingly  the 
ATJ11 gene was re-cloned into the pET11a vector, which does not contain N-
terminal His-tag (Figure 8.6). 
 
 
Figure 8.6 A schematic of the pET11a vector (Novagen) in which the ATJ11 gene 
was cloned using the NdeI and BamHI restriction sites. 
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8.4.6 Maxiprep of pJ8H  
The ATJ11 gene was amplified by maxi-prepping E. coli JM109 cells transformed 
with the pJ8H plasmid. 2L of transformed cells were grown overnight at 37 ˚C. The 
cultures were centrifuged at 3,000 g and 4˚C. Large quantities of plasmid DNA 
were purified from the cell pellet using a Qiagen maxi prep kit (Qiagen Ltd). The 
yield of purified plasmid was determined using the nano-drop spectrophotometer 
and diluted to produce a 1µg/µl stock. 
 
8.4.7 Restriction digestion of pJ8H 
The ATJ11 gene was originally cloned into the NdeI and Bam HI sites in the poly-
linker of pET16b and these enzymes were used to remove the insert from pJ8H for 
sub-cloning into pET11a. The restriction digestion of pJ8H was performed in a 
total volume of 20 µl containing 10 µl of plasmid DNA (1 µg/ µl), 2 µl buffer D 
(10X), 0.2 µl 100 x acetylated BSA, 1 µl NdeI (10U/µl) and 1 µl BamHI (10U/µl). 
For efficient digestion with NdeI, the plasmid was digested overnight at 37 °C with 
NdeI alone and BamHI was added to the reaction mixture next day for a further 4 
hrs incubation. The same protocol was followed for the restriction digestion of the 
pET11a vector into which the excised fragment was to be cloned. 
 
8.4.8 Agarose gel electrophoresis 
 
1% agarose gels were prepared by dissolving 0.5 g agarose in 50 ml 1 x TAE 
buffer in a microwave oven. Once hand-cool, 1µl of ethidium bromide (20 mg/ml) 
was added and the gel poured into the casting trays to set with an eight well comb. 
20µl of digested pJ8H plasmid was mixed with 4ul of 6 x loading dye (0.15% w/v 
bromophenol blue/0.5% w/v SDS/0.15M EDTA/50% glycerol) and loaded onto the 
gel along with 5µl of 1Kb marker (Promega Ltd) in an adjacent lane. The gel was 
electrophoresed  at  100  mA  for  30  mins  and  visualised  with  a  Doc  2000  UV 
transilluminator (BIO RAD). 
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 8.4.9 Gel extraction 
 
The 429bp ATJ11 gene fragment was excised using the UV transilluminator. The 
DNA  was  extracted  from  the  agarose  gel  using  a  QIAquick  gel  extraction  kit 
(Qiagen Ltd). The extracted plasmid DNA and the ATJ11 fragment were both dried 
down in a speedvac and each re-dissolved in 10µl milliQ H2O. The quantities of 
cut  pET11a  plasmid  and  insert  were  determined  using  the  nano-drop 
spectrophotometer and the sizes of both extracted DNA fragments reconfirmed by 
agarose gel electrophoresis. 
 
8.5 Ligation reaction 
 
The molar ratio of pET11a plasmid to the ATJ11fragment used for the ligation 
reaction was 6:1. 
 
For the 100µg/µl of pET11 plasmid the concentration of the ATJ11 fragment was 
calculated using the following formula, which was 45ng/µl  
 
Volume of pET11 º size of ATJ11 fragment º 6 
.      Molecular weight of pET11 
 
 8.5.1 Ligation of the ATJ11 fragment into the pET11a vector 
 
The ligation of ATJ11 into pET11 vector was performed in a 10 µl total reaction 
volume containing 2µl insert, 1µl ligation buffer, 1µl 100 x acetylated BSA, 1µl 
linearized  plasmid  and  1µl  T4  DNA  ligase  (20U/ul)  and  4µl  milliQ  water.  The 
ligation mixture was incubated in a water bath overnight at 16˚C.  
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8.5.2 Transformation of JM109 competent cells 
 
200 µl of high efficiency (>10
8 cfu/ug) competent E. coli JM109 cells (Promega 
Ltd) were transformed with the ligation mixture, plated on LB ampicillin plates and 
incubated at 37˚C overnight. 
 
8.5.3 Plasmid isolation using a mini prep kit 
 
Eight colonies of transformed JM109 cells were individually picked into eight vials 
containing  10  ml  LB  ampicillin  medium  and  incubated  with  shaking  at  37˚C 
overnight. The cells were pelleted at 3,000g for 20 mins and the plasmid DNA 
purified using a Promega Wizard Mini-prep kit (Promega Ltd). The concentration of 
the purified DNA in each of the eight mini-preps was determined using a nano-
drop spectrophotometer. The DNA samples were dried down in a speedvac and 
resuspended at a concentration of 1µg/µl. 
 
8.5.4 pET11a-ATJ11 double-digestion 
 
The purified DNA samples were each double-digested by NdeI and BamHI in a 
total volume of 20 µl containing 1µl buffer D, 5 µl DNA plasmid (5 µg), 0.2 µl 100 x 
acetylated  BSA,  0.5µl  NdeI  and  1µl  BamHI.  For  efficient  NdeI  cleavage  the 
reaction was incubated overnight with NdeI alone and then BamHI was added the 
next day for a further 4 hrs. The double digestion was analysed by electrophoresis 
on a 1% agarose gel electrophoresis. 
 
8.5.5 Plasmid sequence 
 
The  pET11a  plasmid  containing  the  cloned  Arabidopsis  ATJ11  gene  was 
sequenced using the T7 forward and reverse primers (The Sequencing Service, 
University  of  Dundee)  to  confirm  the  correct  sequence  and  orientation  of  the 
ATJ11 gene insert. 
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8.5.6 Starter culture preparation (40ml) 
 
A single colony of pET11a transformed BL21 cells was picked into four sterilized 
vials containing 10ml of autoclaved LB broth containing ampicillin (100µg/ml) and 
cells were grown overnight at 37˚C with shaking at 220 rpm. 
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8.6 Results and discussion 
 
8.6.1 Protein expression 
 
SDS-PAGE  demonstrated  that  ATJ11  expressed  well  in  E.  coli  but  that  the 
majority of the protein was insoluble and present as inclusion bodies (Figure 8.7).  
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
Figure 8.7 SDS-PAGE of ATJ11 expressed in E. coli. M: protein marker (Bio-Rad), 
1: IPTG induced cell lysate containing soluble protein fraction 2: IPTG induced cell 
pellet containing inclusion bodies. 
 
 
 8.6.2 Purification of ATJ11  
 
 
ATJ11  inclusion  bodies  were  dissolved  in  6M  Gm-HCl  and  purified  from 
associated  E.coli  proteins  by  Ni-NTA  column  chromatography.  ATJ11  protein 
refolded by dialysis in steps from 6 to 4 to 2M urea in 50mM phosphate buffer pH 
5.0/100mM  NaCl.  It  was  observed  that  the  initial  purity  of  the  unfolded  protein 
affected the subsequent refolding of the protein, the purer the unfolded protein the 
lower the quantity of insoluble precipitates formed. Partially folded ATJ11 protein 
in 2M urea was further purified by cation exchange chromatography on a MonoS 
cation-exchange column. Positively charged ATJ11 at pH 5.0 was loaded onto the   214 
column and eluted with a linear 0-0.5M NaCl gradient as a single peak at 86% 
(0.43 M)(Figure 8.8).       
 
 
 
 
              
 
 
 
 
 
 
 
                     
Figure 8.8 Cation exchange chromatography of partially folded ATJ11 on a MonoS 
(Pharmacia) column.  
 
The  highly  purified  ATJ11  was  refolded  by  dialysing  the  protein  against  50mM 
phosphate buffer/300mM NaCl at pH 5.0. Once again it was noted that the protein 
concentration was also important for the protein refolding as concentrations above 
0.5 mg/ml increased the quantity of precipitates.  
 
8.6.3 SDS-PAGE of refolded ATJ11 protein 
 
The purity of the ATJ11 preparation was visualised by SDS-PAGE on a 12% gel. A 
band of highly purified ATJ11 was visible at the expected size of 16kDa (Figure 
8.9). 
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Figure  8.9  SDS-PAGE  of  soluble  ATJ11  protein  after  dialysis  against  50mM 
phosphate  pH  5.0/300mM  NaCl/10%  glycerol/5mm  EDTA/5mM  DTT  M:  broad 
range protein marker (Bio-Rad), 1-3: refolded ATJ11 protein fractions. 
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8.6.4 Mass spectrometry 
 
The molecular mass of the purified ATJ11 was determined to be 16,281 Da by 
mass-spectrometry (Figure 8.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  8.10  a)  The  raw  mass-spectrum  of  ATJ11  displaying  the  charged-ion 
peaks.  b)  The  deconvoluted  mass-spectrum  indicating  a  molecular  weight  of 
16281Da.   217 
8.6.5 CD spectrum of the ATJ11 protein 
 
 
The  secondary  structure  of  ATJ11  protein  structure  was  analysed  by  far  UV 
circular dichroism. The CD spectrum obtained from CD is shown in the Figure 8.11 
below. 
              
                                 
Figure 8.11 The far UV CD spectrum of ATJ11 protein in 20mM phosphate pH 
7.0/20mM  NaCl.  The  black  circles  show  the  actual  data  and  the  white  circles 
represents the secondary structure prediction data obtained from the K2d analysis 
online server (www.embl.de). 
 
 
The obtained CD data of ATJ11 protein was analysed using K2d online server 
(www.embl.de). The data analysis study estimated that the secondary structure 
contents of the ATJ11 protein were 30% α-helix, 13% β-sheet and 57% revealed 
that the protein was randomly coiled. 
 
8.6.6 Cloning of the ATJ11 gene   218 
A review of the DnaJ literature indicated that recombinant ATJ11 might be soluble 
without the His-tag (Wall, Zylicz & Georgopoulos, 1994). The ATJ11 gene was 
excised  from  the  His-tag  containing  pJ8H  vector  and  re-cloned  in  the  PET11a 
vector, which is without any tag (Figure 8.12).                                                      
                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                           
 
Figure 8.12 The ATJ11 gene was extracted from pJ8H by double digestion with 
NdeI and BamHI (1% agarose gel). M: 100bp DNA ladder (Bioline) 1 & 2: The 
429bp ATJ11 gene fragment. 
 
 8.6.7 ATJ11 gene fragment ligation and restriction digestion  
 
The  ATJ11  gene  fragment  was  gel  extracted,  ligated  into  NdeI/Bam  HI  double 
digested  and  gel-extracted  pET11a.  Competent  E.coli  JM109  cells  were 
transformed with the ligation mixture and the presence of the ATJ11 gene insert 
was confirmed by double digestion of the pET11a construct with NdeI and BamHI 
enzymes. The gene fragment was analysed on 1% agarose gel (Figure 8.13). 
   219 
 
 
 
 
 
 
 
 
                
 
 
 
 
 
 
 
 
Figure  8.13  Agarose  gel  electrophoresis  of  mini-prep  DNA:  100bp  DNA  ladder 
(Bioline), 1: Double digestion of pET11a-ATJ11 with NdeI and BamHI 
 
 
8.6.8 Maxi-prep and sequencing of pET11a-ATJ11. 
 
Transformed  E.  coli  JM109  cells  containing  the  pET11a-ATJ11  gene  construct 
were  grown  overnight  in  1L  LB  media  containing  100µg/ml  ampicillin.  Plasmid 
DNA was maxi-prepped and quantified by determining the OD260 and the purity 
was assessed on a 1% agarose gel (Figure 8.14). The clone was sequenced to 
confirm the correct sequence and orientation of the ATJ11 gene insert.  
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Figure 8.14 The purity of pET11-ATJ11 after purification by maxi-prep. Lanes 1 
and  2  are  replicates  of  the  pET11  containing  the  ATJ11  fragment.  Lane  M  is 
100bp DNA ladder (Bioline).  
 
8.6.9 ATJ11 expression without a His-tag 
 
 
ATJ11 protein without a His-tag was expressed in E.coli BL21 DE3 cells but the 
solubility of the protein did not improve and most of the protein was still present as 
inclusion bodies (Figure 8.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.15 The expression of ATJ11 protein without His-tag analysed by SDS-
PAGE.  M:  broad  range  protein  marker  (Bio-Rad),  lane  1:  ATJ11  protein  in  the 
insoluble fraction. 
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8.7 Discussion and conclusion 
 
The  aim  of  this  work  was  to  express,  purify,  and  crystallize  the  Arabidopsis 
thaliana ATJ11 protein. The ATJ11 gene was initially cloned into pET16B with an 
N-terminal His-tag (Gupta et al., 2001) but expression from this construct yielded 
only ATJ11 inclusion bodies. After re-solubilisation in 6M urea and purification by 
Ni-NTA cation exchange chromatography, the protein was more than 90% pure by 
SDS-PAGE.  The  partially  folded  purified  protein  was  refolded  by  step  dialysis 
against 50mM phosphate buffer at the optimal pH 5.0, 300mM NaCl. The protein 
concentration for refolding was optimised to 0.5mg/ml.  
 
For the crystallization of proteins high concentrations are desirable. The purified 
ATJ11 was concentrated with a 3,500 MWCO centricon but became sticky and 
aggregated at concentrations more than 3mg/ml. The protein was screened for 
crystallization conditions (Molecular Dimensions Ltd) at room temperature and at 
4°C but crystals could not be obtained. 
 
8.7.1 Cloning of the ATJ11 plant gene 
 
From a previous study on the DnaJ family of proteins (Wall et al., 1994) it was 
observed that the 1kDa His-tag was affecting protein solubility in E.coli. Thrombin 
cleavage of the His-tag was not possible due to the incompatibility of the cleavage 
conditions with protein stability so the ATJ11 gene was cloned into the pET11a 
vector, which does not encode a C-terminal His-tag. Unfortunately the protein still 
expressed as inclusion bodies. 
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9 Summary and Conclusion 
 
 
In this thesis, the crystallographic study of serum amyloid P component (SAP) and 
transthyretin  proteins  in  complex  with  different  chemical  ligands  has  been 
described.  Further  more,  the  three  dimensional  structure  of  BipD  at  atomic 
resolution was also determined and the attempts were made to express, purify and 
crystallise the plant molecular chaperone, ATJ11 (DnaJ domain) protein. 
 
Chapters 1 and 2 described the introduction and general background of SAP. The 
structure  of  SAP  in  complex  with  different  chemical  ligands  was  already 
determined (Emsley et al., 1994; Hohenester et al., 1997; Thompson et al., 2002). 
The structural study revealed that the SAP binds to phosphate or carboxylate head 
groups on its B face calcium dependently. 
 
In chapter 2 and 3 I have explored the crystallographic study of SAP, to determine 
its atomic resolution structure in complex with different alkyl phosphonate ligands. 
Efforts  were  made  to  understand  the  geometry  of  head  group  and  alkyl  chain 
length of ligands used and their potential role in tighter binding to SAP. Three 
different  ligands,  2-aminoethyl,  3-amino  propyl  and  4-amino  butyl  phosphonic 
acids were co-crystallised with SAP in the presence of calcium and their structures 
were  determined  at  atomic  resolution.  These  structures  were  similar  to  the 
previous structure of SAP-PE. The phosphonate head group showed interactions 
with SAP via two calcium ions. The alkyl chain of alkyl phosphonates interacted 
with the hydrophobic pocket of SAP. Two significant structural differences between 
the SAP-PE and SAP-alkyl phosphonate were analysed. In SAP-PE structure, the 
NH group of PE shows the interaction with Glu66 though a water molecule while in 
alkyl phosphonates, the NH group interacted with Tyr74 in the majority of SAP 
monomers, which seems an important factor in the binding event. Secondly, SAP 
is  a  glycoprotein  and  this  is  first  time  I  have  managed  to  visualise  the  high-
resolution structure of covalently bonded sugar chains attached to Asn32 in all 
three structures of SAP-alkyl phosphonates.  
   224 
Chapter 4 presents an isothermal titration calorimetry (ITC) study of SAP and the 
alkyl phosphonate ligands. It shows that changing the phosphate head group to 
phosphonate  decreases  the  ligand  binding  affinity  for  SAP  from  micromolar  to 
millimolar. ITC study of SAP-alkyl phosphonate complexes showed the importance 
of the strict phosphate head group geometry for SAP binding. Furthermore, the 
conformation of the alkyl side chain may affect the binding affinity of small ligands 
to  SAP.  The  study  revealed  that  it  is  crucial  to  understand  the  head  group 
geometry as well as the side chains conformation of the chemical ligands of SAP. 
The findings in this chapter could be useful to design novel compounds containing 
a negatively charged head group, which may block the amyloid recognition site of 
SAP more effectively. 
 
The chapter 5 describes the amyloidogenic TTR and its mutants, L55P TTR and 
V30M, which cause amyloidosis in humans. This section includes a summary of 
TTR research and the different possibilities to stabilize the TTR mutants and inhibit 
amyloid  fibre  formation.  The  crystal  structures  of  L55P  and  V30M  have  been 
determined previously (Benson et al., 1996; Terry et al., 1993). Different chemical 
compounds have been studied to stabilise the TTR tetramer (wild type as well as 
mutant TTR) (Green et al., 2003). To stabilize the TTR mutants, a palindromic 
bivalent  ligand  called  Mds84,  has  been  used  in  this  research.  The  crystal 
structures of TTR mutants in complex with Mds84 have been determined which 
showed very few differences compared to the structure of wild type TTR. It was 
shown that the Mds84 binds at the interface of two dimers of TTR and effectively 
glues them together. The chlorine atoms of Mds84 bind to the inner thyroxine-
binding pocket of the TTR mutants and provide extra stability to the TTR tetramer. 
Further more, the binding of Mds84 has also stabilised the Cys10 of V30M TTR 
mutant. The palindromic Mds84 compound could offer an innovative treatment for 
different types of TTR related amyloidosis. 
 
In chapter 7, research was carried out on the bacterial protein BipD (Burkholderia 
invasive protein D) of the type III secretion system of Burkholderia pseudomallie 
(Erskine  et  al.,  2006).  During  the  ITC  experiments,  BipD  showed  significant 
binding  affinity  for  phosphocholine,  which  encouraged  me  to  conduct  the 
crystallographic  study.  This  chapter  describes  the  expression,  purification  and   225 
crystallisation  of  BipD  in  complex  with  phosphocholine.  Unfortunately, 
phosphocholine could not be seen in the BipD structure but it has clearly acted as 
a  crystallization  additive  to  obtain  an  atomic  resolution  (1.5Å)  structure  of  the 
protein in a new space group C2. The high-resolution structure of BipD can play 
an important role to develop structure based drug design and understanding the 
functional properties of BipD protein. 
 
In  the  final  chapter,  attempts  were  made  to  express  the  Arabidopsis  thaliana 
ATJ11 (Orme et al., 2001) protein in E.coli. ATJ11 protein was purified, refolded 
and efforts were made to crystallize it.  Since ATJ11 protein was expressed as 
inclusion bodies, the inclusion bodies were solubilised in 6M urea and the protein 
was purified by Ni-NTA and cation exchange chromatography. The purified protein 
was refolded by step dialysis. I have managed to carry out a circular dichroism 
(CD) study of ATJ11. The CD study revealed that ATJ11 has predominantly an α-
helical structure. Unfortunately, the protein was prone to aggregation and I was 
unable to get the protein concentration above 3mg/ml. Although the ATJ11 protein 
was screened for crystallization conditions (Molecular Dimensions Ltd) at room 
temperature as well as at 4°C, crystals could not be obtained. 
 
9.1 Future work 
 
In case of the SAP-alkyl phosphonate ligand study, I would like to screen the long 
alkyl chains of phosphonate head groups, which might dip into the hydrophobic 
pocket of SAP and may bind to SAP more tightly than ligands used in this study.  
 
The structural study of TTR mutants in complex with the bivalent ligand Mds84 did 
not  show  a  significantly  different  structure  from  wild  type  TTR.  It  could  be 
crystallographic artifacts that caused the protein to be packed in such a way, that 
masks the structural differences. In future I would like to conduct computational 
energy minimization study to supplement the crystallographic findings.  
 
BipD  protein  is  an  active  component  of  a  Type  III  secretary  system.  It  was 
proposed that BipD assists in a pore formation in the host cell membrane and   226 
facilitates  the  secretion  and  the  injection  of  virulent  proteins  into  the  host  cell 
(Erskine  et  al.,  2006).  These  virulence  proteins  facilitate  the  invasion  of 
Burkholderia pseudomallei bacterium into the host cell, which causes melioidosis 
in humans. Neither the potential ligands nor the binding sites of BipD protein are 
known.  In  future  I  would  like  to  screen  for  different  BipD  high  affinity  binding 
partners and will make efforts to determine their three dimensional structure in 
complex with BipD. 
 
Significant efforts and time were spent on the gene cloning, protein expression, 
purification and refolding of ATJ11 co-chaperone protein. But the crystals of ATJ11 
could not be obtained and in future I would like to explore the possibility of its 
solution structure by NMR. 
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